Quantitative proteomics methods for the analysis of histone post-translational modifications by Abshiru, Nebiyu
  
 
 
 
 
Université de Montréal 
 
 
 
Quantitative Proteomics Methods for the Analysis of 
Histone Post-translational Modifications 
 
 
par 
Nebiyu Ali Abshiru 
 
 
 
Département de Chimie 
Faculté des arts et des sciences 
 
 
Thèse présentée à la Faculté des études supérieures 
et postdoctorales en vue de l’obtention du grade de 
philosophiae  doctor (Ph.D.) en chimie 
 
 
 
Septembre 2015 
©Nebiyu Ali Abshiru, 2015 
i 
 
 
 
Résumé 
 
Les histones sont des protéines nucléaires hautement conservées chez les cellules des 
eucaryotes. Elles permettent d’organiser et de compacter l’ADN sous la forme de 
nucléosomes, ceux-ci representant les sous unités de base de la chromatine. Les histones 
peuvent être modifiées par de nombreuses modifications post-traductionnelles (PTMs) telles 
que l’acétylation, la méthylation et la phosphorylation. Ces modifications jouent un rôle 
essentiel dans la réplication de l’ADN, la transcription et l’assemblage de la chromatine. 
L’abondance de ces modifications peut varier de facon significative lors du developpement 
des maladies incluant plusieurs types de cancer. Par exemple, la perte totale de la 
triméthylation sur H4K20 ainsi que l’acétylation sur H4K16 sont des marqueurs tumoraux 
spécifiques a certains types de cancer chez l’humain. Par conséquent, l’étude de ces 
modifications et des événements determinant la dynamique des leurs changements 
d’abondance sont des atouts importants pour mieux comprendre les fonctions cellulaires et 
moléculaires lors du développement de la maladie. 
De manière générale, les modifications des histones sont étudiées par des approches 
biochimiques telles que les immuno-buvardage de type Western ou les méthodes 
d’immunoprécipitation de la chromatine (ChIP). Cependant, ces approches présentent 
plusieurs inconvénients telles que le manque de spécificité ou la disponibilité des anticorps, 
leur coût ou encore la difficulté de les produire et de les valider. Au cours des dernières 
décennies, la spectrométrie de masse (MS) s’est avérée être une méthode performante pour la 
caractérisation et la quantification des modifications d’histones. La MS offre de nombreux 
avantages par rapport aux techniques traditionnelles. Entre autre, elle permet d’effectuer des 
analyses reproductibles, spécifiques et facilite l’etude d’un large spectre de PTMs en une 
seule analyse. Dans cette thèse, nous présenterons le développement et l’application de 
nouveaux outils analytiques pour l’identification et à la quantification des PTMs modifiant 
les histones. 
Dans un premier temps, une méthode a été développée pour mesurer les changements 
d’acétylation spécifiques à certains sites des histones. Cette méthode combine l’analyse des 
histones intactes et les méthodes de séquençage peptidique afin de déterminer les 
changements d’acétylation suite à la réaction in vitro par l’histone acétyltransférase (HAT) de 
levure Rtt109 en présence de ses chaperonnes (Asf1 ou Vps75). 
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Dans un second temps, nous avons développé une méthode d’analyse des peptides 
isomériques des histones. Cette méthode combine la LC-MS/MS à haute résolution et un 
nouvel outil informatique appelé Iso-PeptidAce qui permet de déconvoluer les spectres 
mixtes de peptides isomériques. Nous avons évalué Iso-PeptidAce avec un mélange de 
peptides synthétiques isomériques. Nous avons également validé les performances de cette 
approche avec des histones isolées de cellules humaines érythroleucémiques (K562) traitées 
avec des inhibiteurs d’histones désacétylases (HDACi) utilisés en clinique, et des histones de 
Saccharomyces cerevisiae liées au facteur d’assemblage de la chromatine (CAF-1) purifiées 
par chromatographie d’affinité. Enfin, en utilisant la méthode présentée précédemment, nous 
avons fait une analyse approfondie de la spécificité de plusieurs HATs et HDACs chez 
Schizosaccharomyces pombe. Nous avons donc déterminé les niveaux d’acétylation 
d’histones purifiées à partir de cellules contrôles ou de souches mutantes auxquelles il 
manque une HAT ou HDAC. Notre analyse nous a permis de valider plusieurs cibles connues 
des HATs et HDACs et d’en identifier de nouvelles. Nos données ont également permis de 
définir le rôle des différentes HATs et HDACs dans le maintien de l’équilibre d’acétylation 
des histones. Dans l’ensemble, nous anticipons que les méthodes décrites dans cette thèse 
permettront de résoudre certains défis rencontrés dans l’étude de la chromatine. De plus, ces 
données apportent de nouvelles connaissances pour l’élaboration d’études génétiques et 
biochimiques utilisant S. pombe. 
Mots clés : Spectrométrie de masse, histones, modifications post-traductionnelles, peptides 
isomérique, histones acétyltranférases, histones déacétylase.  
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Summary 
 
Histones are highly conserved, basic proteins found in eukaryotic cell nuclei. They organize 
and package DNA strands into nucleosome core particles (NCPs), the fundamental repeating 
units of eukaryotic chromatin. The histones are subject to a wide variety of posttranslational 
modifications (PTMs) including acetylation, methylation and phosphorylation. These PTMs 
play an essential role in DNA-replication, transcription, and chromatin assembly. Alterations 
in histone PTM abundances have been implicated in several types of cancer. For example, the 
global loss of trimethylation at H4K20 and acetylation at H4K16 is a hallmark of human 
cancers. Thus, characterization of histone PTMs and their dynamics is extremely useful for 
elucidating normal cellular functions and molecular pathways that lead to diseases.  
Traditionally, histone PTMs are analyzed using antibody-based approaches such as western 
blot and chromatin immunoprecipitation (ChIP) assays. These methods, however, suffer from 
several limitations including antibody cross-reactivity, epitope occlusion, and the cost and 
difficulty in producing and validating antibodies. Over the last decade, mass spectrometry 
(MS) has emerged as a powerful technique for the characterization and quantification of 
histone PTMs. MS offers several advantages over the traditional approaches including 
reproducibility, specificity, and ability to rapidly analyze numerous PTMs in a single 
experiment. In this thesis, the development and applications of novel analytical tools for the 
identification and quantification of histone PTMs are presented.  
First, a method useful for measuring the global and site specific changes in histone 
acetylation is described. This method combines intact mass analysis and peptide sequencing 
approaches to study the global and site specific changes in histone acetylation during in 
vitro assays with yeast Rtt109 and its chaperone (Asf1 or Vps75).  Second, a method for 
analysis of isomeric histone peptides is presented. This method combines a high resolution 
LC-MS/MS with a novel bioinformatics tool called Iso-PeptidAce to deconvolute mixed 
spectra of co-eluting isomeric peptides. We benchmarked Iso-PeptidAce using mixtures of 
synthetic isomeric peptides. We demonstrated its capability in histones isolated from human 
erythroleukemic (K562) cells treated with clinically relevant histone deacetylase inhibitors 
(HDACi) and in affinity-purified S. cerevisiae histones bound to chromatin assembly factor-1 
(CAF-1). Third, by employing the above methods, an in-depth quantitative analysis of the 
substrate specificities of several fission yeast HATs and HDACs was assessed. We 
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determined the acetylation site occupancy of multiple lysines in histones isolated from a 
control or mutant strains lacking specific HAT or HDAC activities. Our analysis identified 
several known and novel HAT and HDAC target sites. Our data also defined the division of 
labor between the different HATs and HDACs in maintaining the steady-state level of histone 
acetylation. Overall, we anticipate that the methods described in this thesis will address some 
of the existing challenges facing the chromatin field. Moreover, the data presented will 
provide valuable insights for future genetic and biochemical studies involving the fission 
yeast. 
Key Words: Mass spectrometry, histones, posttranslational modifications, isomeric peptides, 
histone acetyltransferases, histone deacetylases 
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CHAPTER 1: Introduction 
 
1.1. How is the DNA stuffed into a tiny microscopic cell nucleus?  
The DNA contains all the genetic instructions required for an organism to grow and 
reproduce [1]. It is composed of a phosphate group, a sugar molecule (called deoxyribose) 
and a nitrogen-containing base namely adenine (A), guanine (G), cytosine (C) and thymine 
(T). These components are linked in the order phosphate-sugar-base to form the structural 
unit of DNA known as the nucleotide (Fig. 1.1a). In turn, the nucleotides are joined to one 
another in a chain by a phosphodiester bond between the phosphate of one nucleotide and the 
deoxyribose of the next to form a DNA strand (Fig. 1.1b). The DNA exists in a double-
stranded form whereby two adjacent strands running in opposite directions are joined 
together by hydrogen bonds between complementary bases: A with T, and G with C (Fig. 
1.1c). In the cell, the DNA double-strand mainly exists in right-handed helix structure (Fig. 
1.1d). 
 
Figure 1.1 The building blocks of DNA. 
From reference [1] with permission from Garland Science - Books) 
The nucleotide is formed from a phosphate group, a deoxyribose sugar and a nitrogen-
containing base (a). Successive nucleotides are linked by phosphodiester bonds to form a 
DNA strand (b). Adjacent DNA-strands are joined by hydrogen bonds between 
complementary bases to form a DNA double-strand (c). In the cell, the DNA double-strand is 
present as a helix structure (d). 
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The discovery of the DNA double-strand by James Watson and Francis Crick in 1953 [2] was 
indeed a major advance in the field of science. This discovery gave scientists a vital clue on 
how the DNA carries genetic information and how this information is transmitted between 
generations. But, the idea that a very long DNA double-strand can fit into a tiny microscopic 
cell nucleus and still be accessible for gene-regulatory processes is extremely fascinating. 
Just to illustrate the extent of packaging- the total length of the DNA double-strand in a single 
human cell is approximately 2 meters; and it is believed that the human body is comprised of 
tens of trillions of cells that contain this length of DNA. So, if the entire DNA sequence in all 
the cells were to be stretched end-to-end, it would extend to tens of billions of kilometers. 
Instead, the DNA sequence in each cell is condensed by about 10,000-fold and marvelously 
fit into a nucleus that is only about 10µm wide. The DNA undergoes various layers of 
organizations to achieve such high level of packaging.  
The first level of DNA packaging involves the wrapping of the DNA double-strand around a 
complex of proteins known as histones [3, 4]. These proteins are highly basic and contain 
multiple positively charged amino acid residues that form electrostatic interactions with the 
negatively charged phosphate group of the DNA backbone. Approximately 147 base-pairs 
(bps) of DNA sequences are wrapped almost twice around the histone complex to form a 
bead-like structure called the nucleosome core particle (NCP) [5] (see Fig. 1.2). This 
structure was first elucidated by electron microcopy in the mid-1970s [6]. The packaging of 
DNA into nucleosomes shortens the long, linear double-strand sequence by about seven-fold. 
Adjacent nucleosomes are then joined together by linker DNA sequences (approximately 10 
to 80 bps) to form an 11 nm beads-on-a-string like structure, where the beads represent 
nucleosomes and the string represents the linker DNA. In the next level of DNA packaging, 
arrays of nucleosome cores condense into a 30 nm higher-order chromatin fiber [7]. This is 
achieved through a complex DNA folding processes that involve histone H1 and several non-
histone proteins [8, 9].. Histone H1, also known as linker histone, binds to the entry and exit 
sites of the linker DNA sequence of the NCP.  
The chromatin fiber is further compacted into different layers of higher order chromosomal 
domains. The two major chromosome structural domains are euchromatin and 
heterochromatin [9]. The euchromatin is structurally less condensed and contains a higher 
proportion of genes that are transcriptionally active. In contrast, the heterochromatin region is 
highly condensed and genes located in this region are generally less accessible for 
transcription. The heterochromatin is further classified into two broad structural domains. 
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The first type, which is called constitutive heterochromatin, is found in all cell types and 
comprises genes that are generally permanently inactivated [10]. This type of 
heterochromatin is mainly found near chromosomal regions that contain highly repetitive 
DNA sequences, such as centromeres and telomeres. The second type, facultative 
heterochromatin, refers to regions of the chromosome that are temporarily condensed [11]. 
Most inactive euchromatic genes exist in this form of heterochromatin.  
 
Figure 1.2 Overview of eukaryotic DNA packaging. 
From reference [12] with permission from Nature Publishing Group. 
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1.2.  Histones  
Extensive research in the composition of the cell nuclei resumed in the late 1860s when 
Friedrich Miescher first isolated the “nuclein” (now called DNA) from human white blood 
cells [13]. He later extended his research to other cell types such as salmon spermatocytes, 
and found the DNA bound to a basic molecule, which he named “protamin”. Together, the 
DNA-protamin complex amounted to almost the entire mass of the sperm head. Meanwhile, 
Miescher was deeply interested in the DNA component and paid little attention to the 
protamin. Later in 1884, Albrecht Kossel isolated DNA-bound proteins from the nuclei of 
avian red blood cells [14, 15]. He found major similarities between the proteins and 
Miescher’s protamine. He named the proteins ‘histones’. Kossel later attempted to examine 
the physical and chemical features that distinguish histones from protamins and other nuclear 
proteins. In this respect he found that histones exist in complex with nucleic acids and, are 
highly basic in nature. Moreover, by exploiting the basic property of histones Kossel 
described the first protocol for acid-extraction of histones from the cell nuclei. Kossel 
received the Nobel Prize in Physiology or Medicine in 1910 for his major contribution in the 
discovery of the chemical compositions of the cell nucleus.  
However, it wasn’t until the late 1950s that researchers began to investigate the different 
classes of histone found in eukaryotic cells. Extensive purification and characterization of 
histones in calf thymus and pea seedlings revealed five major classes: Histones H1, H2A, 
H2B, H3 and H4 [16, 17]. Histones H2A, H2B, H3 and H4 (collectively known as core 
histones) form the nucleosomal core around which the DNA is wrapped, whereas H1 acts as a 
scaffold protein for the linker DNA [18]. Early chemical cross-linking experiments showed 
that the nucleosome consists of two copies of each core histone assembled into an octameric 
structure [19]. Moreover, primary sequence analyses showed that histones contain highly 
basic N-terminal sequences and C-terminal fold domains that include amino acid 
distributions characteristic of globular proteins [20]. 
1.2.1. Histone variants 
Each class of histone described in the previous section, except histone H4, has a number of 
primary sequence variants. A total of 55 histone variants have been reported in humans 
(Appendix A, Table S1.1) [21]. Histone H3, for instance, is present in six different variants: 
H3.1, H3.1t, H3.2, H3.3, H3.3C, and CenH3 (see Fig. 1.3). The first five variants share about 
90% amino acid sequence similarity. The CenH3, also known as CENP-A, has longer N-
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terminal domain and less than 50% amino acid sequence similarity with the other five 
variant.  
The canonical histone H3.1 differs from H3.2 and H3.3 by one and five amino acid residues, 
respectively. In H3.1, the residue at position 96 is cysteine, where as in H3.2 and H3.3 the 
cysteine is replaced by serine (highlighted by a blue box in Fig.1.3). The other four residues 
of H3.1 that differ from H3.3 are alanine, serine, valine and methionine located at positions 
31, 87, 89 and 90 (highlighted by a red boxes in Fig.1.3), respectively. Histones H2A and 
H2B have the largest number of variants, each with at least nineteen variants.  
 
Figure 1.3 Sequence alignment of human histone H3 variants. 
(Sequence alignment prepared using the ‘align’ program at http://www.uniprot.org/) 
 
Histone variants play an important role in marking and organizing the nucleosome in 
specialized regions of the chromatin. For instance, CenH3 (also known as CENP-A) is 
incorporated specifically into nucleosomes at the centromere [22], a specialized region on a 
chromosome where two sister chromatids are linked. On the other hand, histones H3.1/H3.2 
and H3.3 mediate distinct nucleosome assembly pathways. In vitro nucleosome assembly 
assays show that deposition of H3.1/H3.2 into the nucleosomes is coupled with DNA-
replication processes, whereas H3.3 deposition takes place independent of DNA replication 
[23]. In accordance with this, studies show that the synthesis of H3.1/H3.2 is highly elevated 
during DNA replication in the S phase of the cell cycle, whereas the H3.3 variant is expressed 
at all stages of the cell cycle [24-26].  
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Histone H2A variants are also implicated in several DNA-associated process including DNA 
damage response, X chromosome inactivation and transcriptional regulation [27-29].  Histone 
H2A.Bbd has less than 50% amino acid sequence identity with the canonical H2A. It is 
believed to promote destabilization of the nucleosome core in mammals [30]. Histone H2A.X 
is highly linked to DNA damage response (DDR) pathways [31]. It is rapidly phosphorylated 
at Ser 139 (in humans) or Ser 129 (in budding yeast) following DNA damage response. The 
phosphorylated H2A.X is commonly referred to as ɣ-H2A.X. Accumulation of ɣ-H2A.X at 
DNA damage sites serves as a mark for the recruitment of several DNA repair protein 
complexes [32]. Recently, histone H2A.Z was also shown to have a role in DNA strand break 
(DSB) repair [33]. It facilitates this process by creating an open chromatin structure at the 
DSB site. On the other hand, despite the crucial role of histone H2B in chromatin formation, 
the functions of its variants remain highly understudied.  
1.2.2. The structure of core histones 
1.2.2.1. Primary and secondary structures 
Although histones were discovered more than a century ago, analysis of their primary and 
higher order structure did not begin until the late 1950s. Meanwhile, significant advances 
were made in developing analytical strategies for the isolation and fractionation of histones 
from different types of cells [16]. These strategies had enabled investigators to carry out 
fundamental structural analysis of the core histones. Initial studies were focused on 
determining the primary sequences of histones. In this regard, histone H4 was the first histone 
for which the complete amino acid sequence was determined [34, 35]. Sequencing of tryptic 
peptides generated from calf thymus or pea seedling histone H4 gave rise to a total of 102 
amino acid residues. The N-terminal region of H4 was found to be highly rich in positively 
charged amino acids such as arginine and lysine, suggesting a potential binding site for the 
DNA phosphate group. Histone H3 is the second histone for which a complete sequence was 
reported [36]. Sequencing of calf thymus H3 peptides generated by trypsin, chymotrypsin and 
cyanogen bromide digestion identified a total of 135 amino acid residues. Similar to histone 
H4, the N-terminal region of H3 contained numerous arginine and lysine residues. Moreover, 
histone H3 had two cysteine residues which are absent in histone H4. The complete primary 
sequences of histones H2A and H2B were also determined around the same period. Both 
histones comprised highly basic N-terminal region and a hydrophobic C-terminal domain. 
The primary sequences of the four core histones are highly conserved across eukaryotes, 
23 
 
 
 
suggesting a similar role for all. The sequence alignment for canonical histone H3 and 
histone H4 in five different species is illustrated in Appendix A, Figure S1.1.            
Soon after sequence analyses of the core histones, researchers began a thorough investigation 
into how the individual histones are assembled into an octameric structure. A number of 
biochemical and structural analyses revealed a pairwise association between core histones 
[37, 38]. Equimolar mixtures of calf thymus H3 and H4 form a very stable (H3-H4)2 tetramer 
at high salt concentrations (~ 2M NaCl). Moreover, CD (circular dichroism) spectra analyses 
showed increased α-helical properties of the tetrameric structure compared to the individual 
histones. Similarly, fluorescence anisotropy and CD measurements indicated that histones 
H2A and H2B form a stable H2A-H2B dimer in high salt solutions [39]. Formation of the 
dimer increases the α-helical content of the H2A-H2B by about 15 residues compared to the 
individual histones. Moreover, CD spectra analyses of trypsin-digested chromatin showed 
increased secondary structure properties at the less basic (or C-terminal) regions of histones 
H2A and H2B [40].  
The discovery of the tetrameric (H3-H4)2 and dimeric H2A-H2B structures led to the 
formulation of the first model for chromatin structure. As such, the chromatin repeating unit 
(or the nucleosome) is comprised of one (H3-H4)2 tetramer and two H2A-H2B dimers 
assembled into an octamer and approximately 200 base-pairs of DNA. These structural 
features were later tested by several research groups and were found to agree substantially 
with the proposed model [18, 19, 41, 42]. At high salt concentrations, the histone octamer 
complex is highly stable even in the absence of the nucleosomal DNA or chemical cross-
linking reagents. Meanwhile at physiological salt concentrations the octamer dissociates into 
one (H3-H4)2 tetramer and two H2A-H2B dimers. These key physical properties were 
fundamental to the successful crystallization of the histone octamer in subsequent structural 
studies.   
1.2.2.2. Higher order structures 
By the late 1970s it was generally accepted that the core of the nucleosome structure is 
comprised of a histone octamer assembled from two copies of each core histone. Meanwhile, 
the physical association between the histones in the octameric complex was not fully 
understood. An early study by Eickbush et al. [42] suggested that the octamer is held together 
by two types of protein-protein interactions. The first type involves hydrophobic interactions 
which hold together the individual subunits of the tetrameric (H3-H4)2 and dimeric H2A-
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H2B structures. The second type involves weak interactions that promote the association 
between one H3-H4 tetramer and two H2A-H2B dimers to form an octamer. The later type 
mainly involves hydrogen bond interactions between specific regions of the tetrameric and 
dimeric subunits. Nonetheless, these interactions were first proposed based solely on results 
obtained from studying the effects of temperature, urea, and pH titration on the dissociation 
of the octamer and hence, further structure analysis of the octamer was needed. 
Initially, researchers were investigating low resolution structures of the histone octamers 
using techniques such as neutron and x-ray diffraction, and electron microscopy [43-47]. 
These studies revealed the disc-like shape of the octamer and the left handed DNA superhelix 
wrapped around the octamer (Fig.s 1.4a-b). Moreover, it was shown that the arrangement of 
histones in the octamer involves two H2A-H2B dimers flanked by one centrally located (H3-
H4)2 tetramer. Meanwhile, due to the low resolution of these models accurate assessment of 
the secondary and tertiary structures of the individual histones could not be achieved. A more 
defined structure of the octamer was later determined by X-ray crystallography at 3.1 Å 
resolution [48]. In addition to the previously described features, the new model revealed three 
dimensional structural motifs (which are now called the histone fold) in each of the core 
histones. The motifs were later confirmed by high resolution X-ray crystallography analysis 
(Fig. 1.4c)  of Xenopus laevis and human nucleosome core particles solved at 2.8 [49] and 2.5 
Å [50], respectively.    
 
Figure 1.4 Three dimensional structural models of the histone octamer/NCP  
 From references  [43, 50] with permission from Nature Publishing Group and Oxford 
University Press, respectively. (models a & b published in 1980 and c in 2005). 
(a) A 3D model of the octamer reconstructed from an electron micrograph. (b) A model 
showing the left handed supercoiling of the DNA around the octamer. (c) A ribbon model 
(top panel) and an axial view (bottom panel) of a 2.5Å crystal structure of the human NCP. 
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Although the four core histones have very low sequence homology, they all share the histone 
fold motif. This motif is characterized by a long central helix flanked on either side by a loop 
and a short helix (Fig. 1.5a). The histones H3 and H4 form two pairs of heterodimers (H3-H4 
and H3’-H4’) mainly through the interaction of their central helices (Fig. 1.5b, left panel). 
The heterodimers are further assembled into a (H3-H4)2 tetramer through hydrogen bonding 
and weak interactions of the central helices, C-terminal helices, and the loops (Fig. 1.5c). The 
two H4 molecules (H4-H4’) comprising the histone octamer are aligned side by side in 
opposite directions (Fig. 1.5c). In contrast, the two H3 molecules in the homodimer H3-H3’ 
are arranged in head-to-tail or ‘handshake’ motif (Fig. 1.5c). In the same way, the H2A and 
H2B histone folds are joined together through several interactions to form the two H2A-H2B 
dimers (Fig. 1.5b, right panel). These dimers, however, do not form tetrameric structures. 
Instead, they each are linked to the (H3-H4)2 tetramer through the interaction of multiple 
residues of H2B and H4. Histone H2B residues E73 and R90 form hydrogen bonds with 
histone H4 residues R92 and E90, respectively. These hydrogen bonds and several other 
hydrophobic interactions promote the formation of the histone octamer (Fig. 1.5d).  
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Figure 1.5 The individual core histones assemble into a histone octamer.  
A representation of (a) the helix-loop-helix-loop structural motif of histones H3, H4, H2A 
and H2B; (b) the structure of H3-H4 (left panel) and H2A-H2B (right panel) heterodimers; 
(c) (H3-H4)2 tetrameric structure; (d) the histone octamer assembled from the (H3-H4)2 
tetramer and the H2A-H2B dimer. (The figures were adapted from Wikimedia Commons- 
https://commons.wikimedia.org, and prepared using The Pymol Molecular Graphics System, 
Version 1.2r 1, based on the crystal structure of Xenopus laevis nucleosome core particle 
(PDB entry 1AO1).   
 
The histone fold domains contact the DNA superhelix chain at a number of sites. One of the 
primary contact sites involves the N-terminal tail region of the core histones [49, 51]. This 
region is highly flexible and as a result it produces weak electron density in X-ray diffraction 
experiments. A segment of about eight and five amino acids lengths of histones H2B and H3 
tails, respectively, pass through the DNA superhelix minor groove channel. The side-chain of 
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these amino acids is involved in stabilizing the histone-DNA interactions by forming a 
hydrogen bond with the DNA phosphate group or by creating favorable positively charged 
density inside the superhelix channel. Another major histone-DNA contact site involves the 
amino acid side-chain of the α-helices. In this regard, a number of arginine side-chains in the 
histone fold were shown to interact with the DNA superhelix. Some of these arginines are 
H2A-R42, R77; H2B-R30, H3-R49, R63, R83; and H4-R48. Other residues are also involved 
in stabilizing the histone-DNA interactions. For example, the side-chains of two proline 
residues in the histone fold (H3-P66 and H4-P32) interact with the DNA deoxyribose moiety.  
1.2.3. Histone post-translational modifications  
Post-translational modifications (PTMs) are covalent modifications that occur at distinct 
amino acid residues in a protein [52]. Most PTMs are mediated by enzymatic activities. They 
are present in cellular proteins of various prokaryotic and eukaryotic organisms, ranging from 
bacteria to humans. PTMs play versatile roles in several cellular processes including the cell 
cycle, gene regulation, signal transduction, and protein-protein interactions [53-56]. Some of 
the most common protein modifications include acetylation, methylation, ubiquitination of 
lysine residues; and phosphorylation of serine, threonine or tyrosine residues. A protein can 
be post-translationally modified at one or more sites. When a PTM occurs on different sites 
of the same protein it creates several versions of that protein. Such proteins are referred to as 
PTM-isoforms.  
While it is known that there are only four types of core histones in humans, extensive 
biochemical and mass spectrometry analyses have identified a number of PTM-isoforms of 
each type. The core histones possess multiple lysine residues on their N-terminal tail. These 
lysines are subject to a wide variety of modifications including acetylation, methylation, 
ubiquitination, butyrylation, crotonylation, and many other modifications [57]. In addition to 
lysines, the histone tails possess multiple arginine residues that are subject to modifications 
such as mono- and di-methylation, and citrullination. Phosphorylation of serine, threonine 
and tyrosine residues was also reported. Among the four core histones, H3 is by far the most 
modified. Almost all of the above PTMs have been identified in various combinations on H3.  
Most histone PTMs carry out their function in a combinatorial fashion although there are 
cases where individual histone PTMs have been shown to have important roles. One of the 
mechanisms by which combinatorial functions are achieved involves histone PTM 
‘crosstalk’, whereby the addition or removal of a PTM at a specific site affects the 
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maintenance of other neighboring PTMs. In the following subsections I will briefly introduce 
two of the most characterized histone PTMs - acetylation and methylation of lysine residues.  
1.2.3.1. Acetylation  
Acetylation is one of the most widely studied histone PTMs. This modification is established 
by the addition of an acetyl group to the ε-amino group of lysine residues, a process catalyzed 
by a group of enzymes known as histone acetyltransferases (HATs) [58]. In this reaction, a 
conserved glutamate residue (Glu) of the HAT activates the ε-amino group  of lysine for 
nucleophilic attack on the carbonyl moiety of acetyl-coenzyme A (CoA-SH) which acts as an 
acetyl donor (Fig. 1.6) [59]. The reverse reaction is catalyzed by histone deacetylases 
(HDAC) enzymes. The two groups of enzymes (HATs and HDACs) will be discussed in 
detail in sections 1.2.5.1 and 1.2.5.2. 
Histone acetylation has been extensively studied in many eukaryotic organisms. Most of the 
identified acetylation sites are conserved from yeast to humans, suggesting a crucial role of 
the modifications in each species. Several studies have shown the role of histone acetylation 
in modulating important DNA-associated processes including replication, transcription, gene 
regulation and the DNA double-strand break (DSB) repair [60, 61].  
 
Figure 1.6 Mechanism of lysine acetylation by HATs. 
Adapted from reference [59] with permission from the American Society for Biochemistry 
and Molecular Biology. 
 
Previous comprehensive mass spectrometry-based analyses have identified over twenty 
acetylation sites on the four core histones in human cells. Some of the known acetylation sites 
are shown in Figure 1.7a-b. The majority of these acetylations are found on the N-terminal 
tails, yet a small number of acetylations are also located in the histone fold domain, for 
example H3K64ac and H4K91ac.  
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Figure 1.7 Known histone acetylation sites. 
(a) An illustration of the N-terminal tails of core histones and sites of acetylation; (b) lists of 
known histone acetylation and methylation sites, labeled ‘ac’, and ‘me’, respectively. Figures 
prepared using Adobe® Illustrator® CS6, version 16.0.0. 
 
Histone acetylation is involved in the modulation of diverse chromatin-associated processes. 
For instance, acetylation of lysine 16 of H4 was shown to inhibit chromatin condensation and 
formation of higher order chromatin fiber [62]. Histone acetylation is also associated with 
transcriptional activity [63], although the mechanism underlying this association is still not 
fully elucidated. One of the proposed mechanisms by which histone acetylation could 
facilitate transcription is via disruption of the histone-DNA interactions [64]. According to 
this model, acetylation neutralizes the electrostatic interactions between the positively 
charged Ɛ-amino group of lysines and the negatively charged phosphate group of DNA, 
thereby increasing the accessibility of DNA for transcriptional machineries.  
In an alternative model, increasing evidences suggest that histone acetylation may mediate 
transcription by acting as docking platforms for recruitment of chromatin-modifying 
complexes [65, 66]. This model is supported by the findings that chromatin regulators often 
recruit specific HATs or HDACs to promoter and transcription start sites of actively 
transcribing genes [67]. This has been observed in budding yeast where CHIP-ChIP assays 
showed elevated levels of acetylated histones in the vicinity of active genes; sites where 
HATs Gcn5 and Esa1 were also found to be recruited [68]. This study found a genome wide 
increase in acetylation of Gcn5 target sites H3K9 and H3K14, and Esa1 target sites H4K5ac, 
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H4K8ac, H4K12ac and H4K16ac. These modifications were found to also correlate with 
transcriptional rates genome-wide, suggesting the association between histone acetylation and 
transcriptional activity. Similar observations were made in humans [69]. ChIP-seq analysis of 
histone modifications in human CD4
+
 T cells showed elevated levels of H2BK12ac, 
H2BK20ac, H2BK120ac, H3K4ac, H4K5ac, H4K8ac, H4K12ac and H4K16ac in the 
promoter and transcription start sites of active genes, whereas the PTMs H2AK9ac, 
H2BK5ac, H3K9ac, H3K18ac, H3K27ac, H3K36ac, H4K91ac were mainly identified at 
regions surrounding the transcription start sites. It is not known whether these combinatorial 
acetylation patterns have distinct functions, or whether they simply reflect differences in the 
specificity of HATs recruited at various stages of transcription. It should be noted that 
transcriptional activation does not always result in increased histone acetylation. Previous 
studies in budding yeast have shown a dramatic decrease in histone H4 acetylation at target 
promoter regions upon activation by specific gene regulators [70]. 
1.2.3.2. Methylation 
Histone methylation is catalyzed by a group of enzymes known as histone methyltransferases 
(HMTs) [71, 72]. The general mechanism of lysine methylation whereby an HMT catalyzes 
the transfer of a methyl group from the cofactor S-adenosylmethionine (SAM) to the ε-amino 
group of a specific lysine residue is illustrated in Figure 1.8. Lysine residues can be mono-, 
di-, or tri-methylated by accepting one, two or three methyl groups on their side chain. Unlike 
acetylation, however, methylation of lysines does not alter the overall charge state of 
histones. Some of the known methylation sites on the four core histones are shown in Figure 
1.7b (labeled ‘me’). Majority of the methylation sites reside in the N-terminal tail. Histone 
H3 is by far the most methylated core histone, with abundant methylation detected at lysines 
4, 9, 27, 36, and 79. The biological role of histone methylation has been implicated in several 
DNA-associated processes including transcription, gene silencing, and chromatin 
condensation [73, 74]. Histone arginine residues are also known to be mono- or di-
methylated, which serve important roles in epigenetic regulation of various genes [75, 76]. 
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Figure 1.8 Mechanism of lysine methylation by HMTs. 
From reference [77] with permission from Nature Publishing Group. 
 
Histone methylation can be associated with transcriptional activation or repression depending 
on the site and level of modification. Increased level of H3K4me3 was found at highly active 
genes, whereas H3K4me1 and H3K4m2 were found at intermediately active group of genes.  
[78-80]. In contrast, the levels of H3K9me2, H3K9me3, H3K27me2, H3K27me3, and 
H4K20me3 are highly associated with repressed or silent genes [80-83]. In contrast, however, 
H3K9me1, H3K27me1 and H4K20me1 are enriched at promoter regions of active genes. In a 
recent report it was shown that non-nucleosomal histone H3 in budding yeast contains high 
levels of H3K9me1, but is devoid of H3K9me2 or H3K9me3 [84], suggesting that this 
modification may not have a major role in transcriptional regulation. On the other hand, 
H3K36me3 and H3K79me3 are found abundantly at active regions, whereas H3K36me1 and 
H3K79me1 did not show any major preference toward either active or silent regions.   
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1.2.4. Combinatorial histone PTMs  
Although histone PTMs correlate with various transcriptional states of genes, their precise 
mechanism of action is still not fully understood. As illustrated in Figure 1.9, a diverse array 
of closely-spaced PTMs co-exists on a short segment of the N-terminal tail of histones. While 
there are few instances where a specific PTM is associated with distinct cellular function 
[85], the majority of studies suggest that histone PTMs exert their function through 
combinatorial patterns [86-88]. For example, synergic interplay between H3S10ph and 
H3K14ac was shown to serve a major role in marking mammalian epidermal growth factor 
stimulation [89]. In another study, phosphorylation at H3S10 was shown to induce increased 
acetylation of H3K14 by the HAT Gcn5 both in vitro and in vivo [90], suggesting a strong 
functional relationship between the two modifications.  
 
Figure 1.9 Histone tail modifications. 
Adapted from reference [91] with permission from Nature Publishing Group). 
Legends: acetylation (A, blue), methylation (M, red), phosphorylation (P, yellow) and 
ubiquitination (U, green). 
 
Functional interactions between PTMs of different core histones have also been identified in 
budding yeast. It was shown that mono-ubiquitination of H2BK123 by Rad6 acts as a signal 
for activation of methylation of H3K4 by HMT complex known as COMPASS, a process 
termed as ‘trans-tail’ regulation of histone modifications [90]. In agreement with this 
observation, S. cerevisiae cells with H2B-K123R mutation lacked H3K4 methylation, 
whereas H2BK123 mono-ubiquitination was not affected in H3-K4R mutants [92]. 
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Moreover, these studies showed that activation of H3K4 methylation via H2BK123 mono-
ubiquitination is functionally linked with transcriptional silencing at telomere regions. The 
same type of PTM interactions has been recently identified in human cells [93]. 
Crosstalk between two different PTMs of the same residue has also been reported. Recently, 
it was shown that H3K4 methylation regulates the global level of H3K4 acetylation in 
budding yeast [94]. Deletion of specific subunits of COMPASS, the complex responsible for 
methylating H3K4, resulted in elevated level of H3K4ac. However, strains lacking Gcn5 or 
Gcn5/Rtt109, the HAT responsible for H3K4 acetylation, did not affect the level of H3K4 
mono-, di- or tri-methylation. According to these results, the global abundances of H3K4me, 
particularly H3K4me2 and H3K4me3, affected the level of H3K4ac, whereas the converse 
was not true. These modifications are mutually exclusive and are enriched at promoter 
regions of actively transcribing genes with H3K4ac located upstream of H3K4me. 
The different types of crosstalk described above represent few examples of how histone 
PTMs could act synergistically or in combination to regulate distinct cellular events. It was 
previously postulated that these type of PTM interactions form a ‘histone code’ [95]. 
According to this hypothesis, first, a histone code is established through a series of addition 
and removal of PTMs by histone modifying enzymes such as HATs, HMTs and HDACs. 
Second, the code is interpreted into meaningful biological outcome. The later process is 
facilitated by protein modules that can specifically recognize or ‘read’ a particular type of 
PTM or combination of PTMs on histones [65]. Some of the most common ‘reader’ modules 
are listed in Table 1.1.  
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Table 1.1  Histone PTM readers. 
From reference [65] with permission from Nature Publishing Group 
 
Bromodomains (BRDs) are protein domains that recognize acetylated lysines in histones and 
non-histone proteins [96]. In humans, a total of 46 BRD-containing proteins have been 
identified, representing various types of transcriptional co-regulators and chromatin 
modifying enzymes [97]. Some of these proteins possess multiple BRDs; for example, the 
transcription co-activator TAF1 contains double BRDs; also the yeast chromatin remodeling 
protein Rsc4 contains tandem BRDs. Bromodomains can recognize a single or combinations 
of acetylated lysines in histones. The Rsc4 tandem BRDs, for example, bind to acetylated 
H3K14 [98]. TAF1 (also denoted as TAFII250) have two adjacent bromodomains that 
efficiently recognize di-acetylated histone H4 [99]. In vitro peptide binding assays revealed 
that TAF1 bromodomains have stronger affinity for the di-acetylation mark H4K5_12ac (Kd 
= 1.4 µM) compared to H4K8_16ac (Kd = 5.6 µM), H4K5_8_12_16ac (Kd = 5.3 µM) and 
H4K16ac (Kd = 39 µM), and no binding affinity for the non-acetylated counterpart. These 
results are, however, inconclusive as the binding assays were conducted with only limited 
combinations of acetylated lysines derived from the N-terminal tail of H4.  
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The Bromodomain and ExtraTerminal (BET) family members Brd2, Brd3 and Brd4 and Brdt 
are additional examples of proteins that recognize multiply acetylated lysines [100, 101]. 
Recently, isothermal calorimetric analysis of the interactions between Brdt and acetylated 
histone peptides showed that Brdt recognizes tetra-acetylated H4 peptide H4K5_8_12_16ac 
with a Kd value of 11.4 µM [102]. This study also showed that Brdt interacts with multiply 
acetylated peptides through the binding pocket of only one of its two bromodomains, 
suggesting a combinatorial binding property of bromodomains.  
On the other hand, unlike acetylated lysines, methylated lysines can be ‘read’ by more than 
one type of protein module including chromodomains, PHD fingers, and MBT proteins 
(Table 1.1). One of the well-characterized chromodomain-containing proteins is HP1 
(heterochromatin-associated protein 1). Analysis of HP1-peptide binding affinity using ITC 
(isothermal titration calorimetry) showed that it interacts with the histone marks H3K9me3 
(Kd = 2.5 µM) and H3K9me2 (Kd = 7 µM), but had no detectable affinity for the non-
methylated counterpart [103]. Meanwhile, it has been shown that HP1 binding to H3K9me is 
diminished in the presence of phosphorylated H3S10 [104]. In addition, methylation of H3K9 
was inhibited in peptides containing phosphorylated H3S10. These results suggest a negative 
correlation between HP1 binding or H3K9 methylation and H3S10 phosphorylation.  
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1.2.5. Histone modifiers - ‘Writers’ and ‘Erasers’ 
Histone modifications are generally mediated by two opposing groups of enzymes, namely 
‘writers’ and ‘erasers’. The ‘writers’ are enzymes such as HATs, HMTs and kinases that 
modify histones by inserting respectively acetyl, methyl and phospho groups on specific 
residues. The ‘erasers’ are enzymes such as HDACs, histone demethylases (HDMTs) and 
phosphatases that reverse the activities of the ‘writers’ by removing the corresponding PTMs. 
Shown in Figure 1.10a is a schematic representation of the opposing activity of writers and 
erasers.  
 
Figure 1.10 Schematic showing the reciprocal activities of ‘writers’ and ‘erasers’.  
(a) The 'writing' and 'erasing' of histone PTMs. (c) The opposing activity of HATs and 
HDACs toward histone lysine residues. (ac-acetyl, me-methyl, ph-phospho). Figures 
prepared using Adobe® Illustrator® CS6, version 16.0.0. 
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1.2.5.1. HATs 
HATs catalyze the transfer of an acetyl moiety from acetyl-CoA to the amino group of 
histone lysine residues (Fig. 1.10b). Their activity toward histones neutralizes the 
electrostatic interaction between the positively charged amino-group of lysines and the 
negatively charged phosphate group of the DNA. This process relaxes the nucleosomal DNA 
and increases its accessibility for transcription. HATs function in a variety of DNA-
associated processes [105]. Several genome-wide analyses have shown that a large proportion 
of acetylation marks and the HATs that installs them are localized at promoter and enhancer 
regions of highly expressed genes [106-108]. They are recruited to these regions via 
interactions with specific activator proteins [67, 109, 110]. For example, in budding yeast, the 
HATs Gcn5 and Esa1 were found to be recruited to the promoter regions of active genes, 
leading to elevated levels of  acetylation at Gcn5 target sites- H3K9 and K14, and Esa1 target 
sites- H4K5, H4K8, H4K12 and K16 [111]. These observations suggested a strong 
correlation between HATs activity and transcriptional activation. In addition to histones, 
HATs also catalyze the acetylation of several non-histone proteins [112, 113]. 
Based on their catalytic domains and sequence homology, eukaryotic HATs are grouped into 
three major families [114, 115]: i) Gcn5-related N-acetyltransferases (GNATs), named after 
the founding member Gcn5; ii) the MYST family HATs, named for the founding members of 
this family: MOZ, Ybf2, Sas2 and Tip60; and iii) CBP/P300. Members of each family share 
high amino acid sequence similarity. For instance, CBP vs. P300, GCN5 vs. PCAF, MOZ vs. 
MORF, and TIP60 vs. MOF share respectively 87%, 89%, 87% and 65% sequence similarity 
[116]. The HATs Rtt109 (found in yeast) and HAT1 (found in most eukaryotes) also catalyze 
histone acetylation in specialized DNA-associated processes, but they share very low 
sequence homology with the three HAT families or with each other. TAF1, one of the 
components of the transcription factor TFIID, also exhibits acetyltransferase activity toward 
histones H3 and H4, and is required in transcriptional activation of genes.  Table 1.2 shows 
the conservation of the different HATs between species.   
 
 
 
 
38 
 
 
 
Table 1.2 Conservation of HATs between species and phyla. 
Adapted from reference [116], Caister Academic Press., 2011 
 
1.2.5.2. HDACs 
HDACs catalyze the deacetylation of histone lysine residues (Fig. 1.10b).  Their activity is 
historically associated with transcriptional repression and heterochromatin formation because 
the removal of acetylation marks from histones often leads to condensed chromatin structure. 
A number of HDACs are present in association with multiple protein transcription 
corepressor complexes [117]. One example is the Sin3 corepressor which was found in 
complex with the HDAC Rpd3 in S. cerevisiae [118] and HDAC1/2 in humans [119]. Most 
HDAC complexes do not directly bind to nucleosomal DNA; instead they are targeted to 
specific genomic loci via interaction with other DNA-binding proteins. For example, in S. 
cerevisiae, the Sin3/Rpd3 complex interacts with the DNA-binding protein called Ume6 to 
target the deacetylation of histone H4K5ac and repress transcription of the adjacent genes 
[120, 121]. The function of HDACs is also tightly coupled with dynamic changes in the 
levels of histone methylation. In addition to hypoacetylation, silenced genes and 
heterochromatin domains are characterized by high levels of H3K9 di- and tri-methylation. It 
could be that the deacetylation of lysine residues by HDACs serves as a prerequisite for 
establishing repressive histone methylation marks.   
Mammalian HDACs are classified into four major classes based on sequence similarity of 
their catalytic domain with the corresponding yeast HDACs [121-123]. These are:  Class I: 
HDAC-1, -2, -3 and -8; Class-II: HDAC-4, -5, -6, -7, -9 and -10; Class III: sirtuins or SIRT 
1–7; and Class IV: HDAC11. The Class I HDACs are mostly localized in the nucleus and are 
known to catalyze the deacetylation of histones and several non-histone proteins. In 
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comparison, the Class II HDACs are located in both the cytoplasm and nucleus. Their 
catalytic domain is located close to the C-terminus. Depending on the number of deacetylase 
domains they contain the Class II HDACs are divided in two subgroups, Class IIa and IIb; the 
latter has two deacetylase domains. HDACs Class I, II, and IV require the Zn
2+
 cofactor for 
their deacetylase activity. Class III HDACs are commonly referred to as sirtuins.  Their 
activity requires the cofactor known as nicotinamide adenine dinucleotide (NAD
+
). The 
different classes of mammalian HDACs and their yeast counterpart are summarized in Table 
1.3 below.  
 
Table 1.3  Classification of mammalian HDAC isotypes. 
 From reference [122] with permission from Elsevier. 
(N-nucleus, C-cytoplasm, M-mitochondia) 
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1.2.5.3. HDAC inhibitors – Emerging drugs for cancer therapy 
The balance between histone acetylation and deacetylation is crucial for the normal 
development of cells. Maintaining this balance requires continuous regulation of the 
interactions of HATs and HDACs with their target sites [124, 125]. Several gene deletion 
studies have shown that dysregulation of the acetylation equilibrium adversely affects 
numerous biological processes including DNA replication, transcription, and chromatin 
assembly [126-128]. While normal cells have dedicated control mechanisms that regulate the 
steady-state dynamic levels of acetylation of histones, as well as non-histone proteins, most 
cancer cells have been shown to possess altered global histone modifications [129-132]. For 
example, a global loss in H4K16ac was found to be a hallmark of human tumor cells [133]. 
The H4K16ac mark was previously shown to have a pivotal role in the regulation of the 
structure of chromatin and its functional interactions with chromatin assembly and 
remodeling factors [62]. The HAT known as MOF is responsible for acetylating H4K16 
[134], whereas the HDAC named SirT1, the orthologue of budding yeast Sir2, is responsible 
for deacetylating H4K16ac [135].  
Numerous studies have reported aberrations in HDAC activities in cancer cells. Increased 
expression of HDAC2 was found in human gastric cancer [136]. HDAC1 was shown to be 
upregulated in hormone refractory (HR) cancer and targets numerous transcription factors 
including the tumor suppressor protein p53 [137]. Increased recruitment of HDACs has also 
been associated with the pathogenesis of acute promyelocytic leukaemia [138]. These 
abnormalities in the recruitment and activities of HDACs in different types of cancers have 
made them strong therapeutic targets.  
As such, a great deal of effort has been made in the discovery and development of new drugs 
that have the potential to reverse the detrimental effects of aberrant HDAC activities. These 
drugs are collectively known as HDAC inhibitors (HDACis). So far, numerous HDACis have 
been discovered and tested for antitumor activity in either cultured cells or model organisms. 
However, only a few were approved or are being investigated at various levels of clinical 
trials. The HDACis are divided into five groups depending on their chemical structure, which 
are, hydroxamates, cyclic tetrapeptides, benzamides, aliphatic acids, and electrophilic ketones 
(see Table 1.4) [139, 140]. The hydroxamates exhibit strong inhibitory activity toward 
HDAC I, and II, and also IV in some cases. SAHA (also known as Vorinostat) was the first to 
be FDA-approved for the treatment of cutaneous T-cell lymphoma [141]. It induces global 
hyperacetylation of histones [142], represses telomerase activity in human lung 
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adenocarcinoma cells [143], and arrests the growth of  several types of cancer cells [144-
146]. Romidepsin (FK228), inhibitor of HDAC I and II, was also FDA-approved for 
treatment of cutaneous T-cell lymphoma [147]. Most recently, the FDA approved a new 
broad-spectrum HDACi called Panobinostat (Farydak) for the treatment of patients with 
multiple myeloma, a type of blood cancer [148]. Panobinostat belongs to the hydroxamate 
HDACi group and has been shown to have activity against HDACs Class I, II, and IV [149]. 
Despite these successes, the three FDA-approved HDACs described above are all pan-HDAC 
inhibitors, meaning that they act indiscriminately on several HDAC classes [150, 151]. In 
addition, these drugs have been shown to have major side effects both in the clinical and 
experimental settings due to their inability to discriminate between normal and cancerous 
cells [152-155]. Thus, target-specific HDAC inhibitors are much needed for a more efficient 
cancer treatment.  
 
 Table 1.4  HDACis currently under clinical trial or FDA-approved. 
 Adapted from from reference [139] 
 
ND – not determined, CT-clinical trial 
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1.3. Mass spectrometry-based proteomics in histone analysis 
Early studies involving histone modifications were conducted mainly using chemical 
approaches. For example, Phillips used a method known as hydrazinolysis to identify 
acetylation on the N-terminal amino group of histone proteins [156, 157]. In this method, first 
N-acetyl groups were derivatized through successive reactions with anhydrous hydrazine and 
1-fluoro-2,4-dinitrobenzene at pH 3. The final product from this reaction was acetic acid 2, 4-
dinitrophenylhydrazide, which changed its color from yellow to brown upon treatment with 
an alkaline solution. Confirmation of the presence of the N-acetyl group was made by a two-
dimensional chromatographic technique and by measuring the absorbance of the product and 
comparing it with the absorbance of a reference hydrazide derivative of acetic acid.  
Although this method enabled the detection of N-acetylated histones, it was not suitable for 
analysis of acetylations that were localized on the ε-amino group of lysine side chains (ε-N-
acetyl-lysine).  
Evidence showing the latter type of acetylation came from the work of Allfrey and colleagues 
[158, 159]. In order to identify acetylated lysines in histones, Allfrey and colleagues relied on 
radiolabeling techniques, where calf thymus nuclei were incubated in vitro with a 
14
C-
labelled sodium acetate. The labelled histones were fractionated and subjected to amino acid 
analysis to characterize and quantify their amino acid composition. The presence of 
acetylated lysines was confirmed based on the radioactivity of standard amino acid mixtures 
containing the reference compound, ε-N-acetyl-lysine. Alternatively, following digestion of 
the histones with trypsin (cleaves c-terminal to Arg or Lys amino acids) and Pronase (digests 
proteins to free amino acids), the peptides and amino acids were fractionated by exclusion 
chromatography and ion exchange chromatography. All radioactivity of the 
14
C-acetate-
labelled histones was recovered in one chromatographic peak identified as ε-N-acetyl-lysine. 
This method, however, was only able to detect abundant acetylations in histones H3 and H4.  
Following the discovery of histone lysine acetylation by Allfrey and colleagues, a number of 
subsequent studies demonstrated the mechanisms through which this PTM can modify 
chromatin structure and transcriptional activity [63, 160-163]. Among the major advances 
achieved during this period is the development of antibodies that can distinguish between 
acetylated and non-acetylated forms of histones [164, 165]. These antibodies mainly 
contributed to our current understanding of the role of histone PTMs in various biological 
processes. Pfeffer and colleagues developed an antibody specific for a tetra-acetylated H4 
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peptide (a.a 1-37) [165]. Their procedure involves two major steps: Preparation of acetylated 
histone peptides and assessment of site-specificity of the antibody. In the first step, Pfeffer 
and colleagues prepared the N-terminal H4 peptide (amino acids 1-37) by dissociating the 
intact histone H4 isolated from calf thymus nuclei. This peptide was subjected to 
hyperacetylation by in vitro chemical reaction with excess acetic anhydride. The acetylated 
peptides were then separated from the reaction mixture by exclusion chromatography. The 
extent of acetylation of the peptide was estimated from its reaction with a fluorophore reagent 
called fluorescamine under conditions which limit the reaction of the reagent with free amino 
groups. This preparative step yielded a large proportion of the tetra-acetylated form of the H4 
peptide. In the second step, Pfeffer and colleagues immunized a particular breed of rabbits 
with the tetra-acetylated peptides, which acted as antigens. Antiserum activity against the 
antigens was assessed using ELISA and further validated by peptide competition assays. 
Ideally, in addition to the ELISA and competition assays, the specificity of an antibody is 
also validated by assessing its activity toward mutant histones (e.g. histone H4 with Lys5 
mutated to Arg or Ala) expressed in model organisms such as yeast. The later approach 
provides a more precise verification of the specificity of the antibodies.  
The antibody-based approach is still a powerful tool in the chromatin field. Its applications 
are demonstrated in several traditional biochemical techniques including Western blot, ChIP, 
ChIP-DNA microarray (ChIP-on-chip), and immunofluorescence assays. Despite these 
achievements, however, the antibodies used in histone PTM analysis still suffer from several 
limitations. Site-specific antibody detection requires one specific antibody for each site that 
needs to be examined, and hence lacks the capability to detect co-occurring histone PTMs 
(e.g. H3-K9me3_K14ac). Recent findings show that antibodies exhibit promiscuity when two 
or more histone PTMs are placed too close together [87]. Many antibodies also lack the 
desired specificity to distinguish subtle differences in the chemical composition of PTMs 
(e.g. K9me2 and K9me3). In addition, antibodies are limited in their ability to determine 
PTM stoichiometries, which have proven valuable in monitoring PTM dynamics in various 
biological processes [166, 167]. 
Meanwhile, in the last decade, mass spectrometry (MS) has emerged as the most powerful 
analytical tool for identification and quantification of histone PTMs. Many high-throughput 
MS-based approaches have been developed for this purpose, and their combined effort has 
dramatically improved our understanding of the role histone PTMs play in various chromatin-
associated processes. Histone PTM analyses using MS have so far been performed in three 
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different approaches: bottom-up, middle-down and top-down (Fig. 1.11) [168, 169]. The 
most widely used procedure is the bottom-up approach. In this approach, histone proteins are 
derivatized using deuterated acetic anhydride or propionic anhydride, digested into smaller 
peptides (usually less than 30 amino acids) using trypsin and analyzed by reverse-phase (RP)-
LC-MS/MS. Identification of histone PTMs is achieved with the help of database search tools 
via peptide-spectrum matching processes [170, 171]. This approach is simple, straightforward 
and provides a relatively better quantification of site-specific changes in histone PTMs. 
However, the method is limited in terms of the length of peptide that can be analyzed and as a 
result long-range combinatorial PTMs and potential crosstalk between them cannot be 
investigated.  
In the middle-down approach, histone proteins are digested into relatively longer peptide 
segments (upto 50 amino acids length) using proteases such as Glu-C and Asp-N, and 
separated on hydrophilic or reverse-phase analytical columns and analyzed by ETD-MS/MS 
[169]. The application of ETD in this approach improves the dissociation of the large and 
highly charged peptides, thereby increasing the number of PTMs per peptide that can be 
investigated. One major advantage of the middle-down approach is that it enables 
identification of multiple co-existing PTMs on the N-terminal tails of histones. However, due 
to the complexity of the ETD-MS/MS spectra, site-specific quantification of the individual 
PTMs is very challenging. Several computational tools have so far been developed to aid the 
deconvolution of such MS/MS spectra [172] but they often require extensive manual 
validation. Unlike the two previous approaches, the top-down approach does not require 
digestion of histones into peptides; instead the intact protein is fragmented in the MS by 
ETD. One major advantage of this technique is that it allows investigation of combinatorial 
histone PTMs at the proteome level, which is perhaps the ideal way to study the role of 
histone PTMs on chromatin architecture. However, the full application of this technique still 
demands major improvements in the following three areas. First, just like the middle-down 
approach, fragmentation of the intact histones generates very complex and composite MS/MS 
spectra and there are only few computational tools that can deal with such spectra. Even, the 
existing tools require rigorous manual validation and often a complete fragmentation spectra 
is rarely achieved. Second, very poor separation of histones into individual proteoforms is 
achieved using currently available chromatographic technologies. For this reason, some 
investigators choose to directly infuse the intact protein into the MS without chromatographic 
separation. This approach, however, generates MS/MS spectra containing fragments of a 
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variety of proteoforms, which complicates the data analysis. Third, some of the most widely 
used mass spectrometers are better suited for analysis of smaller polypeptides (usually less 
than 5 KDa) and they have lower performances when it comes to larger polypeptides. In 
addition, a complete dissociation of the proteoforms using the available fragmentation 
techniques is so far not achievable.  
 
 
Figure 1.11 Bottom up, middle down, and top down MS approaches.  
From reference [169] with permission from John Wiley and Sons.  
WCX-HILIC: weak cation exchange hydrophilic interaction liquid chromatography 
RP-LC: Reverse phase liquid chromatography; ETD: Electron transfer dissociation; CID: 
Collision induced dissociation 
 
Despite their inherent limitations, the three aforementioned MS-based approaches have so far 
enabled the characterization of over fifteen different types of PTMs on the core histones [57]. 
The majority of these PTMs are localized on the unstructured N-terminal histone tails which 
extend outside the nucleosome core. Moreover, we can now investigate combinatorial PTM 
marks, as well as short- and long-range PTM crosstalk within the same histone molecule or 
even across different histones. These approaches offer several advantages over the traditional 
antibody-based analysis including good reproducibility, higher specificity, and ability to 
rapidly analyze numerous histone PTMs in a single LC-MS/MS experiment.  
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1.3.1. Basic steps in histone PTM analysis by mass spectrometry 
1.3.1.1. Proteolytic digestion  
Enzymes that cleave peptide bonds in proteins are called proteases [173]. Trypsin is the most 
commonly used enzyme for protein digestion in the bottom-up approach. It cleaves proteins 
on the C-terminal side of lysine or arginine residues, except when either amino acid is 
followed by proline or chemically modified. Trypsin has the advantage of high proteolytic 
specificity, wide sequence coverage and relatively lower auto-proteolysis (self-cleavage). It 
generates relatively short peptides, usually 5 to 30 amino acids long. Since histone proteins 
contain multiple arginine and lysine residues (20 to 25 %), their cleavage using trypsin 
generates peptides too short to be efficiently analyzed by MS. Moreover, tryptic digestion of 
histones produces varying lengths of heterogeneously modified peptides. A single lysine 
residue may end up being present in more than one type of tryptic peptide. This complicates 
the assignment and quantitation of histone PTMs. To circumvent these problems researchers 
have developed a chemical derivatization technique which helps to generate longer and more 
hydrophobic tryptic histone peptides. The derivatization of histones is commonly performed 
using a propionic anhydride ((CH₃CH₂CO)₂O) reagent which serves to transfer a propionyl 
group (CH₃CH₂CO-) to the ε-amino group of unmodified or mono-methylated lysine 
residues. This modification results in a shift in the mass of lysine residues by +56.02 Da. 
Moreover, propionylation of lysines effectively blocks the activity of trypsin at these sites, 
rendering peptides suitable for analysis by MS.  
Alternatively, peptides of longer lengths can be obtained using endoproteinases such as Asp-
N and Glu-C. Asp-N hydrolyzes peptide bonds mainly on the N-terminal side of aspartic 
acid, whereas Glu-C cleaves on the N-terminal side of mainly glutamic acid. Asp-N digestion 
of, for example, histone H4 generates an N-terminal peptide that is 23 amino acids long 
consisting of five internal lysines and one arginine residue (2-
GRGKGGKGLGKGGAKRHRKVLRD-24). On the other hand, Glu-C digestion of histone 
H3 generates an N-terminal peptide 49 amino acid long and consisting of eight lysines and 
seven arginine residues (2-ARTKQTARKSTGGKAPRKQLATKAARKSA PATGGVKKPH 
RYRPGTVALRE-50). These two proteases are widely used in studies involving the 
characterization of combinatorial histone modifications and long-range PTM crosstalk.  
However, the complexity of PTM isoforms generated from Asp-N or Glu-C digestion of 
histones presents a major challenge for PTM identification using the existing bioinformatics 
tools.  
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There are two major approaches of proteolytic digestion [173]: In-gel and in-solution 
digestions. In the former approach, histone proteins are first resolved by gel electrophoresis 
then stained using MS compatible reagents such as coomassie blue or silver staining reagent. 
Then the gel bands corresponding to the proteins of interest are excised and cut into small 
pieces for proteolytic digestion using trypsin [174]. The peptide digests are extracted from the 
gel bands using high concentrations of organic solvents such as methanol or acetonitrile. This 
approach is not widely used for histone analysis because digestion of histones using trypsin 
without derivatization of the unmodified and mono-methylated lysines results in peptides too 
short to be detected by MS. On the other hand, the derivatization of histones inside a gel band 
is relatively less efficient.  
In the later approach, the protease is directly added to the protein solution [175]. In typical 
large scale experiments, tryptic digestion is preceded by several steps including (1) protein 
denaturation using MS-compatible surfactants (e.g. urea, SDC (Sodium deoxycholate), 
ProteaseMAX) or by heating to open up globular proteins; (2) reduction using reagents such 
as DTT (dithiothreitol), TCEP (tris(2-carboxyethyl)phosphine)), or β-mercaptoethanol to 
break disulfide bridges (or S-S bonds); (3) alkylation using IAA (iodoacetamide) or CAA 
(chloroacetamide) reagent to block the reformation of disulfide bonds. However, histone 
proteins are relatively small and do not have that many cysteine residues that could form 
disulfide bridges, and as a result the denaturation, reduction, and alkylation steps are not 
required in histones analyses.   
1.3.1.2. RP-HPLC separation  
Reverse-phase high performace liquid chromatography (RP-HPLC) is the most commonly 
used separation technique for histone peptide or protein mixtures. RP-HPLC separates 
molecules based on their hydrophicity [176, 177]. This is achieved through continuous 
partitioning of analyte molecules between two different phases: a mobile phase and an 
immobilized hydrophobic stationary phase. The mobile phase is a binary mixture of aqueous 
and polar organic solvents. Both solvents are maintained at low pH by adding a small amount 
of organic acid (commonly 0.2% formic or acetic acid). The low pH aids in the separation 
and protonation of peptides or proteins. Acetonitrile is the most frequently used mobile phase 
organic solvent.  
On the other hand, the stationary phase is usually packed in a column made from narrow bore 
stainless steel tube or fused silica capillary. Most RP columns are packed with hydrophobic 
alkyl chains containing four (C4), eight (C8), or eighteen (C18) carbons [178]. The alkyl 
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chains are chemically linked to porous, spherical silica particles with internal diameter (i.d.) 
of 3 to 10 µm and pores of about 100 or 300Å diameter. For high grade separations, the 
stationary phase is packed in a column with a very narrow i.d, usually between 75 and 200 
µm. The ultra small diameter  of the columns helps to improve sensitivity by reducing excess 
dilution of the analyte by the mobile phase solvents. High performance and durable RP 
columns are obtained when the stationary phase is uniformly distributed, since this will create 
a homogeneous hydrophobic surface on which peptide and protein molecules are efficiently 
adsorbed [179]. For separation of intact histone proteins, analytical columns packed with 
shorter hydrocarbon chains (C4 or C8) and larger particle pore sizes (300 Å) are highly 
recommended (see Fig. 1.12). This is because large proteins form very strong hydrophobic 
interactions with the stationary phase, and thus are difficult to elute from the column. Such 
proteins are also too large to enter pores of smaller diameter. In contrast, separation of 
histone peptides is most efficient using RP columns packed with the n-octyldecyl (C18) 
hydrocarbon chain.  
Elution of peptides or proteins from the RP column can be achieved via isocratic or gradient 
approach [180, 181]. In the isocratic approach, the concentration of the organic solvent in the 
mobile phase is kept constant, whereas in the later approach the amount of the organic 
solvent is slowly increased till it reaches a desired level. Moreover, in isocratic elution, the 
same mobile solvent strength is used for both the less hydrophobic and strongly hydrophobic 
molecules, and as a result efficient elution of mainly one of the molecules is achieved. This 
approach is less common in histone analyses because peptides generated from tryptic 
digestion of histones exhibit wide variations in their hydrophobicity. Comparatively, in 
gradient elution, as the amount of the organic solvent increases, the adsorbed proteins or 
peptides are eluted in order of least to most hydrophobic molecules. Most researches use the 
gradient approach as it allows efficient separation, even for highly complex protein and 
peptide mixtures.   
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Figure 1.12 Recommended RP particle size versus protein MW. 
From reference [182] 
 
1.3.1.3. Sample ionization  
Any mass spectrometer consists of three basic components: (1) an ion source, (2) a mass 
analyzer, and (3) a detector. An illustration of the three components is shown in Figure 1.13a. 
The ion source is the section where ionization of analyte molecules takes place. Based on 
their effects on the analyte currently available ionization techniques are generally grouped 
into two major categories: hard and soft ionizations [183]. The hard ionization technique, in 
addition to forming ions of the analyte, results in breaking of chemical bonds. One common 
example of such technique is the electron ionization (EI) where gaseous analyte molecules 
are bombarded with a beam of electrons to generate radical cations [184]. This technique is 
commonly used in analysis of volatile and thermally stable organic compounds. The EI is a 
standard ionization technique in GC-MS instruments.  
Comparatively, the soft ionization technique allows formation of ions of analyte molecules 
with little to no breakage of chemical bonds. The two most common soft ionization 
techniques used in analysis of biomolecules are MALDI and ESI. In MALDI, ionization of 
analyte molecules is achieved via laser irradiation of co-crystallized analyte-matrix mixtures 
[185]. The matrix serves to absorb the laser energy and transfers proton to the analyte, 
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thereby ionizing the analyte. This technique, in addition to low-mass ions, allows ionization 
of intact proteins larger than 100 kDa [186]. MALDI is widely used in mass fingerprinting 
analysis of peptides, nucleic acids and lipids.  
The generation of analyte ions using the ESI technique was first described by J. B. Fenn 
[187]. It is the most commonly used ionization technique for peptides and proteins analyses. 
The exact mechanism of the ESI process is not fully understood; yet, several studies have 
postulated on the general behavior of analyte ions during the ESI [188], which is illustrated in 
Figure 1.13b . Samples are dissolved in a buffer similar to the mobile phase solvents and are 
directly sprayed across an electric field generated between the tip of the spray needle and a 
counter-electrode. The electric field helps to form highly charged liquid droplets consisting of 
the analyte molecules (denoted as ‘M’ in Figure 1.13b). A beam of nebulizing gas, usually 
nitrogen, passing across the tip of the spray needle evaporates the excess solvent leaving 
behind a solvent-free protonated analyte droplet with a diminished size. The decrease in 
droplet size results in increased repulsive force between neighboring like charged analytes. 
When the repulsive force reaches the Rayleigh limit (the maximum repulsive force that can 
exist between like charges before they overcome cohesive forces), the large analyte droplet 
disintegrates into smaller droplets due to the effect known as ‘coulombic explosion’. The 
analyte ions formed in this process carry multiple charges, and as a result they have a small 
mass-to-charge ratios. This property of the ESI method allows analysis of molecules that 
have a larger mass than the upper mass limit of the mass spectrometer.  
 
 
 
 
 
 
 
 
 
a) 
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Figure 1.13 Basic components of mass spectrometry. 
(a) Basic components of a mass spectrometer, (b) the ESI ionization process (adapted from 
Reference [188] with permission from John Wiley and Sons) 
 
 
 
b) 
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1.3.1.4. Mass analysis  
A mass spectrometer separates the mass-to-charge ratio (m/z) of ionized (charged) analytes 
following their transmission through a mass analyzer. Most MS instruments are named after 
their mass analyzer. Some of the most common mass analyzers used in peptide/protein 
analyses include Quadrupole (Q), Quadrupole Ion Trap (QIT), Time-of-Flight (ToF), Fourier 
Transform Ion Cyclotron Resonance (FTICR) and Orbitrap [189, 190]). Each mass analyzer 
has its own distinct features and its own advantages and limitations. There are a number of 
characteristics that are used as a basis to compare the performances of the different mass 
analyzers. Some of these characteristics are mass resolving power, mass accuracy, dynamic 
range, and mass range.  The mass resolving power is defined as M/ΔM, where M represents 
the ion m/z, and ΔM is the difference in m/z between two adjacent peaks in a mass spectrum 
[188]. For example, a mass analyzer with a resolving power of 1000 can effectively resolve 
ions of m/z 200.0 and m/z 200.2. The resolving power is also defined as the peak width at full 
width half maximum (FWHM). This definition is based on a single well-resolved peak where 
the M in the M/ΔM equation represents the m/z at the apex of the peak and ΔM represents the 
peak width at half maximum height of the peak. The mass accuracy represents the mass 
measurement error expressed in Dalton or part per million (ppm). It is determined by dividing 
the difference between the measured and the theoretical m/z by the theoretical m/z. The 
dynamic range is the number of orders of magnitude of analyte concentration over which the 
MS signal response is linear. The mass range is the range of m/z values over which a mass 
analyzer is able to detect ions or record a mass spectrum.  
The Quadrupole mass analyzer is composed of four parallel, circular electric rods (Fig. 1.14 
a) [191, 192]. Ions are filtered in the quadrupole based on the stability of their trajectory in a 
combined DC (direct current) and RF (radio frequency) potential applied to each of the 
opposing pair of rods.  The applied potential can be adjusted to pass only a selected m/z ratio 
or mass range. This property of the quadrupole makes it particularly suitable for targeted MS 
analysis. However, the Quadrupole is limited to low resolution (usually unit resolution) and 
low mass accuracy MS analysis. On the other hand, the QIT (Quadrupole Ion Trap) analyzer 
is distinct in that it allows dynamic trapping and accumulation of large amounts of ions in a 
quadrupole device (Fig. 1.14b) [193]. The trapped ions can be manipulated by varying the 
applied RF potential; ions of a particular m/z range can be selectively ejected for detection or 
allowed to react with inert gases for the purpose of fragmentation. Despite such capabilities, 
the performance of the QIT is often limited by the phenomenon called ‘space-charge effects’ 
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(characterized by ion coalescence, ion-ion repulsion), which is due to the accumulation of a 
large amount of ions in the trap. The space-charge effect severely affects the dynamic range 
and the mass accuracy of ion trap analyzers. To circumvent this problem, modern MS 
instruments are designed to have automatic ion-gauging mechanisms to control the amount of 
ions entering into the trap.  
The TOF mass analyzer uses the differences in transit time through a high vacuum field-free 
region to separate ions of different m/z (Fig. 1.14c) [194]. Lighter ions travel faster than 
heavy ions, and thus reach the detector sooner. Unlike the quadrupole analyzers, all ions 
entering the TOF field-free region reach the detector. Moreover, the TOF analyzer has a 
unique capability of detecting ions with high mass range, even up to 10
6
 Da [195, 196].  
The FTICR analyzer is famous for its capability to provide superior resolving power (usually 
> 10
6
 FWHM) and very high mass accuracy (sub-ppm errors are achievable) [197]. Mass 
analysis in the FTICR-MS is conducted in a very small closed analyzer cell (usually cube-
shaped) which is kept under high vacuum and inside a strong magnetic field produced by a 
superconducting magnet (Fig. 1.14d). A combination of DC and RF potentials applied to the 
analyzer cell allows the trapping of ions at the center of the cell. For detection, the trapped 
ions are excited simultaneously by a pulse of RF electric field applied perpendicularly to the 
magnet. This causes the ions to move in a circular motion at a frequency known as the 
cyclotron frequency, which is inversely proportional to the m/z ratio. Each ion of a certain 
m/z is characterized by a particular cyclotron frequency, which is the basis for the separation 
and detection of ions in the FTICR-MS. Although the FTICR provides ultra-high resolution 
data, its capabilities are limited by the relatively slow acquisition rate and low dynamic range. 
The analyzer cell is also susceptible to the ‘space-charge effect’ due to the accumulation of 
large amounts of ions in a very limited space.   
The Orbitrap is one of the latest and the most widely used mass analyzer in current 
proteomics studies. It has undergone a dramatic improvement since its introduction by 
Alexander Makarov in 2000 [198].  Like the FTICR and QIT analyzers, the Orbitrap 
functions as an ion trapping device. In contrast, however, the Orbitrap does not require a 
magnetic field or an RF potential for trapping ions or mass analysis. Instead, ion separation is 
achieved based on the motion of ions in an electric field applied between an outer barrel-like 
electrode and a central electrode (Fig. 1.14e). The ions rotate around the central electrode and 
at the same time oscillate left and right along the horizontal axis of the electrode. These 
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motions of the ions generate three characteristic frequencies: a rotational frequency, a radial 
frequency, and an axial frequency. Of the three, the axial frequency is used in mass resolving, 
since this frequency is dependent only on the m/z ratio of the oscillating ions and the applied 
potential between the central and outer electrode (which is held constant). The axial 
frequency is inversely proportional to the square-root of the ion m/z. The oscillatory motion 
of ions along the horizontal axis of the central electrode induces an image current on the outer 
electrode. This image current is subsequently converted into an m/z spectrum via Fourier 
transformation. At the current stage, the Orbitrap allows mass analysis at resolutions of 
several hundred thousand (the latest Orbitrap Fusion, Lumos, has a resolving power up to 
500,000 (FWHM) at m/z 200). Mass accuracies in the low ppm to sub-ppm ranges are 
routinely achieved using the Orbitrap.    
 
Figure 1.14 Schematics of some of the most common mass analyzers.  
(a) Linear quadrupole, (b) Ion trap quadrupole, (c) TOF, (d) FTICR, and (e) Orbitrap 
mass analyzers. Adapted from  reference [199]  
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1.3.1.5. Tandem mass analysis  
Multiple stages of mass analysis (MSn) can be performed either in a single mass analyzer 
with each stage of analysis separated in time (tandem-in-time) or in more than one mass 
analyzer aligned in tandem (tandem-in-space) [189]. Tandem-in-time mass spectrometers 
have the capability to store ions and analyze them selectively at different times. The FTICR 
and QIT are equipped with such capability. In FTICR, in the first stage of mass analysis 
(MS1), ions of a certain m/z range are simultaneously selected and excited by applying an RF 
potential. The excited ions are detected as they undergo a cyclotron motion in the ICR cell. In 
the second stage of mass analysis (MS2), the ions are selectively excited and subjected to 
fragmentation via collision induced dissociation [197]. The MS1 analysis generates precursor 
or parent ion mass spectrum, whereas the MS2 (also denoted as MS/MS) analysis produces 
fragment or product ion mass spectrum.  
On the other hand, tandem-in-space instruments have two or more mass analyzers configured 
in tandem. In one type of configuration, multiple identical mass analyzers are arranged in 
tandem. Typical examples of such instruments are the Triple Quadrupole (QQQ) and the 
TOF/TOF analyzers. In the second type of configuration, different mass analyzers are 
arranged in tandem, thereby forming hybrid mass spectrometers. Few examples of such 
instruments are Q-TOF, LTQ-Orbitrap, and Q-Exactive Plus, which are hybrid of, 
respectively, Quadrupole and TOF, Ion Trap and Orbitrap, and Quadrupole and Orbitrap 
analyzers. One important advantage of the tandem-in-space instruments is that they allow 
dissociation of the precursor ions in a specialized sector. This is particularly useful for the 
analysis of complex mixtures of peptides because the division of labor between the different 
analyzers improves the acquisition rate and minimizes the adverse effect of ion coalescence 
and the space-charge phenomenon observed mainly in tandem-in-time instruments.  
Mass spectrometers are equipped with specialized techniques for fragmentation of peptides or 
proteins. Some of the common techniques are collision-induced dissociation (CID), High-
energy collision dissociation (HCD), and electron transfer dissociation (ETD). Peptide 
dissociation using these techniques generates two categories of fragment ions (see Fig. 1.15): 
those that are charged on the N-terminal side are denoted as a-, b- and c-ions, whereas C-
terminal charged fragments are termed x-, y- and z-ions.  
 
 
 
 
56 
 
 
 
 
 
Figure 1.15 The Roepstorff nomenclature for peptide fragment ions.  
From reference [200] with permission from John Wiley and Sons.  
 
CID is by far the most commonly used method in peptide sequencing by MS/MS. In the CID 
mode, multiple collisions of a precursor peptide with a neutral gas molecule (e.g. Helium) 
induce a vibrational energy which redistributes along the backbone of the peptide ion [201]. 
The vibrational energy rapidly increases the internal energy of the peptide ion, which 
subsequently results in dissociation of the amide bonds along the peptide backbone. CID 
fragmentation primarily generates b- and y-ion fragments. Occasionally, the b-ion fragments 
are subject to lose of a carbonyl group (C=O, ≈ 28 Da), thereby generating a-ion fragments. 
Despite its widespread use, the CID mode is limited to analysis of relatively short peptide 
segments (usually less than 30 amino acids) and low-charged peptides (+2 and +3 charge 
states). Moreover, abundant internal fragmentation and loss of labile PTMs such as 
phosphorylation are frequently observed using this technique. One very common alternative 
fragmentation technique is the HCD [202, 203], which is basically a beam-type, high energy 
CID. Fragmentation by HCD also generates b- and y-ion fragments. Meanwhile, due to the 
high energy employed in this technique, HCD fragment spectra are dominated by y-ions; and 
the b-ions are usually dissociated into a-ions and other internal fragments. The HCD MS/MS 
spectra are analyzed at high resolution, high mass accuracy in the Orbitrap analyzers, and as 
such they provide higher quality peptide sequence information.   
ETD is different from the CID-based methods in many ways. In this mode, first, radical 
anions are generated from a neutral molecule (e.g. fluoranthene, anthracene) in a separate 
chemical ionization source attached externally to the mass spectrometer [204]. The radical 
anions are then transferred to the fragmentation cell where the peptides are stored. In the cell, 
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the anions transfer an electron to multiply protonated peptides and induce fragmentation of 
the peptide backbone. This process leads to cleavage of the N─Cα bonds, thereby generating 
c- and z-ion fragments. ETD is particularly suited for fragmentation of highly charged and 
large peptides, even intact proteins. Moreover, in contrast to CID, ETD enables efficient 
analysis of labile PTMs such as phosphorylation and glycosylation.  
1.3.1.6. Peptide identification  
Classical approaches for histone PTM identification or detection involves Edman 
degradation, amino acid analysis coupled with thin-layer chromatography, and site-specific 
antibody-based assays. These approaches, however, are hampered by several technical 
limitations including the requirement for large amount of starting materials, inability to 
provide comprehensive and quantitative information, and due to the time-consuming, labor-
intensive nature of the methods. On the other hand, MS-based approaches use database 
search algorithms to interpret the rich sequence information available in peptide fragment 
(MS/MS) spectra to identify site-specific modifications. In this approach, every MS/MS 
spectrum obtained from the collisional dissociation is compared with fragment ion mass 
values of in silico peptide sequences generated by applying appropriate cleavage rules in the 
sequence database [205, 206]. Typical peptide-spectrum matching (PSM) using search 
algorithms starts by setting appropriate search parameters on the user interface. As an 
example, the Mascot MS/MS ions search user interface is shown in Figure 1.16. The search 
begins by selecting a database (for instance - SWISS-PROT, NCBInr or the protein sequence, 
if known) to be searched. Prior knowledge of the protein sequence greatly simplifies the 
identification process by eliminating the need to look for possible matches in a database 
containing a large number of protein sequences. Next, the enzyme used for cleavage (e.g. 
trypsin, chymotrypsin etc.) is selected and maximum values for the number of missed 
cleavages that may result from incomplete digestion are specified. The variable and fixed (if 
any) PTMs that need to be considered in the search can be selected. PTMs result in a shift in 
mass of fragment ions consisting of the site(s) of modification compared to the corresponding 
fragment ions of the unmodified counterpart. This mass difference can be used to assign the 
identity of a PTM in a peptide. For example, acetylation of lysine side chains in histones 
result in an increase in mass of the residue by 42.02 Da, and mono-, di-, and tri-methylation 
result in an increase in mass by, respectively, 14.01, 28.02, or 42.06 Da. Some ambiguity can 
be encountered when identifying a trimethylated and an acetylated lysine residue since the 
mass difference between these two PTMs is only 0.036 Da. Meanwhile, this difference can 
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easily be resolved by analyzing the MS/MS spectra of peptides consisting of these PTMs at 
high mass accuracy and high resolution. Then, a desirable mass tolerance (in ppm or Da) for 
both the precursor peptide and the fragment ions is set based on the known mass accuracy of 
the MS analyzer.  Finally, the raw MS/MS data are uploaded and submitted for database 
searching. In general, the success of peptide/PTM identification by the PSM approach 
depends on the quality of the MS/MS data, the performance of the search algorithm used by 
the search engine and the database accuracy. 
 
 
Figure 1.16 The user interface for Mascot MS/MS database search engine.  
(Source: http://www.matrixscience.com/cgi/search_form.pl?FORMVER=2&SEARCH=MIS, 
July 2015.) 
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Most MS-based approaches for histone PTM analysis employ database search engines for the 
identification of modified residues. However, due to their complex modification patterns, 
histones are often difficult to analyze using conventional search engines. Yuan et al., have 
recently investigated the performance of eight different search engines (pFind, Mascot, 
SEQUEST, ProteinPilot, PEAKS, OMSSA in COMPASS, X!Tandem in TPP, and 
Andromeda in MaxQuant) for analysis of histone PTMs [171]. A comparison was made 
based on proportion of confident identifications, proportion of overlapp of confident 
identifications (to evaluate the similarity of search engines), search time and data storage 
space. The results from this study found Mascot and PFind to be the best search engines for 
the analysis of histone modifications as both identified relatively higher number of confident 
MS/MS spectra. However, almost all of the above search engines performed poorly in 
identifying combinatorial histone modifications. The combinatorial search consisting of 
PTMs - propionylation, acetylation, phosphorylation, and mono-, di-, tri-methylation resulted 
in large data storage space and also more false positive identifications. In addition, the search 
engines allowed limited number of PTMs that can be searched, for example - SEQUEST and 
Mascot could not identify more than six and nine modifications, respectively, in a single 
search although it is known that histones can be modified by more than fifteen different types 
of PTMs.  
Also, the above search engines have poor performance in identifying PTMs present in 
isomeric histone peptides. Most histone tryptic peptides consist of multiple internal lysine 
residues (e.g. H3 peptide 27-KSAPATGGVKKPHR-40 and H4 peptide 4-
GKGGKGLGKGGAKR-17). Often the same peptide can be modified on the side chain of 
different lysine residues thereby forming positional isomers.  Such isomers have virtually the 
same m/z and they produce composite MS/MS spectra consisting of multiple shared fragment 
ions. Due to the lack of sufficient distinguishing fragment ions, conventional search engines 
often misassign sites of modification. To resolve the above problems some research labs have 
developed custom software tools that can aid the deconvolution of composite MS/MS spectra 
generated from mixtures of isomeric peptides. However, these tools also suffer from several 
limitations. For example, the algorithm called ByOnic [207] was able to deconvolute MS/MS 
spectra of an isomeric mixture of only two peptides. The recently developed algorithms 
isoScale [172] and EpiProfile [208] are only applicable for composite MS/MS spectra 
consisting of unique fragment ions representing each of the isomers in the mixture. 
Therefore, the development of a more comprehensive algorithm that does not necessarily rely 
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on the presence of unique fragment ions is much needed. Our lab has recently developed such 
algorithm, which is described in detail in Chapter 3 of the Thesis.  
1.3.1.7. Peptide quantification 
So far, numerous strategies have been developed for quantification of peptides or proteins in 
large scale proteomics studies. These strategies can be generally grouped into two categories: 
isotopic labeling and label-free approaches [209, 210]. Each approach has its own advantages 
and its own drawbacks and limitations. In the labeling approach, changes in the relative 
quantity of a given peptide/protein in response to a particular treatment can be evaluated by 
comparing its abundance in the untreated versus treated within a single LC-MS/MS run. In 
this approach, the two conditions are mixed into a single sample, and in order for the MS to 
distinguish between them one of the conditions, either the untreated or treated, is isotopically 
labeled. The labeling of peptides or proteins can be achieved via two approaches. One is by 
chemically incorporating isotope-coded mass tags on a specific amino acid comprising a 
highly reactive side chain (e.g. the ε-amino group of lysines). A few examples of methods 
using this labeling technique include the isotope-coded protein label (ICPL) [211], isotope 
tags for relative and absolute quantification (iTRAQ) [212], and tandem  mass tags (TMT) 
[213].  
The other labeling approach is the so-called metabolic labeling, which is basically performed 
in vivo via stable isotope labeling by amino acids in cell culture (SILAC) [214]. Here, cells 
are treated with amino acids containing heavy isotopes (e.g. nitrogen (
15
N) or carbon (
13
C)). 
The mass shift introduced as a result of incorporation of the heavy isotope can be recognized 
by the MS and at the same time provides the basis for quantification. The advantage of the 
SILAC approach is that the differentially treated samples can be mixed at the level of intact 
cells, and as a result it is unaffected by experimental errors introduced during subsequent 
sample preparation procedures, which is critical for unbiased and accurate quantification of 
peptides. However, this method is expensive, time consuming, and often less than 100% 
labeling is achieved, particularly in higher eukaryotes. Moreover, the SILAC approach allows 
comparison of only few conditions (usually three) due to the limited number of commercially 
available labels.  
In contrast, the label-free approach does not require incorporation of specific mass tags or 
labels for quantification purpose. Here, quantitative information can be obtained by 
comparing the LC/MS signal intensity (or extracted ion chromatogram, XIC, intensity) of a 
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given precursor ion across several differentially treated samples [215]. Unlike the SILAC 
approach, however, the label-free approach is susceptible to experimental errors since each 
sample is independently processed and analyzed. This may cause unexpected variations in the 
overall intensity of peptides among the different conditions or among replicates within the 
same experimental condition. In such cases, the MS data are normalized for comparison. 
Global normalization is one of the most common normalization techniques used in  label-free 
quantification [216]. In global normalization, it is assumed that the total MS abundances 
summed over all detected peptides should be the same in each sample, provided that equal 
amounts of starting materials are used. Given this assumption, a normalization factor can be 
calculated from the ratio of total abundances of, for example, untreated to treated samples. 
Then, by choosing the untreated sample as a reference, the individual abundance values in the 
treated samples can be adjusted by multiplying each value by the normalization factor. 
Alternatively, instead of the total abundance, the abundances of an unmodifiable peptide(s) 
reproducibly and abundantly detected in both the untreated and treated samples can be used 
to calculate the normalization factor. The label-free approach in principle does not have 
limitations in the number of conditions that can be compared, which is one of the major 
advantages of this method over stable isotope labeling techniques. Moreover, this approach is 
relatively less expensive, less time consuming and results in lower mass spectral complexity 
since the MS do not have to acquire labeled peptides.  
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1.4. Thesis objectives  
A number of biochemical and/or mass-spectrometry-based methods have previously been 
developed to identify and characterize various types of histone modifications. While these 
methods have played an important role in advancing our current view of the biological 
functions of the modifications, there is still much room for improvement. In the MS-based 
proteomics field, there are three potential areas of improvement which are chromatography, 
mass spectrometry and bioinformatics. In this regard, the cutting-edge capabilities of the 
latest mass spectrometry technology platforms need be exploited to address some of the 
limitations observed in the currently available biochemical and analytical proteomics 
approaches.  
Thus, the aim of this thesis was to develop improved quantitative MS-based methods that can 
be used for (1) measuring global changes in histone PTMs; (2) identifying and characterizing 
individual and combinatorial histone PTMs; and (3) defining the site specificity of HATs and 
HDACs toward histone substrates. This was achieved through the following three research 
objectives.  
The first objective involved developing an improved MS-based strategy for determining the 
site specificity of S. cerevisiae HAT Rtt109 toward histones H3 and H4. Rtt109 is a fungal-
specific HAT that was previously known to acetylate histone H3. Interestingly, early 
structural and biochemical studies showed that the specificity of Rtt109 toward H3 sites is 
modulated by the chaperone proteins Asf1 and Vps5. However, there were conflicting reports 
as to which sites are most preferred when Rtt109 binds to Asf1 versus Vps75. Therefore, in 
this particular study our objective was to (1) develop an improved MS-based workflow that 
can be used for measuring the global and site specific acetylation of histones; and (2) 
determine the role of Asf1 and Vps75 in directing the site specificity of Rtt109 during in vitro 
assay with histones H3 and H4. 
The second objective involves developing a novel MS-based approach for deconvolution and 
quantification of isomeric histone peptides. Histone peptides suitable for bottom-up analysis 
are typically generated by tryptic digestion, which cleaves at the C-terminal side of arginine 
and unmodified or mono-methylated lysine residues. Unfortunately, peptides produced using 
this approach bear more than one internal lysine residue. These peptides can be acetylated at 
a single or multiple sites. Often a single acetylation can occur on different lysine residues of 
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the same peptide thereby forming positional isomers. Such isomers cannot be efficiently 
resolved using conventional RP-LC/MS, and appear as a single chromatographic peak. 
Moreover, CID of isomeric peptides generates composite MS/MS spectra. Conventional 
database search engines such as Mascot have difficulties assigning peptide sequences to this 
type of spectra because of lack of distinguishing fragment ions representing each isomer. 
Therefore, in order to address these problems we set out three objectives: (1) Using synthetic 
histone peptides, examine the detection efficiencies, fragmentation efficiencies and patterns, 
and chromatographic features of the individual and mixed isomers; (2) based on composite 
MS/MS spectra of isomeric synthetic peptides,develop a bioinformatics tool that can aid the 
deconvolution of both the composite MS/MS spectra and the co-eluting precursor 
chromatographic peaks; (3) validate the applicability of the method using different biological 
problems.  
The third objective involves, using the aforementioned methods to determine the role of 
several fission yeast HATs and HDACs in regulating the steady-state levels of histone 
acetylation. A number of previous studies used biochemical approaches such as Western blot 
and ChIP in order to characterize the site specificity of fission yeast HATs and HDACs. 
These approaches, however, suffer from several limitations. First, the antibody-based 
approach requires prior knowledge of the sites of acetylation, and thus cannot be used to 
identify novel sites. Second, many antibodies used in studies of histone acetylation lack the 
desired specificity, particularly when two or more acetylation sites are too close together. 
Third, the antibody-based approach would only allow semi-quantitative assessment of histone 
acetylation. Therefore, we employed the above validated MS-based methods to investigate 
the global and site-specific changes of histone acetylation in fission yeast mutants lacking 
major HAT and HDAC activities. We were particularly interested in finding out the enzymes’ 
distinct roles in acetylating or deacetylating histones H3 and H4. In addition, we wanted to 
shed light on the mechanisms underlying the dynamic interplay between HATs and HDACs 
in establishing the steady-state level of histone acetylation.  
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1.5. Thesis outline  
The second chapter of the thesis presents a quantitative MS-based method that can be used 
for determining the global and site-specific acetylation of histones. The method was used in 
investigating the acetylation of histones H3 and H4 during in vitro acetylation assays with 
Rtt109-Vps75 or Rtt109-Asf1. Our results showed that Rtt109–Vps75 preferentially 
acetylates H3K9 and H3K23, whereas Rtt109–Asf1 showed a far greater specificity for 
H3K56 acetylation. Moreover, Rtt109–Vps75 exhibited moderate activity toward H4 sites, 
whereas Rtt109–Asf1 showed no detectable activity toward H4. 
The third chapter presents a novel MS-based approach that is useful for analysis of isomeric 
histone peptides. The approach employs an in-house developed algorithm called Iso-
PeptidAce to deconvolute composite MS/MS spectra of mixtures of isomers. The algorithm 
was built based on several chromatographic and fragmentation features of synthetic isomeric 
histone peptides. The applicability of the method was demonstrated using different biological 
problems including the identification of site-specific acetylation patterns in affinity-purified 
histones bound to CAF1 and profiling of histone acetylation in cells treated with different 
HDAC inhibitors. 
In the fourth chapter, a study aimed at investigating the substrate specificity of several fission 
yeast HATs and HDACs is described. Bulk histones isolated from wild type or mutant fission 
yeast strains were fractionated into individual core histones using offline reverse-phase 
HPLC. Tryptic digests of derivatized H3/H4 were analyzed by a multiplexed parallel reaction 
monitoring (PRM) method on a QExactive Plus instrument. Data analyses were performed 
manually using Thermo Xcalibure Qual Browser software and the in-house built algorithm, 
Iso-PeptidAce. The site-specificity of each HAT and HDAC as determined based on the fold 
change ratios of mutant-to-control acetylation site occupancies of lysine residues on the N-
terminal tails of H3 and H4. Our analysis identified several known and novel HAT and 
HDAC target sites.  
The fifth chapter summarizes the different analytical tools developed and the results obtained 
in the above studies. A perspective on both the potential of our method and the remaining 
challenges in MS-based histone PTM analysis is also described.   
 
 
65 
 
 
 
1.6. References 
1. Bruce Alberts, A.J., Julian Lewis, Martin Raff, Keith Roberts, and Peter Walter, Molecular 
Biology of the Cell. 2002, Garland Science: New York. p. 263 - 399. 
2. Watson, J.D. and F.H.C. Crick, Molecular Structure of Nucleic Acids: A Structure for 
Deoxyribose Nucleic Acid. Nature, 1953. 171(4356): p. 737-738. 
3. Kornberg, R.D. and Y. Lorch, Twenty-five years of the nucleosome, fundamental particle of 
the eukaryote chromosome. Cell, 1999. 98(3): p. 285-294. 
4. Kornberg, R.D., Chromatin structure: a repeating unit of histones and DNA. Science, 1974. 
184(4139): p. 868-871. 
5. Richmond, T. and J. Finch, The structure of the nucleosome core particle. Nature (London), 
1984. 311: p. 532-537. 
6. Olins, D.E. and A.L. Olins, Chromatin history: our view from the bridge. Nature Reviews 
Molecular Cell Biology, 2003. 4(10): p. 809-814. 
7. Woodcock, F., Structure of the 30 nm chromatin fiber. 1986. 
8. Bednar, J., et al., Nucleosomes, linker DNA, and linker histone form a unique structural motif 
that directs the higher-order folding and compaction of chromatin. Proceedings of the 
National Academy of Sciences, 1998. 95(24): p. 14173-14178. 
9. Thomas, J.O., Histone H1: location and role. Current opinion in cell biology, 1999. 11(3): p. 
312-317. 
10. Hsu, T. and F.E. Arrighi, Distribution of constitutive heterochromatin in mammalian 
chromosomes. Chromosoma, 1971. 34(3): p. 243-253. 
11. Trojer, P. and D. Reinberg, Facultative heterochromatin: is there a distinctive molecular 
signature? Molecular cell, 2007. 28(1): p. 1-13. 
12. Felsenfeld, G. and M. Groudine, Controlling the double helix. Nature, 2003. 421(6921): p. 
448-453. 
13. Dahm, R., Friedrich Miescher and the discovery of DNA. Developmental Biology, 2005. 
278(2): p. 274-288. 
14. Doenecke, D. and P. Karlson, Albrecht Kossel and the discovery of histones. Trends in 
Biochemical Sciences. 9(9): p. 404-405. 
15. Kossel, A., Protamines and histones. 1928. 
16. Rasmussen, P.S., K. Murray, and J.M. Luck, On the Complexity of Calf Thymus Histone. 
Biochemistry, 1962. 1(1): p. 79-89. 
17. Kornberg, R.D., Structure of Chromatin. Annual Review of Biochemistry, 1977. 46(1): p. 931-
954. 
18. Oudet, P., M. Gross-Bellard, and P. Chambon, Electron microscopic and biochemical evidence 
that chromatin structure is a repeating unit. Cell, 1975. 4(4): p. 281-300. 
19. Thomas, J.O. and R.D. Kornberg, An octamer of histones in chromatin and free in solution. 
Proceedings of the National Academy of Sciences, 1975. 72(7): p. 2626-2630. 
20. Isenberg, I., HISTONES Ann. Rev. Biochem. , 1979. 48: p. IS9-91  
21. Khare, S.P., et al., HIstome—a relational knowledgebase of human histone proteins and 
histone modifying enzymes. Nucleic Acids Research, 2011. 
22. Henikoff, S. and Y. Dalal, Centromeric chromatin: what makes it unique? Current Opinion in 
Genetics & Development, 2005. 15(2): p. 177-184. 
23. Tagami, H., et al., Histone H3.1 and H3.3 Complexes Mediate Nucleosome Assembly 
Pathways Dependent or Independent of DNA Synthesis. Cell, 2004. 116(1): p. 51-61. 
24. Jackson, V. and R. Chalkley, Histone synthesis and deposition in the G1 and S phases of 
hepatoma tissue culture cells. Biochemistry, 1985. 24(24): p. 6921-6930. 
25. NAKATANI, Y., et al., Two Distinct Nucleosome Assembly Pathways: Dependent or 
Independent of DNA Synthesis Promoted by Histone H3.1 and H3.3 Complexes. Cold Spring 
Harbor Symposia on Quantitative Biology, 2004. 69: p. 273-280. 
66 
 
 
 
26. Corpet, A. and G. Almouzni, Making copies of chromatin: the challenge of nucleosomal 
organization and epigenetic information. Trends in Cell Biology, 2009. 19(1): p. 29-41. 
27. Rogakou, E.P., et al., DNA Double-stranded Breaks Induce Histone H2AX Phosphorylation on 
Serine 139. Journal of Biological Chemistry, 1998. 273(10): p. 5858-5868. 
28. Nakagawa, T., et al., Deubiquitylation of histone H2A activates transcriptional initiation via 
trans-histone cross-talk with H3K4 di- and trimethylation. Genes & Development, 2008. 
22(1): p. 37-49. 
29. Chadwick, B.P. and H.F. Willard, Histone H2A variants and the inactive X chromosome: 
identification of a second macroH2A variant. Human Molecular Genetics, 2001. 10(10): p. 
1101-1113. 
30. Eirín-López, J.M., T. Ishibashi, and J. Ausió, H2A.Bbd: a quickly evolving hypervariable 
mammalian histone that destabilizes nucleosomes in an acetylation-independent way. The 
FASEB Journal, 2008. 22(1): p. 316-326. 
31. Sharma, A., K. Singh, and A. Almasan, Histone H2AX Phosphorylation: A Marker for DNA 
Damage, in DNA Repair Protocols, L. Bjergbæk, Editor. 2012, Humana Press. p. 613-626. 
32. Revet, I., et al., Functional relevance of the histone γH2Ax in the response to DNA damaging 
agents. Proceedings of the National Academy of Sciences, 2011. 108(21): p. 8663-8667. 
33. Xu, Y., et al., Histone H2A.Z Controls a Critical Chromatin Remodeling Step Required for DNA 
Double-Strand Break Repair. Molecular Cell, 2012. 48(5): p. 723-733. 
34. DeLange, R.J., et al., Calf and Pea Histone IV: II. The complete amino acid sequence of calf 
thymus histone IV; presence of ε-N-acetyllysine. Journal of Biological Chemistry, 1969. 
244(2): p. 319-334. 
35. DeLange, R.J., et al., Calf and Pea Histone IV: III. Complete amino acid sequence of pea 
seedling histone IV; comparison with the hologous calf thymus histone. Journal of Biological 
Chemistry, 1969. 244(20): p. 5669-5679. 
36. Delange, R.J., J.A. Hooper, and E.L. Smith, Complete Amino-Acid Sequence of Calf-Thymus 
Histone III. Proceedings of the National Academy of Sciences, 1972. 69(4): p. 882-884. 
37. Kornberg, R.D. and J.O. Thonmas, Chromatin Structure: Oligomers of the Histones. Science, 
1974. 184(4139): p. 865-868. 
38. D'Anna, J.A. and I. Isenberg, Histone cross-complexing pattern. Biochemistry, 1974. 13(24): p. 
4992-4997. 
39. D'Anna, J.A. and I. Isenberg, Interactions of histone LAK (f2a2) with histones KAS (f2b) and 
GRK (f2a1). Biochemistry, 1974. 13(10): p. 2098-2104. 
40. Li, H.J., et al., Circular dichroism of histone-bound regions in chromatin. Biopolymers, 1975. 
14(1): p. 211-226. 
41. Noll, M., Subunit structure of chromatin. Nature, 1974. 251(5472): p. 249-251. 
42. Eickbush, T.H. and E.N. Moudrianakis, The histone core complex: an octamer assembled by 
two sets of protein-protein interactions. Biochemistry, 1978. 17(23): p. 4955-4964. 
43. Klug, A., et al., A low resolution structure for the histone core of the nucleosome. Nature, 
1980. 287(5782): p. 509-516. 
44. Finch, J.T., et al., Structure of nucleosome core particles of chromatin. Nature, 1977. 
269(5623): p. 29-36. 
45. Richmond, T.J., et al., Structure of the nucleosome core particle at 7 Å resolution. Nature, 
1984. 311(5986): p. 532-537. 
46. Burlingame, R., et al., Crystallographic structure of the octameric histone core of the 
nucleosome at a resolution of 3.3 A. Science, 1985. 228(4699): p. 546-553. 
47. Bentley, G.A., et al., Crystal structure of the nucleosome core particle at 16 Å resolution. 
Journal of Molecular Biology, 1984. 176(1): p. 55-75. 
48. Arents, G., et al., The Nucleosomal Core Histone Octamer at 3.1 ⚬ A Resolution: A Tripartite 
Protein Assembly and a Left-Handed Superhelix. Proceedings of the National Academy of 
Sciences of the United States of America, 1991. 88(22): p. 10148-10152. 
67 
 
 
 
49. Luger, K., et al., Crystal structure of the nucleosome core particle at 2.8 Å resolution. Nature, 
1997. 389(6648): p. 251-260. 
50. Tsunaka, Y., et al., Alteration of the nucleosomal DNA path in the crystal structure of a 
human nucleosome core particle. Nucleic Acids Research, 2005. 33(10): p. 3424-3434. 
51. Ramakrishnan, V., Histone structure and the organization of the nucleosome. Annual Review 
of Biophysics and Biomolecular Structure, 1997. 26(1): p. 83-112. 
52. Walsh, C.T., S. Garneau-Tsodikova, and G.J. Gatto, Protein Posttranslational Modifications: 
The Chemistry of Proteome Diversifications. Angewandte Chemie International Edition, 2005. 
44(45): p. 7342-7372. 
53. Knorre, D., N. Kudryashova, and T. Godovikova, Chemical and functional aspects of 
posttranslational modification of proteins. Acta naturae, 2009. 1(3): p. 29. 
54. Duan, G. and D. Walther, The Roles of Post-translational Modifications in the Context of 
Protein Interaction Networks. PLoS Comput Biol, 2015. 11(2): p. e1004049. 
55. Gu, Y., J. Rosenblatt, and D. Morgan, Cell cycle regulation of CDK2 activity by phosphorylation 
of Thr160 and Tyr15. The EMBO journal, 1992. 11(11): p. 3995. 
56. Spencer, V.A. and J.R. Davie, Role of covalent modifications of histones in regulating gene 
expression. Gene, 1999. 240(1): p. 1-12. 
57. Huang, H., et al., SnapShot: Histone Modifications. Cell, 2014. 159(2): p. 458-458.e1. 
58. Ito, K., P. J. Barnes, and I. M. Adcock, Histone Acetylation and Deacetylation, in Asthma, K. 
Fan Chung and I. Adcock, Editors. 2000, Humana Press. p. 309-319. 
59. Tanner, K.G., et al., Catalytic Mechanism and Function of Invariant Glutamic Acid 173 from 
the Histone Acetyltransferase GCN5 Transcriptional Coactivator. Journal of Biological 
Chemistry, 1999. 274(26): p. 18157-18160. 
60. Bird, A.W., et al., Acetylation of histone H4 by Esa1 is required for DNA double-strand break 
repair. Nature, 2002. 419(6905): p. 411-415. 
61. Vogelauer, M., et al., Histone Acetylation Regulates the Time of Replication Origin Firing. 
Molecular Cell, 2002. 10(5): p. 1223-1233. 
62. Shogren-Knaak, M., et al., Histone H4-K16 Acetylation Controls Chromatin Structure and 
Protein Interactions. Science, 2006. 311(5762): p. 844-847. 
63. Hebbes, T.R., A.W. Thorne, and C. Crane-Robinson, A direct link between core histone 
acetylation and transcriptionally active chromatin. The EMBO journal, 1988. 7(5): p. 1395. 
64. Davie, J.R. and D.N. Chadee, Regulation and regulatory parameters of histone modifications. 
Journal of Cellular Biochemistry, 1998. 72(S30‒31): p. 203-213. 
65. Taverna, S.D., et al., How chromatin-binding modules interpret histone modifications: lessons 
from professional pocket pickers. Nature Structural & Molecular Biology, 2007. 14(11): p. 
1025-1040. 
66. Bannister, A.J. and T. Kouzarides, Regulation of chromatin by histone modifications. Cell 
research, 2011. 21(3): p. 381-395. 
67. Robert, F., et al., Global position and recruitment of HATs and HDACs in the yeast genome. 
Molecular Cell, 2004. 16(2): p. 199-209. 
68. Pokholok, D.K., et al., Genome-wide map of nucleosome acetylation and methylation in 
yeast. Cell, 2005. 122(4): p. 517-527. 
69. Wang, Z., et al., Combinatorial patterns of histone acetylations and methylations in the 
human genome. Nature genetics, 2008. 40(7): p. 897-903. 
70. Deckert, J. and K. Struhl, Histone Acetylation at Promoters Is Differentially Affected by 
Specific Activators and Repressors. Molecular and Cellular Biology, 2001. 21(8): p. 2726-
2735. 
71. Black, Joshua C., C. Van Rechem, and Johnathan R. Whetstine, Histone Lysine Methylation 
Dynamics: Establishment, Regulation, and Biological Impact. Molecular Cell, 2012. 48(4): p. 
491-507. 
68 
 
 
 
72. Sims Iii, R.J., K. Nishioka, and D. Reinberg, Histone lysine methylation: a signature for 
chromatin function. Trends in Genetics, 2003. 19(11): p. 629-639. 
73. Vaissière, T., C. Sawan, and Z. Herceg, Epigenetic interplay between histone modifications 
and DNA methylation in gene silencing. Mutation Research/Reviews in Mutation Research, 
2008. 659(1–2): p. 40-48. 
74. Zhang, Y. and D. Reinberg, Transcription regulation by histone methylation: interplay 
between different covalent modifications of the core histone tails. Genes & Development, 
2001. 15(18): p. 2343-2360. 
75. Schmitz, R.J., S. Sung, and R.M. Amasino, Histone arginine methylation is required for 
vernalization-induced epigenetic silencing of FLC in winter-annual Arabidopsis thaliana. 
Proceedings of the National Academy of Sciences, 2008. 105(2): p. 411-416. 
76. Balint, B.L., et al., Arginine Methylation Provides Epigenetic Transcription Memory for 
Retinoid-Induced Differentiation in Myeloid Cells. Molecular and Cellular Biology, 2005. 
25(13): p. 5648-5663. 
77. Helin, K. and D. Dhanak, Chromatin proteins and modifications as drug targets. Nature, 2013. 
502(7472): p. 480-488. 
78. Liang, G., et al., Distinct localization of histone H3 acetylation and H3-K4 methylation to the 
transcription start sites in the human genome. Proceedings of the National Academy of 
Sciences of the United States of America, 2004. 101(19): p. 7357-7362. 
79. Pokholok, D.K., et al., Genome-wide Map of Nucleosome Acetylation and Methylation in 
Yeast. Cell, 2005. 122(4): p. 517-527. 
80. Barski, A., et al., High-Resolution Profiling of Histone Methylations in the Human Genome. 
Cell, 2007. 129(4): p. 823-837. 
81. Roh, T.-Y., et al., The genomic landscape of histone modifications in human T cells. 
Proceedings of the National Academy of Sciences, 2006. 103(43): p. 15782-15787. 
82. Bannister, A.J., et al., Selective recognition of methylated lysine 9 on histone H3 by the HP1 
chromo domain. Nature, 2001. 410(6824): p. 120-124. 
83. Schotta, G., et al., A silencing pathway to induce H3-K9 and H4-K20 trimethylation at 
constitutive heterochromatin. Genes & Development, 2004. 18(11): p. 1251-1262. 
84. Loyola, A., et al., PTMs on H3 Variants before Chromatin Assembly Potentiate Their Final 
Epigenetic State. Molecular Cell, 2006. 24(2): p. 309-316. 
85. Yuan, J., et al., Histone H3-K56 acetylation is important for genomic stability in mammals. 
Cell cycle, 2009. 8(11): p. 1747-1753. 
86. Lee, J.-S., E. Smith, and A. Shilatifard, The language of histone crosstalk. Cell, 2010. 142(5): p. 
682-685. 
87. Fuchs, S.M., et al., Influence of Combinatorial Histone Modifications on Antibody and Effector 
Protein Recognition. Current Biology, 2011. 21(1): p. 53-58. 
88. Schwämmle, V., et al., Large Scale Analysis of Co-existing Post-translational Modifications in 
Histone Tails Reveals Global Fine Structure of Cross-talk. Molecular & Cellular Proteomics, 
2014. 13(7): p. 1855-1865. 
89. Cheung, P., et al., Synergistic coupling of histone H3 phosphorylation and acetylation in 
response to epidermal growth factor stimulation. Molecular cell, 2000. 5(6): p. 905-915. 
90. Lo, W.-S., et al., Phosphorylation of serine 10 in histone H3 is functionally linked in vitro and 
in vivo to Gcn5-mediated acetylation at lysine 14. Molecular cell, 2000. 5(6): p. 917-926. 
91. Portela, A. and M. Esteller, Epigenetic modifications and human disease. Nat Biotech, 2010. 
28(10): p. 1057-1068. 
92. Sun, Z.-W. and C.D. Allis, Ubiquitination of histone H2B regulates H3 methylation and gene 
silencing in yeast. Nature, 2002. 418(6893): p. 104-108. 
93. Kim, J., et al., RAD6-Mediated transcription-coupled H2B ubiquitylation directly stimulates 
H3K4 methylation in human cells. Cell, 2009. 137(3): p. 459-471. 
69 
 
 
 
94. Guillemette, B., et al., H3 lysine 4 is acetylated at active gene promoters and is regulated by 
H3 lysine 4 methylation. 2011. 
95. Strahl, B.D. and C.D. Allis, The language of covalent histone modifications. Nature, 2000. 
403(6765): p. 41-45. 
96. Zeng, L. and M.-M. Zhou, Bromodomain: an acetyl-lysine binding domain. FEBS letters, 2002. 
513(1): p. 124-128. 
97. Filippakopoulos, P. and S. Knapp, The bromodomain interaction module. FEBS letters, 2012. 
586(17): p. 2692-2704. 
98. Kasten, M., et al., Tandem bromodomains in the chromatin remodeler RSC recognize 
acetylated histone H3 Lys14. The EMBO journal, 2004. 23(6): p. 1348-1359. 
99. Jacobson, R.H., et al., Structure and function of a human TAFII250 double bromodomain 
module. Science, 2000. 288(5470): p. 1422-1425. 
100. Florence, B. and D.V. Faller, You bet-cha: a novel family of transcriptional regulators. 
Frontiers in bioscience: a journal and virtual library, 2001. 6: p. D1008-18. 
101. LeRoy, G., B. Rickards, and S. Flint, The double bromodomain proteins Brd2 and Brd3 couple 
histone acetylation to transcription. Molecular cell, 2008. 30(1): p. 51-60. 
102. Morinière, J., et al., Cooperative binding of two acetylation marks on a histone tail by a single 
bromodomain. Nature, 2009. 461(7264): p. 664-668. 
103. Nielsen, P.R., et al., Structure of the HP1 chromodomain bound to histone H3 methylated at 
lysine 9. Nature, 2002. 416(6876): p. 103-107. 
104. Rea, S., et al., Regulation of chromatin structure by site-specific histone H3 
methyltransferases. Nature, 2000. 406(6796): p. 593-599. 
105. Carrozza, M.J., et al., The diverse functions of histone acetyltransferase complexes. Trends in 
Genetics, 2003. 19(6): p. 321-329. 
106. Taylor, G.C.A., et al., H4K16 acetylation marks active genes and enhancers of embryonic stem 
cells, but does not alter chromatin compaction. Genome Research, 2013. 23(12): p. 2053-
2065. 
107. Papait, R., et al., Genome-wide analysis of histone marks identifying an epigenetic signature 
of promoters and enhancers underlying cardiac hypertrophy. Proceedings of the National 
Academy of Sciences, 2013. 110(50): p. 20164-20169. 
108. Wang, Z., et al., Genome-wide Mapping of HATs and HDACs Reveals Distinct Functions in 
Active and Inactive Genes. Cell. 138(5): p. 1019-1031. 
109. Struhl, K., Histone acetylation and transcriptional regulatory mechanisms. Genes & 
Development, 1998. 12(5): p. 599-606. 
110. Utley, R.T., et al., Transcriptional activators direct histone acetyltransferase complexes to 
nucleosomes. Nature, 1998. 394(6692): p. 498-502. 
111. Pokholok, D., et al., Genome-wide map of nucleosome acetylation and methylation in yeast. 
Cell, 2005. 122(4): p. 517 - 527. 
112. Singh, B.N., et al., Nonhistone protein acetylation as cancer therapy targets. 2010. 
113. Friedmann, D.R. and R. Marmorstein, Structure and mechanism of non‐histone protein 
acetyltransferase enzymes. FEBS Journal, 2013. 280(22): p. 5570-5581. 
114. Roth, S.Y., J.M. Denu, and C.D. Allis, HISTONE ACETYLTRANSFERASES. Annual Review of 
Biochemistry, 2001. 70(1): p. 81-120. 
115. Lee, K.K. and J.L. Workman, Histone acetyltransferase complexes: one size doesn't fit all. Nat 
Rev Mol Cell Biol, 2007. 8(4): p. 284-295. 
116. Craig, J.M. and N.C. Wong, Epigenetics: a reference manual. Concepts in Histone 
Acetyltransferase Biology. 2011, Norfolk, UK: Horizon Scientific Press. 
117. Hayakawa, T. and J.-i. Nakayama, Physiological roles of class I HDAC complex and histone 
demethylase. BioMed Research International, 2010. 2011. 
70 
 
 
 
118. Kasten, M.M., S. Dorland, and D.J. Stillman, A large protein complex containing the yeast 
Sin3p and Rpd3p transcriptional regulators. Molecular and Cellular Biology, 1997. 17(8): p. 
4852-8. 
119. Zhang, Y., et al., Histone Deacetylases and SAP18, a Novel Polypeptide, Are Components of a 
Human Sin3 Complex. Cell, 1997. 89(3): p. 357-364. 
120. Rundlett, S.E., et al., Transcriptional repression by UME6 involves deacetylation of lysine 5 of 
histone H4 by RPD3. Nature, 1998. 392(6678): p. 831-835. 
121. Kadosh, D. and K. Struhl, Repression by Ume6 Involves Recruitment of a Complex Containing 
Sin3 Corepressor and Rpd3 Histone Deacetylase to Target Promoters. Cell, 1997. 89(3): p. 
365-371. 
122. Shirakawa, K., et al., Reactivation of latent HIV by histone deacetylase inhibitors. Trends in 
Microbiology, 2013. 21(6): p. 277-285. 
123. Grozinger, C.M. and S.L. Schreiber, Deacetylase enzymes: biological functions and the use of 
small-molecule inhibitors. Chemistry & biology, 2002. 9(1): p. 3-16. 
124. Johnsson, A., et al., HAT–HDAC interplay modulates global histone H3K14 acetylation in 
gene‐coding regions during stress. Vol. 10. 2009. 1009-1014. 
125. Yamagoe, S., et al., Interaction of Histone Acetylases and Deacetylases In Vivo. Molecular 
and Cellular Biology, 2003. 23(3): p. 1025-1033. 
126. Che, J., et al., Hyper-Acetylation of Histone H3K56 Limits Break-Induced Replication by 
Inhibiting Extensive Repair Synthesis. PLoS Genet, 2015. 11(2): p. e1004990. 
127. Taylor, J.P., et al., Aberrant histone acetylation, altered transcription, and retinal 
degeneration in a Drosophila model of polyglutamine disease are rescued by CREB-binding 
protein. Genes & Development, 2003. 17(12): p. 1463-1468. 
128. Yang, F., et al., Histone hyperacetylation during meiosis interferes with large-scale chromatin 
remodeling, axial chromatid condensation and sister chromatid separation in the 
mammalian oocyte. Int J Dev Biol, 2012. 56: p. 889-899. 
129. Song, J.S., et al., Global histone modification pattern associated with recurrence and disease-
free survival in non-small cell lung cancer patients. Pathology International, 2012. 62(3): p. 
182-190. 
130. Seligson, D.B., et al., Global histone modification patterns predict risk of prostate cancer 
recurrence. Nature, 2005. 435(7046): p. 1262-1266. 
131. Barlési, F., et al., Global Histone Modifications Predict Prognosis of Resected Non–Small-Cell 
Lung Cancer. Journal of Clinical Oncology, 2007. 25(28): p. 4358-4364. 
132. Elsheikh, S.E., et al., Global Histone Modifications in Breast Cancer Correlate with Tumor 
Phenotypes, Prognostic Factors, and Patient Outcome. Cancer Research, 2009. 69(9): p. 
3802-3809. 
133. Fraga, M.F., et al., Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a 
common hallmark of human cancer. Nat Genet, 2005. 37(4): p. 391-400. 
134. Sharma, G.G., et al., MOF and Histone H4 Acetylation at Lysine 16 Are Critical for DNA 
Damage Response and Double-Strand Break Repair. Molecular and Cellular Biology, 2010. 
30(14): p. 3582-3595. 
135. Vaquero, A., et al., Human SirT1 Interacts with Histone H1 and Promotes Formation of 
Facultative Heterochromatin. Molecular Cell, 2004. 16(1): p. 93-105. 
136. Song, J., et al., Increased expression of histone deacetylase 2 is found in human gastric 
cancer. APMIS, 2005. 113(4): p. 264-268. 
137. Halkidou, K., et al., Upregulation and Nuclear Recruitment of HDAC1 in Hormone Refractory 
Prostate Cancer. The Prostate, 2004. 59(2): p. 177-189. 
138. Minucci, S., et al., Histone deacetylases: a common molecular target for differentiation 
treatment of acute myeloid leukemias? Oncogene, 2001. 20(24): p. 3110-3115. 
71 
 
 
 
139. Li, Z. and W.-G. Zhu, Targeting histone deacetylases for cancer therapy: from molecular 
mechanisms to clinical implications. International journal of biological sciences, 2014. 10(7): 
p. 757. 
140. Dokmanovic, M., C. Clarke, and P.A. Marks, Histone Deacetylase Inhibitors: Overview and 
Perspectives. Molecular Cancer Research, 2007. 5(10): p. 981-989. 
141. Mann, B.S., Johnson, John R., Cohen, Martin H., Justice, Robert, Pazdur, Richard, FDA 
Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell 
Lymphoma. The Oncologist, 2007. 12(10): p. 1247-1252. 
142. Drogaris, P., et al., Histone Deacetylase Inhibitors Globally Enhance H3/H4 Tail Acetylation 
Without Affecting H3 Lysine 56 Acetylation. Sci. Rep., 2012. 2. 
143. Li, C.T., et al., Vorinostat, SAHA, represses telomerase activity via epigenetic regulation of 
telomerase reverse transcriptase in non‐small cell lung cancer cells. Journal of cellular 
biochemistry, 2011. 112(10): p. 3044-3053. 
144. Butler, L.M., et al., The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-
regulates thioredoxin-binding protein-2, and down-regulates thioredoxin. Proceedings of the 
National Academy of Sciences, 2002. 99(18): p. 11700-11705. 
145. Butler, L.M., et al., Suberoylanilide Hydroxamic Acid, an Inhibitor of Histone Deacetylase, 
Suppresses the Growth of Prostate Cancer Cells in Vitro and in Vivo. Cancer Research, 2000. 
60(18): p. 5165-5170. 
146. VanderMolen, K.M., et al., Romidepsin (Istodax, NSC 630176, FR901228, FK228, 
depsipeptide): a natural product recently approved for cutaneous T-cell lymphoma. J 
Antibiot, 2011. 64(8): p. 525-531. 
147. Grant, C., et al., Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential 
therapy for solid tumors. Expert Review of Anticancer Therapy, 2010. 10(7): p. 997-1008. 
148. DiGiulio, S., FDA Approves Farydak (Panobinostat) for Multiple Myeloma. Oncology Times, 
2015. 
149. Tate, C.R., et al., Targeting triple-negative breast cancer cells with the histone deacetylase 
inhibitor panobinostat. Breast Cancer Res, 2012. 14(3): p. R79. 
150. Beckers, T., et al., Distinct pharmacological properties of second generation HDAC inhibitors 
with the benzamide or hydroxamate head group. International Journal of Cancer, 2007. 
121(5): p. 1138-1148. 
151. Minucci, S. and P.G. Pelicci, Histone deacetylase inhibitors and the promise of epigenetic (and 
more) treatments for cancer. Nat Rev Cancer, 2006. 6(1): p. 38-51. 
152. McGee-Lawrence, M.E., et al., Suberoylanilide hydroxamic acid (SAHA; vorinostat) causes 
bone loss by inhibiting immature osteoblasts. Bone, 2011. 48(5): p. 1117-1126. 
153. Pratap, J., et al., The Histone Deacetylase Inhibitor, Vorinostat, Reduces Tumor Growth at the 
Metastatic Bone Site and Associated Osteolysis, but Promotes Normal Bone Loss. Molecular 
Cancer Therapeutics, 2010. 9(12): p. 3210-3220. 
154. Duvic, M. and C. Zhang, Clinical and laboratory experience of vorinostat (suberoylanilide 
hydroxamic acid) in the treatment of cutaneous T-cell lymphoma. Br J Cancer, 0000. 95(S1): 
p. S13-S19. 
155. Andreu-Vieyra, C.V. and J.R. Berenson, The potential of panobinostat as a treatment option 
in patients with relapsed and refractory multiple myeloma. Therapeutic Advances in 
Hematology, 2014. 5(6): p. 197-210. 
156. Phillips, D., The presence of acetyl groups in histones. Biochemical Journal, 1963. 87(2): p. 
258. 
157. Phillips, D., A micromethod for the determination of N-and O-acetyl groups. Biochemical 
Journal, 1963. 86(3): p. 397. 
158. Gershey, E., G. Vidali, and V. Allfrey, Chemical Studies of Histone Acetylation: The occurrence 
of ε-N-acetyllysine in the f2a1 histone Journal of Biological Chemistry, 1968. 243(19): p. 
5018-5022. 
72 
 
 
 
159. Vidali, G., E. Gershey, and V. Allfrey, Chemical Studies of Histone Acetylation: The distribution 
of ε-N-acetyllysine in calf thymus histones. Journal of Biological Chemistry, 1968. 243(24): p. 
6361-6366. 
160. BODE, J., K. HENCO, and E. WINGENDER, Modulation of the nucleosome structure by histone 
acetylation. European Journal of Biochemistry, 1980. 110(1): p. 143-152. 
161. BODE, J., M. GÓMEZ‐LIRA, and H. SCHRÖTER, Nucleosomal particles open as the histone core 
becomes hyperacetylated. European Journal of Biochemistry, 1983. 130(3): p. 437-445. 
162. Garcia-Ramirez, M., C. Rocchini, and J. Ausio, Modulation of Chromatin Folding by Histone 
Acetylation. Journal of Biological Chemistry, 1995. 270(30): p. 17923-17928. 
163. Chahal, S.S., H.R. Matthews, and E.M. Bradbury, Acetylation of histone H4 and its role in 
chromatin structure and function. Nature, 1980. 287(5777): p. 76-79. 
164. Muller, S., et al., Specificity of antibodies raised against triacetylated histone H4. Molecular 
immunology, 1987. 24(7): p. 779-789. 
165. Pfeffer, U., N. Ferrari, and G. Vidali, Availability of hyperacetylated H4 histone in intact 
nucleosomes to specific antibodies. Journal of Biological Chemistry, 1986. 261(6): p. 2496-
2498. 
166. Baeza, J., et al., Stoichiometry of site-specific lysine acetylation in an entire proteome. Journal 
of Biological Chemistry, 2014. 
167. Weinert, B.T., et al., Acetylation dynamics and stoichiometry in Saccharomyces cerevisiae. 
Vol. 10. 2014. 
168. Zee, B.M., N.L. Young, and B.A. Garcia, Suppl 1: Quantitative Proteomic Approaches to 
Studying Histone Modifications. Current chemical genomics, 2011. 5: p. 106. 
169. Moradian, A., et al., The top-down, middle-down, and bottom-up mass spectrometry 
approaches for characterization of histone variants and their post-translational 
modifications. PROTEOMICS, 2014. 14(4-5): p. 489-497. 
170. Guan, S. and A.L. Burlingame, Data Processing Algorithms for Analysis of High Resolution 
MSMS Spectra of Peptides with Complex Patterns of Posttranslational Modifications. 
Molecular & Cellular Proteomics, 2010. 9(5): p. 804-810. 
171. Yuan, Z.-F., et al., Evaluation of Proteomic Search Engines for the Analysis of Histone 
Modifications. Journal of Proteome Research, 2014. 13(10): p. 4470-4478. 
172. Sidoli, S., et al., Middle-down hybrid chromatography/tandem mass spectrometry workflow 
for characterization of combinatorial post-translational modifications in histones. 
PROTEOMICS, 2014. 14(19): p. 2200-2211. 
173. Walker, J.M., The Protein Protocols Handbook. 2 ed. 2002, Totowa, NJ Humana Press Inc. 
174. Shevchenko, A., et al., Mass Spectrometric Sequencing of Proteins from Silver-Stained 
Polyacrylamide Gels. Analytical Chemistry, 1996. 68(5): p. 850-858. 
175. Riviere, L.R. and P. Tempst, Current Protocols in Protein Science. June, 1995, Brooklyn: John 
Wiley & Sons, Inc. 
176. Aguilar, M.-I., Reversed-Phase High-Performance Liquid Chromatography #, in T HPLC of 
Peptides and Proteins. 2003. p. 9-22. 
177. Vailaya, A. and C. Horváth, Retention in reversed-phase chromatography: partition or 
adsorption? Journal of Chromatography A, 1998. 829(1): p. 1-27. 
178. Pearson, J.D. and F.E. Regnier, The Influence of Reversed-Phase n-Alkyl Chain Length on 
Protein Retention, Resolution and Recovery: Implications for Preparative HPLC. Journal of 
Liquid Chromatography, 1983. 6(3): p. 497-510. 
179. Engelhardt, H. and H. Müller, Optimal conditions for the reversed-phase chromatography of 
proteins. Chromatographia, 1984. 19(1): p. 77-84. 
180. Shrivastava, A. and V.B. Gupta, HPLC: Isocratic or Gradient Elution and Assessment of 
Linearity In Analytical Methods. Journal of Advanced Scientific Research, 2012. 3(2). 
181. McGuffin, V.L., High-Performance Gradient Elution: The Practical Application of the Linear-
Solvent-Strength Model By Lloyd R. Snyder (LC Resources, Inc., Orinda, CA) and John W. 
73 
 
 
 
Dolan (LC Resources, Inc., Amity, OR). J. Wiley & Sons, Inc.: Hoboken, NJ. 2007. xxviii+ 462 pp. 
$115.00. ISBN 0-471-70646-9. Journal of the American Chemical Society, 2007. 129(27): p. 
8669-8670. 
182. Carr, D., The handbook of analysis and purification of peptides and proteins by reversed-
phase HPLC. Hesperia, CA, USA: Grace Vydac, 2002. 
183. Vestal, M.L., Methods of ion generation. Chemical reviews, 2001. 101(2): p. 361-376. 
184. Aiken, A.C., P.F. DeCarlo, and J.L. Jimenez, Elemental analysis of organic species with electron 
ionization high-resolution mass spectrometry. Analytical Chemistry, 2007. 79(21): p. 8350-
8358. 
185. Knochenmuss, R. and R. Zenobi, MALDI ionization: the role of in-plume processes. Chemical 
reviews, 2003. 103(2): p. 441-452. 
186. Signor, L. and E.B. Erba, Matrix-assisted Laser Desorption/Ionization Time of Flight (MALDI-
TOF) Mass Spectrometric Analysis of Intact Proteins Larger than 100 kDa. Journal of 
visualized experiments: JoVE, 2013(79). 
187. Fenn, J., et al., Electrospray ionization for mass spectrometry of large biomolecules. Science, 
1989. 246(4926): p. 64-71. 
188. Watson, J.T. and O.D. Sparkman, Introduction to mass spectrometry: instrumentation, 
applications, and strategies for data interpretation. 2007: John Wiley & Sons. 
189. McLuckey, S.A. and J.M. Wells, Mass analysis at the advent of the 21st century. Chemical 
reviews, 2001. 101(2): p. 571-606. 
190. Scigelova, M. and A. Makarov, Orbitrap mass analyzer-overview and applications in 
proteomics. Proteomics, 2006. 6(Suppl 2): p. 16-21. 
191. Dawson, P., Quadrupole mass analyzers: performance, design and some recent applications. 
Mass Spectrometry Reviews, 1986. 5(1): p. 1-37. 
192. Miller, P.E. and M.B. Denton, The quadrupole mass filter: basic operating concepts. Journal 
of chemical education, 1986. 63(7): p. 617. 
193. March, R.E., An introduction to quadrupole ion trap mass spectrometry. Journal of mass 
spectrometry, 1997. 32(4): p. 351-369. 
194. Guilhaus, M., Principles and instrumentation in time-of-flight mass spectrometry. Physical 
and instrumental concepts. Journal of Mass Spectrometry, 1995. 30(11): p. 1519-1532. 
195. Van Berkel, W.J., et al., Detection of intact megaDalton protein assemblies of vanillyl‐alcohol 
oxidase by mass spectrometry. Protein Science, 2000. 9(3): p. 435-439. 
196. Wenzel, R.J., et al., Analysis of megadalton ions using cryodetection MALDI time-of-flight 
mass spectrometry. Analytical chemistry, 2005. 77(14): p. 4329-4337. 
197. Marshall, A.G., C.L. Hendrickson, and G.S. Jackson, Fourier transform ion cyclotron resonance 
mass spectrometry: a primer. Mass spectrometry reviews, 1998. 17(1): p. 1-35. 
198. Makarov, A., Electrostatic axially harmonic orbital trapping: a high-performance technique of 
mass analysis. Analytical chemistry, 2000. 72(6): p. 1156-1162. 
199. Demartini, D.R., A Short Overview of the Components in Mass Spectrometry Instrumentation 
for Proteomics Analyses. 2013. 
200. Roepstorff, P. and J. Fohlman, Proposal for a common nomenclature for sequence ions in 
mass spectra of peptides. Biomedical mass spectrometry, 1984. 11(11). 
201. Tang, X.J., P. Thibault, and R.K. Boyd, Fragmentation reactions of multiply-protonated 
peptides and implications for sequencing by tandem mass spectrometry with low-energy 
collision-induced dissociation. Analytical Chemistry, 1993. 65(20): p. 2824-2834. 
202. McAlister, G.C., et al., Higher-energy Collision-activated Dissociation Without a Dedicated 
Collision Cell. Molecular & Cellular Proteomics, 2011. 10(5). 
203. Olsen, J.V., et al., Higher-energy C-trap dissociation for peptide modification analysis. Nat 
Meth, 2007. 4(9): p. 709-712. 
74 
 
 
 
204. Syka, J.E.P., et al., Peptide and protein sequence analysis by electron transfer dissociation 
mass spectrometry. Proceedings of the National Academy of Sciences of the United States of 
America, 2004. 101(26): p. 9528-9533. 
205. Fenyö, D., Identifying the proteome: software tools. Current Opinion in Biotechnology, 2000. 
11(4): p. 391-395. 
206. Eng, J., A. McCormack, and J. Yates, An approach to correlate tandem mass spectral data of 
peptides with amino acid sequences in a protein database. Journal of the American Society 
for Mass Spectrometry, 1994. 5(11): p. 976-989. 
207. Chen, X., P. Drogaris, and M. Bern, Identification of Tandem Mass Spectra of Mixtures of 
Isomeric Peptides. Journal of Proteome Research, 2010. 9(6): p. 3270-3279. 
208. Yuan, Z.-F., et al., EpiProfile Quantifies Histone Peptides With Modifications by Extracting 
Retention Time and Intensity in High-resolution Mass Spectra. Molecular & Cellular 
Proteomics, 2015. 14(6): p. 1696-1707. 
209. Bantscheff, M., et al., Quantitative mass spectrometry in proteomics: a critical review. 
Analytical and Bioanalytical Chemistry, 2007. 389(4): p. 1017-1031. 
210. Patel, V.J., et al., A Comparison of Labeling and Label-Free Mass Spectrometry-Based 
Proteomics Approaches. Journal of Proteome Research, 2009. 8(7): p. 3752-3759. 
211. Schmidt, A., J. Kellermann, and F. Lottspeich, A novel strategy for quantitative proteomics 
using isotope-coded protein labels. PROTEOMICS, 2005. 5(1): p. 4-15. 
212. Ross, P.L., et al., Multiplexed Protein Quantitation in Saccharomyces cerevisiae Using Amine-
reactive Isobaric Tagging Reagents. Molecular & Cellular Proteomics, 2004. 3(12): p. 1154-
1169. 
213. Thompson, A., et al., Tandem Mass Tags:  A Novel Quantification Strategy for Comparative 
Analysis of Complex Protein Mixtures by MS/MS. Analytical Chemistry, 2003. 75(8): p. 1895-
1904. 
214. Ong, S.-E., et al., Stable Isotope Labeling by Amino Acids in Cell Culture, SILAC, as a Simple 
and Accurate Approach to Expression Proteomics. Molecular & Cellular Proteomics, 2002. 
1(5): p. 376-386. 
215. Neilson, K.A., et al., Less label, more free: Approaches in label-free quantitative mass 
spectrometry. PROTEOMICS, 2011. 11(4): p. 535-553. 
216. Listgarten, J. and A. Emili, Statistical and Computational Methods for Comparative Proteomic 
Profiling Using Liquid Chromatography-Tandem Mass Spectrometry. Molecular & Cellular 
Proteomics, 2005. 4(4): p. 419-434. 
 
 
 
 
 
 
 
 
 
 
75 
 
 
 
 
 
CHAPTER 2 : Chaperone-mediated Acetylation of Histones by Rtt109 
Identified by Quantitative Proteomics 
 
Nebiyu Abshiru
1, 2
, Kevin Ippersiel
2
, Yong Tang
4, 5
, Hua Yuan
4, 5
, Ronen Marmorstein
4,5
, 
Alain Verreault
1, 3,  
, Pierre Thibault
1, 2 
 
1
 Institute for Research in Immunology and Cancer, Université de Montréal, Montréal, 
Canada 
2
 Department of Chemistry, Université de Montréal, Montréal, Canada 
3
 Department of Pathology and Cell Biology, Faculty of Medicine, Université de 
Montréal, Canada 
4
 The Wistar Institute, Philadelphia, PA 19104, USA 
5
 Department of Chemistry, University of Pennsylvania, Philadelphia, PA 19104, USA 
 
Published: J. Proteomics. 2013 April 9; 81: 80–90. 
 
Author contributions: 
N.A. designed and carried out the in vitro enzyme assay and the proteomics experiment. K.I. assisted 
in the proteomics experiment. Y.T, H.Y and R.M provided recombinant enzymes. N.A. analyzed data, 
wrote the first draft of the manuscript, and generated figures. P.T and A.V. conceived and led the 
project. N.A., P.T. and A.V. wrote the final draft of the manuscript, with input from all authors. 
 
 
 
 
 
 
76 
 
 
 
2.1. Abstract 
 
Rtt109 is a fungal-specific histone acetyltransferase (HAT) that associates with either Vps75 
or Asf1 to acetylate histone H3. Recent biochemical and structural studies suggest that site-
specific acetylation of H3 by Rtt109 is dictated by the binding chaperone where Rtt109-Asf1 
acetylates K56, while Rtt109-Vps75 acetylates K9 and K27. To gain further insights into the 
roles of Vps75 and Asf1 in directing site-specific acetylation of H3, we used quantitative 
proteomics to profile the global and site-specific changes in H3 and H4 during in vitro 
acetylation assays with Rtt109 and its chaperones. Our analyses showed that Rtt109-Vps75 
preferentially acetylates H3 K9 and K23, the former residue being the major acetylation site. 
At high enzyme to substrate ratio, Rtt109 also acetylated K14, K18, K27 and to a lower 
extent K56 of histone H3. Importantly, this study revealed that in contrast to Rtt109-Vps75, 
Rtt109-Asf1 displayed a far greater site-specificity, with K56 being the primary site of 
acetylation. For the first time, we also report the acetylation of histone H4 K12 by Rtt109-
Vps75, whereas Rtt109-Asf1 showed no detectable activity toward H4. 
 
Graphical abstract 
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2.2. Introduction  
Eukaryotic DNA is assembled into a highly compact and dynamic nucleoprotein structure 
known as chromatin. The basic repeating subunit of chromatin is the nucleosome core 
particle (NCP) that comprises 147 base pairs of DNA wrapped nearly twice around a histone 
octamer [1]. The octamer is formed of an (H3–H4)2 tetramer (two molecules each of both H3 
and H4) paired with two H2A/H2B dimers. Neighboring NCPs are joined by variable lengths 
of linker DNA (10–80 bp) [2] thatbinds to histone H1 family members to promote chromatin 
compaction into a 30-nm fiber [3]. The N-terminal tails of core histones protrude from the 
nucleosome, and contain multiple lysine residues that can be modified by post-translational 
modifications (PTMs) such as acetylation, methylation, ubiquitylation and sumoylation. 
These modifications can act individually or in a combinatorial fashion to mediate epigenetic 
regulation of chromatin structure [4,5]. The acetylation of lysine residues represents one of 
the most extensively studied histone modifications thus far. This modification can directly 
affect the chromatin structure and/or favor the recruitment of other binding partners by 
providing a docking platform for histone modifying enzymes or ATP-dependent chromatin 
remodeling machineries [6–9]. The acetylation of specific lysine residues can also provide a 
chromatin mark for the regulation of gene expression [10] or to identify sites of DNA 
damage. For instance, recent studies have shown that acetylation of H3K56 and H4K16 is 
significantly elevated in mammalian cells in response to DNA damage [11–13].  
Histone acetylation is regulated by two enzyme families known as histone acetyltransferases 
(HATs) and histone deacetylases (HDACs) [14,15]. HATs catalyze the transfer of acetyl 
groups from acetyl-coenzyme A (CoA) to the ε-amino group of specific lysines on histone 
substrates while HDACs remove N-acetyl moieties on target lysine residues. These two 
enzyme families act antagonistically to modulate gene expression [16], and abnormal activity 
of some of these enzymes have been observed in different types of cancer [17]. For example, 
mutations in CBP (which encodes a HAT) and chromosomal translocation with MLL are 
hallmarks of different human diseases including specific types of leukemia [17–19].  
The regulator of Ty1 transposition gene product 109 (Rtt109) is a fungal-specific HAT that 
acetylates newly synthesized histone H3 prior to its incorporation into chromatin. Rtt109 is 
involved in the response to genotoxic agents and the regulation of gene expression [20,21]. 
Rtt109 has a conserved core region that is structurally related to other HAT enzymes though 
they share limited sequence homology. Recent structural and biochemical analyses of Rtt109 
78 
 
 
 
revealed significant homology to the metazoan p300/CBP HAT domain, and also highlighted 
important differences in their catalytic properties [22]. The enzyme activity of Rtt109 is 
greatly enhanced by its association with either Vps75 or Asf1 histone chaperones [23,24]. 
These two chaperones are not structurally related but they both bind to new H3/H4 molecules 
[25,26]. While Rtt109 interacts only weakly with Asf1, crystal structures revealed the 
formation of a tight and stable complex with the chaperone Vps75 [27–29]. The chaperones 
are required to present the substrate in a distinct orientation that confers target specificity to 
Rtt109. A recent review by D'Arcy et al. indicated that Rtt109–Vps75 sequentially acetylates 
histone H3 at K9 and K27, whereas the Rtt109–Asf1 complex primarily acetylates K56 [29]. 
However, the exact sites of acetylation targeted by Rtt109–Vps75 are not entirely clear as an 
early study by Berndsen et al. [30] reported that this enzyme acetylated H3K9 and H3K23 but 
not H3K27.  
In the present study, we used quantitative proteomics to determine the site-specific 
acetylation of histones by Rtt109 associated with either the Vps75 or the Asf1 histone 
chaperone. This is achieved by using a two-pronged approach that we previously developed 
to profile changes in histone modifications between wild-type and HAT mutant yeast strains 
[31] and for human cells incubated with different HDAC inhibitors [32]. First, temporal 
changes in H3–H4 acetylation following incubation with Rtt109–Vps75 and Rtt109–Asf1 are 
determined from the LC–MS mass profiles of intact histones. Second, the acetylated histones 
are subjected to propionylation, tryptic digestion and LC–MS/MS analyses to identify 
acetylated lysine residues and their respective changes in stoichiometry. This strategy enabled 
precise and comprehensive determination of acetylated lysine stoichiometry to 
unambiguously identify chaperone-mediated acetylation of histones H3 and H4 by Rtt109. 
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2.3. Methods 
2.3.1. Reagents  
Capillary LC columns for nano LC–MS were packed in-house using Jupiter C18 (3 μm 
particle Phenomenex), and fused silica tubing (Polymicro Technologies). Trapping columns 
were packed in-house using the same bulk material in Teflon tubing (Supelco). Water and 
acetonitrile (ACN) for chromatographic analysis were all HPLC grade (Fisher Scientific and 
in-house Milli-Q water). Trifluoroacetic acid (TFA), anhydrous methanol, ammonium 
bicarbonate, ammonium hydroxide, and propionic anhydride were all purchased from Sigma. 
Formic acid (FA) was obtained from EMD Science. Porcine modified trypsin (sequencing 
grade) was obtained from Promega.  
 
2.3.2. Histone purification 
Recombinant (H3–H4)2 tetramers or monomeric H3 were purified from Escherichia coli as 
previously described [33]. The holoenzyme Rtt109–Vps75 was expressed and purified 
according to methods reported by Tang et al. [28]. Because Asf1 and Rtt109 do not form a 
stable complex, the two polypeptides were expressed and purified separately. The gene 
encoding full-length Rtt109 was cloned into a modified pET Duet vector (Novagen) with a 
TEV-cleavable GST tag, as previously described [22]. A gene encoding Saccharomyces 
cerevisiae 6His-Asf1N(1–154) was constructed into a modified pET Duet vector (Novagen) 
with a thrombin/TEV-cleavable 6His tag. Both recombinant proteins were expressed in E. 
coli BL21(DE3). After induction with 0.8 mM IPTG, cells were incubated overnight at 18 °C 
and then harvested for protein purification. The GST-Rtt109 protein was purified using a 
standard GST-affinity procedure with on-resin TEV protease digestion. The cleaved Rtt109 
protein was eluted off the resin using PBS buffer and then flash frozen using liquid nitrogen 
and stored at −80 °C for future use. The 6His-tagged Asf1 protein was purified through Ni-
NTA affinity and ion exchange chromatography before being subjected to TEV protease 
cleavage in solution and size exclusion chromatography.  
 
2.3.3. HAT assay  
In vitro HAT assays were performed using recombinant (H3–H4)2 tetramer (or H3 
monomer), acetyl-CoA and Rtt109–Vps75/Asf1 enzyme–chaperone complexes. The assays 
were performed byincubating the substrates and enzyme/chaperone complexes for different 
time periods (0 to 90 min) at 30 °C. Unless otherwise indicated, histone tetramers or 
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monomers were incubated with Rtt109–Vps75/Asf1 enzyme–chaperone complexes at a 1:1 
enzyme-to-substrate ratio. Acetyl-CoA was added to all samples to a final concentration of 
100 μM. The reaction buffer consisted of 1 mM DTT in 25 mM ammonium bicarbonate 
solution (pH 7.8). The enzymatic reactions were quenched with 5% TFA. A control sample 
(without Rtt109) was included to monitor assay conditions. 
2.3.4. Sample preparation and protein digestion  
Histone samples were desalted on a pre-equilibrated C18 ZipTip pipette tips (Millipore). 
Desalting was performed according to manufacturer's instructions. Each eluate was divided 
into two portions and dried in a speed-vac. The first portion of samples was resuspended in 
0.2% FA for analysis of intact histones by LC/MS. The remaining samples were subjected to 
propionylation, tryptic digestion and peptide sequencing by LC–MS/MS. The propionylation 
reaction is performed by adding 200 μl of the propionylation reagent (de-ionized water: 
propionic anhydride, 2:1 (v/v)) to the histone samples and vortexing the mixture for 1 h at 
room temperature. Samples were then dried, resuspended in 0.1 M ammonium bicarbonate 
(pH 7.8), and digested overnight at 37 °C using trypsin (1:50, enzyme:substrate ratio). 
Digests were resuspended in 0.2 % FA in water (v/v) prior to LC–MS/MS analyses [31].  
2.3.5. LC/MS analysis of intact histones  
Intact histone analysis was performed on an Agilent QTOF 6520 LC/MS system equipped 
with nano-ESI source. The mass spectrometer was operated in positive ion mode and scanned 
from m/z 400 to 1600. Prior to injection, histone samples were diluted to 200 ng/μl using 
0.2% FA in water. An aliquot of 5 μl was loaded on a custom C18 trap column (4 mm length, 
360 μm i.d.) for 5 min at 15 μl/min using 0.2% FA. Histones were then eluted onto a C18 
analytical column (10 cm length, 150 μm i.d.) using a gradient of 5 to 60% aqueous ACN 
(0.2% FA) in 60 min at 600 nl/min. The Agilent MassHunter Workstation Software (version 
B.01.04) was used to deconvolute the multiply-charged protein ions over a discrete time-
segment of the LC–MS run.  
2.3.6. LC–MS/MS analysis of tryptic peptides  
Tryptic digests of propionylated histone samples were analyzed on LTQ-Orbitrap XL mass 
spectrometer (Thermo Fisher scientific) coupled to an Eksigent nano-LC system. The same 
column and solvent systems were used as described above for the LC/MS analysis of intact 
histones. The mass spectrometer was operated in a data-dependent acquisition mode with full 
scan (m/z 300–2000) resolution set to 60,000, with a target value of 1.0×106 . The six most 
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abundant precursor ions were selected for fragmentation in the LTQ by CID at a normalized 
CE setting of 35. Fragment ions were analyzed in the LTQ ion trap over the mass range of 
m/z 200–2000 with a target value of 1.0×104. 
2.3.7. Database searching and peptide clustering  
MS data were analyzed using the Xcalibur software (version 2.0.7). Peak lists were generated 
using the Mascot distiller software (version 2.3.2.0, Matrix science) where MS processing 
was achieved using the LCQ_plus_zoom script. Database searches were performed using the 
search engine Mascot (version 2.2.0, Matrix Science, London, UK) with the concatenated 
forward and reverse Saccharomyces Genome Database (SGD, version 64.1). The tolerance 
window for experimental precursor mass values and fragment ion mass values were set to 
±15 ppm and 0.5 Da, respectively. The number of allowed missed cleavage sites for trypsin 
was set to 5 and acetylation (K), propionylation (K), oxidation (M), and deamidation (NQ) 
were all selected as variable modifications. No fixed modification was included in the search. 
All peptide identifications were transferred to ProteoConnections [34], an in-house developed 
bioinformatics tool, to generate a .csv (comma separated value) file that can be opened and 
modified in Excel. The .csv output file contained only distinct peptides (peptide with 
maximum score is kept) with assigned Mascot score of greater than or equal to 20. Manual 
MS/MS spectra verification was performed on each modified peptide to confirm the sequence 
assignment. 
The clustering of peptide abundances across different experimental conditions was performed 
using in-house tools as described previously [32]. Briefly, raw data files (.raw) from the 
Xcalibur software were converted into peptide map files representing all ions according to 
their corresponding m/z values, retention time, intensity, and charge state. An intensity 
threshold of 5000 counts was set as a cut-off for peptide detection. Peptide abundances were 
determined using the peak top intensity values. Clustering of peptide maps across different 
sample sets were performed on peptides associated to a Mascot entry using hierarchical 
clustering with tolerances of ±15 ppm and ±1 min for peptide mass and retention time, 
respectively. Normalization of retention time is performed on the initial peptide cluster list 
using a dynamic and nonlinear correction that confines the retention time distribution to less 
than 0.1 min (< 0.3% relative standard deviation, RSD) on average. Global intensities were 
normalized based on the average intensity of all peptide signals. Peptide clusters showing 
reproducible changes in abundance across conditions were manually inspected to validate 
identification and changes in abundance. 
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2.4. Results  
2.4.1. nLC/MS analysis of histones  
Our MS analysis of histones involves a two-pronged strategy to profile the distribution of 
molecular mass and identify sites of modification [31]. This approach utilizes both intact 
histones and tryptic peptides to profile global and site-specific changes in histone 
modifications. First, intact histones are analyzed to determine changes in their mass profiles 
that can be attributed to specific modifications. Second, peptide maps generated from nano 
LC–MS/MS analysis of the corresponding tryptic digests are compared to identify peptides 
showing statistically meaningful changes in abundance across conditions. In the present 
study, we extended the application of this approach to determine the kinetics and site-
specificity of Rtt109 toward histones H3 and H4. The experimental workflow is illustrated in 
Fig. 2.1. Prior to MS analysis, recombinant histones H3 and H4 (monomeric or tetrameric 
forms) were incubated with either Rtt109–Vps75 or Rtt109–Asf1 HAT complex for different 
time periods (0 to 90 min). A portion of each intact histone sample was analyzed by LC/MS 
on a QTOF instrument, while the remaining sample was propionylated and digested by 
trypsin prior to peptide sequencing by LC–MS/MS on a LTQ-Orbitrap XL mass 
spectrometer. 
 
 
 
 
 
 
 
 
 
 
83 
 
 
 
 
Figure 2.1 Overview of the analytical scheme for profiling histone modifications. 
 
2.4.2. Histone acetylation by Rtt109–Vps75/Asf1 complexes 
To profile the progressive changes in acetylation of the H3:H4 tetramers upon incubation 
with either Rtt109–Vps75 or Rtt109–Asf1 complexes, we first analyzed the enzymatic 
products using LC–MS. An enzyme-to-substrate ratio of 1:1 was maintained in all cases. H3 
and H4 histones along with Rtt109 and its chaperones were chromatographically separated 
and displayed abundant multiply-charged ion spectra from which the molecular mass could 
be determined. Under the present chromatographic conditions, we identified H4 (Mobs: 
11,237 Da), and H3 (Mobs: 15,225 Da), at 43.6 and 47.1 min respectively (Fig. S2.1). The 
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observed molecular mass was within ±1 Da of the value calculated from the protein 
sequence. To account for changes in histone acetylation over different incubation periods, we 
normalized the intensity of individual peak to that of histones from the control sample. The 
relative proportion of histones displaying different degrees of acetylation was determined 
from the abundance ratio of a specific acetylated form to the sum of all forms of identified 
histones.  
Fig. 2.2 shows the intact mass profiles of acetylated histone H3 (M.theor. 15,225 Da) 
following the in vitro HAT assay with Rtt109–Vps75 and Rtt109–Asf1 complexes. As 
expected, a progressive increase in histone H3 acetylation is observed over the first 90 min of 
incubation. Interestingly, a broader distribution of acetylated products is observed for 
Rtt109–Vps75compared to Rtt109–Asf1 although identical enzyme:substrate ratios were used 
in all cases. Acetylation of H3 by Rtt109–Vps75 proceeded rapidly, and up to three acetyl 
groups were detected within the first minute of incubation (Fig. 2.2A). In contrast, acetylation 
of H3 by Rtt109–Asf1 progressed more slowly, and the first acetylated form of H3 was 
detected only after 5 min of incubation (Fig. 2.2B). We observed that incubation of H3 with 
Rtt109–Vps75 yielded up to 5 acetylation sites over the first 90 min of the in vitro HAT 
assay. The relative proportion of each acetylated form of H3 is shown in Fig. 2.2C. As 
indicated, H3 is rapidly acetylated by Rtt109–Vps75 within the first 15 min. The successive 
acetylation resulted in mono- to penta-acetylated H3 with the tetra acetylated form being 
predominant beyond 30 min of incubation. In contrast, Rtt109–Asf1 showed a narrower 
distribution of H3 acetylation, and no more than three sites were detected over the same 
incubation period (Fig. 2.2D). The relative proportion of unmodified H3 decreased very 
slowly, and the mono-acetylated H3 remained the most abundant form detected after 90 min 
of incubation. 
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Figure 2.2  LC/MS analyses of intact histone H3 obtained from in vitro HAT assay. 
 (A) Intact mass profiles of histone H3 obtained from in vitro HAT assay with Rtt109–Vps75 
and (B) with Rtt109–Asf1. Incubation times (from top to bottom) are 0, 1, 5, 15, 30, 60 and 
90 min. (C) Bar graph represents the extent of H3 acetylation after HAT assay with Rtt109–
Vps75 (raw intensity data: Table S2.1)  and (D) with Rtt109–Asf1 (raw intensity data: Table 
S2.2). 
 
Although Vps75 and Asf1 were previously reported to affect the acetylation status of histone 
H3, we also examined the activity of these chaperones on the acetylation of H4 by Rtt109. 
Similar to that described before, we determined the extent of acetylation of histone H4 
following incubation of the H3:H4 tetramers with Rtt109–Vps75 and Rtt109–Asf1 (Fig. 2.3). 
Upon incubation with Rtt109–Vps75, no significant acetylation of histone H4 (Mobs: 11,237 
Da) was observed until 5 min of incubation (Fig. 2.3A). Longer incubation periods led to 
increased abundance of the mono-, di-, and tri-acetylated forms of H4 at 11,279, 11,321 and 
11,363 Da, respectively. However, the mono-acetylated form of H4 was the predominant 
reaction product of Rtt109–Vps75, while the original H4 substrate remained present over the 
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entire incubation period (Fig. 2.3B). In contrast, Rtt109–Asf1 did not show any activity 
towards histone H4 acetylation in spite of the high enzyme-to-substrate ratio used (Fig. 2.3C). 
To our knowledge, no previous study has reported the activity of Rtt109 on the acetylation of 
histone H4.  
 
Figure 2.3  LC/MS analyses of intact histone H4 obtained from in vitro HAT assay. 
 (A) Intact mass profiles of histone H4 obtained from in vitro HAT assay with Rtt109–Vps75. 
(B) Bar graph showing the extent of H4 acetylation after assay with Rtt109–Vps75. (C) Intact 
mass profiles of histone H4 obtained from in vitro HAT assay with Rtt109–Asf1. Incubation 
times (top to bottom) are 0, 1, 5, 15, 30, 60, 90 min. 
To address whether acetylation of histones H3 and H4 was dependent on the oligomeric state 
of the substrates, we performed in vitro HAT assays using tetrameric histones (H3–H4)2 or 
individual H3 or H4 histones. These experiments indicated that the chaperone-dependent 
activity of Rtt109 is not significantly affected by the oligomeric state of the histone 
substrates, and trends in acetylation observed for histone monomers were similar to those of 
tetramers (Fig. S2.2). 
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2.4.3. Effect of enzyme-substrate ratios on histone acetylation 
Next, we examined the activity of Rtt109–Vps75 at different enzyme-to-substrate ratios. We 
performed in vitro HAT assays at enzyme-to-substrate molar ratios of 1:200, 1:100, 1:50 and 
1:10 for a fixed incubation period of 15 min. The relative proportion of all detected acetylated 
histones at different enzyme:substrate ratios is shown in Fig. 2.4. At a molar ratio of 1:200 
we observed two acetylated forms of H3, though their relative abundances were generally 
low (Fig. 2.4A). Further analyses of these tryptic digests using LC–MS/MS identified two 
acetylation sites at positions K9 and K23 of H3, with K9 being the most abundant (see 
Section 3.4). The relative proportion of the mono-acetylated form increased by 10-fold for an 
enzyme-to-substrate ratio of 1:100 and further increases in the mono and multiacetylated 
forms of H3 were observed for higher enzyme:substrate ratios. We also examined the 
acetylation profiles of H4 under the same incubation conditions (Fig. 2.4B). These analyses 
revealed that a mono-acetylated form of H4 is typically observed irrespective of the enzyme-
to-substrate ratio used. These observations are consistent with those noted previously for an 
enzyme-to-substrate ratio of 1:1. LC–MS/MS analyses of the corresponding tryptic digests 
indicated that the primary site of H4 acetylation by Rtt109–Vps75 is K12 (see Section 3.4). It 
is noteworthy that only the mono-acetylated histone H3 was detected for incubation periods 
of 15 min and 60 min when experiments were performed using Rtt109 alone (Fig. 2.4C). 
Consistent with previous reports, we identified K9 as the mono-acetylated residue of H3 
using LC–MS/MS of the corresponding tryptic digest [30]. 
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Figure 2.4  Relative proportion of histone acetylation by Rtt109–Vps75.  
Distribution of unmodified, mono- (1ac), di-(2ac), tri-(3ac), and tetra-acetylated (4ac) histone 
(A) H3 and (B) H4 at different enzyme to substrate ratios. (C) In vitro acetylation of histone 
H3 acetylation by Rtt109 alone (without chaperone) after an incubation period of 15 min 
(upper panel) and 60 min (lower panel). 
 
2.4.4. Peptide identification and determination of acetylation stoichiometry  
To determine the extent and location of acetylation sites following in vitro HAT assay, all 
samples were subjected to propionylation, tryptic digestion and LC–MS/MS analyses. 
Propionylation of free Lys residues of histones was required to prevent the formation of small 
hydrophilic tryptic peptides that would be either too short for MS detection or could not be 
retained efficiently by reversed phase LC [31]. The LC–MS/MS analyses of the 
corresponding tryptic digests enabled the identification of at least 18 distinct peptides 
comprising 20 Lys residues, and these peptides typically contained one or two modified sites 
(see Tables S2.3–2.4). The extent of acetylation of a specific Lys residue was determined 
from the intensity ratio of the acetylated peptide to the sum of all forms of the corresponding 
tryptic peptide (acetylated and propionylated). For example, Fig. 2.5A shows representative 
extracted ion chromatograms of the doubly-protonated peptide ions corresponding to the 
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mono-acetylated (K9ac, K14pr) and di-propionylated (K9pr, K14pr) forms of the tryptic 
peptide 9 KSTGGKAPR17 at an incubation time of 1 min. The intensity ratio of the 9 
KacSTGGKprAPR17 peptide to that of all forms of this peptide corresponded to 0.2 or an 
acetylation stoichiometry of 20%. The MS/MS spectrum of m/z 500.282+ assigned to the 
mono-acetylated tryptic peptide 9 K(ac) STGGK(pr)APR17 is shown in Fig. 2.5B. The 
incremental 42 Da mass shift of the b2–b5 fragment ions confirmed the acetylation of K9 
residue while an additional mass shift of 56 Da on b6–b8 fragment ions was consistent with a 
propionylated K14 residue. The doubly-propionylated form of the same tryptic peptide 
displayed similar fragmentation patterns except that 56 Da shifts were observed for both K9 
and K14 residues. Manual validation was performed on each MS/MS spectrum to confirm the 
identity of the modified peptides and to correlate the abundance of all peptides across the 
entire incubation period. Fig. 2.5C shows the site occupancy of Lys acetylation following in 
vitro incubation with Rtt109–Vps75. This graph indicates that Rtt109–Vps75 preferentially 
acetylates H3 at K9 and K23 residues with the former site displaying the most significant 
changes in acetylation during this period. Additional acetylation sites at K14, K18, K27 and 
K56 were also identified beyond 15 min suggesting that Rtt109–Vps75 can promiscuously 
catalyze reactions on other sites when long incubation periods or high enzyme-to-substrate 
ratios are used. 
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Figure 2.5  Analysis of acetylation stoichiometry of H3 incubated with Rtt109–Vps75. 
 (A) Extracted ion chromatograms of the doubly charged tryptic peptides corresponding to 
the acetylated and propionylated forms of 9 KSTGGKAPR17. (B) MS/MS spectrum of the 
acetylated tryptic peptide 9 KacSTGGKAPR17. Acetylation stoichiometry of H3 lysine 
residues following incubation with (C) Rtt109–Vps75 and (D) Rtt109–Asf1. (E) Primary 
acetylation sites of Rtt109–Vps75 (K9 and K23 located on the N-terminus tail of H3) and 
Rtt109–Asf1 (K56 located on the H3 fold domain). The cartoon representation of yeast 
histone H3 (red) and H4 (blue) are taken from nucleosome PDB 1ID3 (prepared using the 
Pymol Molecular Graphics system, version 1.2r1). (F) Amino acid sequence of yeast histone 
H3. 
 
In contrast, in vitro reactions performed with histone H3 incubated with Rtt109–Asf1 showed 
strikingly different patterns with a limited number of acetylated residues (Fig. 2.5D). We 
noted that Rtt109–Asf1 displayed greater substrate specificity towards K56 acetylation, a 
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residue that is located in the histone fold domain unlike the N-terminal Lys residues (e.g. K9, 
K23) modified by Rtt109–Vps75 (Fig. 2.5E). Extended incubation periods with Rtt109–Asf1 
led to the acetylation of K14 and K23 residues although these sites could arise from 
promiscuous enzymatic reactions. 
We also examined the enzymatic activity of Rtt109–Vps75 and Rtt109–Asf1 on the 
acetylation of H4 also present in the histone tetramer. Fig. 2.6 shows the sites and extent of 
acetylation of histone H4 following in vitro incubation with Rtt109–Vps75. We identified a 
total of 3 acetylation sites on H4, consistent with that observed from intact mass 
measurements (Fig. 2.3). The LC–MS/MS analysis for the tryptic digest of histone tetramers 
after 15 min incubation with Rtt109–Vps75 is shown in Fig. 2.6A for the mono-acetylated 
(K12ac, K5pr, K8pr, K16pr) and the fully propionylated tryptic peptide 4 
GKGGKGLGKGGAKR17. The MS/MS spectrum of m/z 740.942+ corresponding to the 
mono-acetylated tryptic peptide 4 GKGGKGLGKacGGAKR17 is shown in Fig. 2.6B. An 
incremental shift of 56 Da is observed for fragment ions y2–5 and y10–12 consistent with 
propionylation at K16 and K8 residues. The location of the acetylated K12 residue was 
confirmed by the observation of a mass shift of 42 Da for y6–9 fragment ions while b2 (m/z 
242.0) and b3 (m/z 299.3) displayed a 56 Da shift, in agreement with a propionylated K5 
residue. The acetylation profiles of K5, K8 and K12 residues are shown in Fig. 2.6C for the 
90 min incubation period with Rtt109–Vps75. The acetylation of H4K12 proceeded more 
rapidly than that of K5 and K8 residues (Fig. 2.6C). An Rtt109–Vps75-dependent acetylation 
of histone H4 has not been reported in a literature, thus far. Interestingly, no acetylation of 
H4 was observed when the same reaction was performed using Rtt109–Asf1 suggesting again 
that this chaperone exerts more specific catalytic activity toward its histone substrate. 
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Figure 2.6  Analysis of acetylation stoichiometry of H4 incubated with Rtt109–Vps75. 
 (A) Extracted ion chromatograms of the doubly charged tryptic peptides corresponding to 
the acetylated and propionylated forms of 4 GKGGKGLGKGGAKR17. (B) MS/MS 
spectrum of the acetylated tryptic peptide 4 GKGGKGLGKacGGAKR17. (C) Acetylation 
stoichiometry of H4 lysine residues (K5, K8, K12) following incubation with Rtt109–Vps75. 
(D) Amino acid sequence of yeast histone H4. 
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2.5. Discussion 
This study describes a comprehensive proteomics approach to determine the chaperone-
dependent specificity of the Rtt109 enzyme. This approach is based on a two-pronged 
strategy used previously to profile global and site-specific changes in histone acetylation 
upon HDACi treatment [31]. Our global analyses revealed that the sites acetylated in histones 
H3 and H4 vary significantly depending on the type of chaperone associated with the Rtt109 
HAT. While this enzyme can acetylate H3K9 on its own, its association with either Vps75 or 
Asf1 chaperones not only increases its catalytic activity but also confers additional substrate 
selectivity. In vitro, Rtt109–Vps75 catalyzed the acetylation of histone H3 and exhibited a 
broader substrate activity asevidenced by the number of acetylated forms detected (Figs. 2.2A 
and 2.3B). Our peptide sequencing analysis identified two preferential acetylation sites on H3 
(K9 and K23) and only one on H4 (K12). It is known that H4K12 is acetylated in vivo. 
However, we cannot exclude the possibility that promiscuous acetylation of H4K12 by the 
Rtt109–Vps75 enzyme could take place in vivo as observed here for the in vitro HAT assay. 
The significance of this finding would clearly require further functional analyses given recent 
evidences indicating that acetylation of H4K12 was shown to regulate dynamic telomere 
properties in S. cerevisiae [35].  
The identification of H3K23 acetylation using quantitative proteomics also provided clear 
information on the site-specific activity of Rtt109–Vps75. Although several studies agree on 
K9 as a primary H3 acetylation site, conflicting results were reported regarding a second 
acetylation site at positions K23 or K27 [24,30,36]. These sites were previously characterized 
using western blotting, and ambiguity on site assignment could possibly arise from cross 
reactivity of antibodies against H3 N-terminal tail acetylation sites that harbor similar 
sequences flanking acetylated residues [32,37]. By using quantitative proteomics we 
unambiguously identified H3K23 as a second acetylation site targeted by Rtt109–Vps75. It is 
noteworthy that additional acetylation sites (e.g. K14, K18, K27 and K56) were observed 
after extended incubation periods (or at high enzymeto-substrate ratio) showing that, at least 
in vitro, Rtt109–Vps75 can promiscuously acetylate sites other than K9 and K23. The 
physiological significance of the acetylation site preference exhibited by Rtt109–Vps75 is 
still unknown. Additional biochemical, structural and in vivo studies will be necessary to 
address the functional significance of this finding.  
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In contrast to Rtt109–Vps75, Rtt109–Asf1 catalyzed the acetylation of histone H3 but not H4 
(Figs. 2.2D and 2.3C). This complex showed a striking specificity toward H3K56 acetylation, 
even at very high enzyme-to-substrate ratios. H3K56 is located at the C-terminal edge of an 
α-helix that is unique to histone H3 and is not part of the histone-fold domain. In addition, 
H3K56 cannot be acetylated by Rtt109 when H3 is incorporated into nucleosomes [38]. 
Rtt109 acetylation is mostly associated with non-nucleosomal, nascent histone H3 in yeast 
[39,40]. Rtt109 acetylation of newly synthesized H3 is consistent with recent evidences on its 
activity in the cytoplasm [41]. It is noteworthy that the orderly sequence by which H3 is 
acetylated or the events leading to the specific recruitment of Vps75 and Asf1 chaperones to 
Rtt109 are presently unknown. However, the possibility of determining enzyme-specificity in 
vitro or in vivo using quantitative proteomics opens up new perspectives to decipher the roles 
of chaperones in regulating HAT activity and substrate selectivity. 
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2.7. Supplementary data 
 
 
Figure S2.1 Intact mass analysis of intact proteins.  
A) Total Ion Chromatogram (TIC) and Extracted Ion Chromatogram 
(EIC) of proteins obtained from ESI-LC/MS analysis of H3-H4/Rtt109-Vps75 assay, B) 
Shows the deconvoluted mass of the corresponding EIC of H4, Vps75, H3 and Rtt109. 
 
 
 
 
 
 
 
96 
 
 
 
 
 
 
 
 
 
Figure S2.2 The proportion of histone H3 acetylation during 90min H3\Rtt109-Vps75 
assay.  
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Table S2.1  H3/Rtt109-Vps75 assay intact histone intensity data (0 to 90 min) 
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Table S2.2  H3/Rtt109-Asf1 assay intact histone intensity data (0 to 90 min) 
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Table S2.3  H3/Rtt109-Vps75 assay peptide IDs and normalized intensities. 
 
 
Table S2.4  H3/Rtt109-Asf1 assay peptide IDs and normalized intensities. 
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3.1. Abstract  
 
Protein post-translational modifications play an important role in the control of various 
biological processes including protein-protein interactions, epigenetics and cell cycle 
regulation. Mass spectrometry-based proteomics approaches enable comprehensive 
identification and quantitation of numerous types of PTMs. However, the analysis of PTMs is 
complicated by the presence of indistinguishable co-eluting isomeric peptides resulting in 
composite spectra with overlapping features that prevent the identification of individual 
components. In this study, we present Iso-PeptidAce, a novel software tool that enables 
deconvolution of composite MS/MS spectra of isomeric peptides based on features associated 
with their characteristic fragment ion patterns. We benchmark Iso-PeptidAce using dilution 
series prepared from mixtures of known amounts of synthetic acetylated isomers. We also 
demonstrate its applicability to different biological problems including the identification of 
site-specific acetylation patterns in affinity-purified histones bound to chromatin assembly 
factor-1 and profiling of histone acetylation in cells treated with different classes of HDAC 
inhibitors.  
 
Graphical abstract 
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3.2. Introduction 
Histone post-translational modifications (PTMs) control access to genetic information and, 
consequently, participate in several important cellular processes such as DNA repair and 
replication, nucleosome assembly and transcriptional regulation. 
1, 2
 It is now clear that many 
chromatin-modifying enzymes and enzymes that bind non-histone proteins, recognize 
"combinatorial patterns of PTMs", rather than single protein modification. For instance, ATP-
dependent chromatin remodelers often recognize histones that contain more than one 
acetylated lysine residue that are located in close proximity to each other.
3,4 
Although 
valuable to infer the functions of PTMs, accurately determining patterns and stoichiometries 
of PTMs located in isomeric and isobaric peptides, remains extremely difficult to achieve 
even by mass spectrometry (MS). This is because isomeric peptides, which are identical 
except for the position of the PTMs along the peptide chain, often co-elute during liquid 
chromatography and generate composite tandem mass spectra (MS/MS) containing 
indistinguishable fragment ions derived from two or more peptide isomers.  
A few MS/MS methods were previously developed to quantify co-eluting isobaric histone 
peptides. Smith et al. were first to use a fragment ion-based approach to determine the 
fraction of histone H4 molecules acetylated at specific residues based on the normalized 
intensity ratio of peptide fragment ions containing either protiated or deuterated acetyl groups 
to distinguish lysine residues that were respectively acetylated or free in vivo.
5
 However, this 
approach was limited by the lack of automated data analysis software and the difficulty to 
deconvolute co-eluting isomers. Recently, Feller et al. described a similar approach in which 
second generation fragment ions (known as MS
3
) were necessary to obtain diagnostic 
fragment ions that can be used to estimate the abundance of each isomer by solving a set of 
linear equations.
6
 A limitation of this approach is that singly charged MS
2
 fragments, and 
particularly those with a nonmobile proton, fragment poorly and generate MS
3
 spectra that 
are impossible to assign to specific isomers.
7, 8
 Sidoli et al., designed a software known as 
isoScale that can be used to determine the relative abundance of isobaric peptides, based on 
intensity ratios of fragment ions unique to each isomer.
9
 isoScale relies on search engine 
outputs (e.g. Mascot.csv result files) to select isomer-specific fragments used in this analysis. 
The algorithm EpiProfile recently described by Yuan et al. quantifies isobaric histone 
peptides by solving a series of linear equations derived from peak heights of unique 
fragments representative of each isobaric species.
10
 Several other approaches have also been 
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proposed to deconvolute mixed MS/MS spectra of peptide ions with different sequences 
11-13
, 
however, their application is limited when analyzing MS/MS spectra of co-fragmented 
isomeric ions that incorporate the same modification at different sites. 
In this study, we present Iso-PeptidAce, a novel software tool that exploits high resolution 
LC-MS/MS data for deconvolution of mixed spectra and quantification of site-specific 
acetylation. The resolution of composite MS/MS spectra derived from isomeric peptides is 
based on features associated with their characteristic fragment ion patterns obtained from the 
corresponding synthetic peptides, and does not rely on unique fragment ions to distinguish 
isomers. The application of Iso-PeptidAce is presented here for peptide isomers that contain 
multiple acetylated lysine residues but can also be applied to other types of modifications 
such as isomeric phosphopeptides.
14
 The use of Iso-PeptidAce is demonstrated to monitor 
temporal changes in acetylation patterns of histones H3 and H4 from human erythroleukemic 
(K562) cells treated with different classes of histone deacetylase inhibitors (HDACi), and for 
determining acetylation patterns in histones bound to S. cerevisiae chromatin assembly 
factor-1 (CAF1). 
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3.3. Methods  
3.3.1. Synthetic peptide preparations 
Synthetic histone H3 and H4 peptides were purchased from GenScript and include four 
variants of the H3 peptide 17-RKQLATKAAR-26: one with unmodified lysines, two 
peptides with one acetylated lysine and one peptide with both lysines acetylated (Table 
S3.1A). A total of sixteen H4 peptides were purchased. These included one unmodified, four 
mono-acetylated, six di-acetylated, four tri-acetylated and one tetra-acetylated form of 
peptide 1-SGRGKGGKGLGKGGAKRHR-19 (Table S3.1B). The concentration of each 
peptide was determined based on triplicate UV absorbance measurements at 205 nm using an 
Ultraspec 2100 Pro spectrophotometer (GE Healthcare). Each peptide solution was nominally 
in 1μg/μl range. We verified the purity and identity of each peptide by injecting directly 1 
pmol of the peptides on a Q-Exactive Mass spectrometer (Thermo scientific). All MS files 
will be publicly available from PeptideAtlas database (data identifier: PASS00658, 
http://www.peptideatlas.org/PASS/PASS00658). For convenience MS/MS spectra of each 
isomeric peptide are provided in Appendix A. 
3.3.2. Synthetic peptide standard dilutions  
Standard curves for seven dilutions of mixtures of H4 peptides with peptide amounts ranging 
from 5 to 320 fmol were prepared (Table S3.2A-C). Two or three peptides from each group 
of isomers were selected and added to the mixtures at a fixed amount of 80 fmols. The 
peptide mixtures were subjected to propionylation, tryptic digestion and LC-MS/MS analysis 
on a Q Exactive mass spectrometer coupled to an EASY nLC II system (Thermo scientific). 
3.3.3. Assessment of relative detection efficiency of H3 and H4 acetylated peptides  
We prepared five mixtures of H3 or H4 synthetic peptides. The amount of each peptide in 
mixtures 1,2 3, 4 and 5 are 25, 50, 100, 200 and 400 fmols, respectively. These samples were 
subjected to propionylation, tryptic digestion and LC-MS/MS analysis on a Q Exactive Plus 
instrument. The signal intensity of each peptide was plotted against the amount of peptide 
injected as shown in Figs.S3.2 A and B. 
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3.3.4. Cell treatment with HDAC inhibitors  
Suspension cultures of K-562 (human erythroleukemic) cells were grown in T-75 flasks at 
37°C and 5% CO2 in RPMI-1640 medium (Gibco) supplemented with 10% FBS (Wisent) 
and 1% Penicillin/Streptomycin. Asynchronously growing cells were treated with 1 μM of 
SAHA, MS-275 or JNJ-26481585 (Selleck Chemicals) for 1, 6 and 24 hours. Control cells 
were treated with DMSO. Two biological replicates were prepared for each condition. After 
treatment, the cells were harvested, centrifuged at 1000 rpm at room temperature, washed 
with PBS, and flash frozen in liquid nitrogen. Histones were isolated using acid extraction as 
previously described.
37
 Briefly, nuclei from 10
7
 cells were isolated with a hypotonic lysis 
buffer, followed by histone extraction using 0.2 M H2SO4 and TCA precipitation. The 
concentration of histone samples was determined by a Micro-BCA assay (Pierce). Further 
purification of core histones was performed by reverse-phase HPLC. 
3.3.5. Purification of yeast CAF1  
The Cac2-TAP purification was adapted from Zhou et. al.
28
 Briefly, exponentially growing 
yeast cells (4L at approximately 1.8 x 10
7
 cells/ml in YPD medium) were harvested by 
centrifugation and washed twice with ice-cold water. All further steps were carried out on ice. 
The pellet was resuspended in an equal volume of lysis buffer (25mM Tris-HCl pH 7.5, 
100mM NaCl, 10mM of MgCl2, 0.1% NP-40, 1mM EDTA, 10% glycerol, 1mM DTT, 1mM 
PMSF) containing a cocktail of protease inhibitors (5μM Leupeptin, 25μM Aprotinin, 5μM 
Pepstatin A) and HDAC inhibitors (10mM nicotinamide, 10mM sodium butyrate, 10 μM 
trichostatin A and 100μM SAHA). Cell suspensions were frozen in liquid nitrogen and lysed 
in a freezer mill (Spex Certiprep) using two repeats of 4 cycles with 2 min of grinding and 2 
min (15 impacts per second) of cooling per cycle. The resulting cell lysate powder was 
thawed out on ice. Ethidium bromide (75μg/mL) was added and the lysate was incubated on 
ice for 1 h with benzonase (25U/mL). The extract was clarified by centrifugation at 25,000 
rpm for 30 min. The supernatant was then incubated with 200 μL of IgG-Sepharose beads 
(SIGMA) for 2 h at 4°C. The beads were recovered by centrifugation, extensively washed 
with lysis buffer followed by several washes with TEV cleavage buffer (10mM Tris-HCl, pH 
8, 100mM NaCl, 1mM DTT, 0.5mM EDTA) containing the protease inhibitors and HDAC 
inhibitor mixture. In order to elute the Cac2-TAP, the beads were incubated with TEV 
protease, at 4°C overnight in TEV cleavage buffer. A portion of the TEV eluate (30µl) was 
resolved by SDS-PAGE and the presence of Cac2-CBP and histones H3 and H4 was 
confirmed by immunoblotting. The remainder of the TEV eluate (170µL) was dried in a 
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Speed-Vac, resuspended in 1ml H2O and applied to a C18 column equilibrated with 0.1% 
TFA in water. The C18 column was washed twice with 1ml of 0.1% TFA in 5% methanol 
and eluted with 1ml of 70% acetonitrile. The eluate was dried in a Speed-Vac and 
resuspended in 0.1% TFA for purification of intact histones by offline HPLC. 
3.3.6. Fractionation of core histones by RP-HPLC  
Separation of core histones was achieved using a narrow-bore Zorbax C8 reverse-phase 
column (2.1 x 150 mm, 5μm, 300Å) on an Agilent 1200 HPLC system. Solvent A was 
aqueous 0.1% TFA (Sigma) and solvent B was 0.1% TFA in 100% acetonitrile (ACN). 
Approximately 2 μg of acid extracted histones were loaded onto the C8 column at a flow rate 
of 150 μl/min. Histones were eluted from the column using a gradient of 5 – 80% solvent B 
in 60 minutes. Fractions were collected in a 96-well plate at a rate of one fraction per minute. 
Fractions containing histones H3 or H4 were pooled and dried completely in a Speed-vac 
concentrator. 
3.3.7. Propionylation and trypsin digestion of histone peptides/proteins  
In-solution tryptic digestion of synthetic peptides or core histones was performed as 
previously described.
38
 Briefly, a total of 2 μg of HPLC purified histones H3 and H4 were 
subjected to propionylation by adding 200 μl of freshly prepared 2:1 (v/v) water: propionic 
anhydride (Sigma) mixture and vortexing the mixture for 1 h at room temperature. The 
samples were then dried in a Speed-vac at 4
o
C. The dried samples were resuspended in 50 
mM ammonium bicarbonate, vortexed for 2 minutes and subjected to a second round of 
evaporation at 4oC. The samples were collected and resuspended in 100 μl of 50 mM 
ammonium bicarbonate and vortexed for 5 minutes in order to re-dissolve the proteins. Our 
digestion solution was prepared by adding 200 μl of 50 mM ammonium bicarbonate in a vial 
containing 20 μg of lyophilized trypsin (Promega). About 0.5 μl of this solution was added to 
each histone sample and digested overnight at 37
o
C. After digestion, samples were dried 
completely in a Speed-vac and then resuspended in 0.2% formic acid prior to LC-MS/MS 
analyses. 
3.3.8. LC-MS/MS analyses of histone digests  
MS data were acquired in duplicate on a Q Exactive Plus mass spectrometer (Thermo 
scientific) coupled to an EASY nLC II system (Thermo scientific). A total of 1μg of histone 
H3 and H4 digests generated from the control or HDACi-treated cells were first desalted on a 
Jupiter C18 (3μm particles, Phenomenex) trap column (4mm length, 360μm i.d.) for 5 min at 
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10 μl/min, prior to their elution onto a C18 analytical column (18 cm length, 150 μm i.d.). A 
linear gradient from 5 to 60% acetonitrile (containing 0.2% formic acid) at 600 nl/min over 
60 min was used for peptide elution. The MS instrument was operated in positive ion mode, 
and capillary voltage of 1.6 kV. MS scans were acquired in the Orbitrap analyzer over the 
range of 300 – 1500 m/z at a resolution of 70,000 and automatic gain control target value of 
1.0 x 10
6
. An inclusion list containing m/z, charge state and collision energy CE values of H3 
and H4 peptides were used to trigger MS/MS acquisition. Every precursor ion found in the 
inclusion list was automatically selected for fragmentation in the HCD cell at a normalized 
CE setting of 27. The fragments were analyzed in the Orbitrap at a resolution of 35,000 and a 
target value of 5.5 x 10
5
. The dynamic exclusion setting was disabled in order to acquire 
multiple MS/MS spectra per peptide. 
3.3.9. Data analysis  
Data analysis was performed using the Iso-PeptidAce software. Raw MS and MS/MS files of 
individual isomeric peptides, peptide mixtures or histone digests and Fasta files with H3 and 
H4 protein sequences were submitted to Iso-PeptidAce. The default settings for 
deconvolution of mixture MS/MS spectra are: Precursor mass tolerance: 8 ppm, fragment 
mass tolerance: 0.05 Da, the minimum number of fragment ions (per isomer) considered for 
deconvolution: 5, types of fragment ions considered: b and y, digestion enzyme: trypsin, 
missed cleavages: Iso-PeptidAce uses no-enzyme in-silico protein digestion routine to parse 
the provided FASTA file for potential matches. PTMs included in peptide-spectrum 
matching: carbamidomethylation of cysteine (C, 57.0215 Da), oxidation of methionine 
residue (M, 15.9949), phosphorylation of serine, threonine or tyrosine (S/T/Y, 79.9663), 
deamidation of aspargine and glutamine (N/Q 0.98400.9847), acetylation of lysine (K, 
42.0106), propionylation of lysine (K, 56.0262), methylation of lysine (K, 14.0157), di-
methylation of lysine ( K, 28.0313), tri-methylation of lysine (K, 42.0470), acetylation of 
protein N-terminus ( 42.0106). All the PTMs were considered as variable modifications. The 
output from Iso-PeptidAce is a combined result file (spreadsheet) containing intensity values 
for all the acetylated and non-acetylated forms of deconvoluted H3 and H4 peptides. A 
representative result file for the H4 peptide GKGGKGLGKGGAKR is shown in Table S3.7. 
A total of 16 different isoforms of this peptide were detected (shown in each column in Table 
S3.7). These peptides are divided into five groups (per sample) based on their m/z values 
(shown in each row in Table S3.7): one un-acetylated (0Ac, m/z 747.94), four mono-
acetylated (1Ac, m/z 740.93), six di-acetylated (2Ac, 733.93), four tri-acetylated (3Ac, m/z 
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726.92) and one tetra-acetylated (4Ac, m/z 719.91). Each intensity value in Table S3.7 is 
normalized based on the peptide’s response factor, which is determined from the slope of the 
lines shown in Fig.s S3.2 A and B. The slope of each line was determined from the linear 
equation that best-fit the MS signal responses. Acetylation site occupancy at a specific Lys 
residue was determined from the ratio of the sum of intensities of peptides bearing the ac-Lys 
to the sum of intensities of all the 16 peptide isoforms. Iso-PeptidAce can be downloaded 
from the website: http://proteomics.iric.ca/tools/Iso-PeptidAce. Detailed information on Iso-
PeptidAce is also provided as Supplementary Method. 
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3.4. Results  
3.4.1. Deconvolution of mixed MS/MS spectra by Iso-PeptidAce 
We designed a new software tool named Iso-PeptidAce that deconvolutes mixed MS/MS 
spectra of known isomeric peptides. The software takes as input raw MS and MS/MS files of 
the individual and the mixed isomers, the FASTA sequence file of the protein of interest, and 
a set of parameters for peptide-spectrum matching (PSM) such as modifications, precursor 
and fragment ion tolerances (See the ‘Data analysis’ section of the Method). The raw files are 
processed to extract precursor intensity, MS1 and MS2 injection times, and MS2 peak lists 
containing m/z and intensity values (see Supplementary Method for a detailed section on 
spectral deconvolution and normalization of MS signal intensities).  
Iso-PeptidAce computes the proportion of individual isomers in mixed MS/MS spectra based 
on their fragment ion patterns. In Iso-PeptidAce, ion patterns are reduced to a set of 
maximum network flow problems, for which a number of efficient algorithms are known.
15
 
This approach has previously been used in a wide-range of complex problems, such as in 
predicting molecular pathways in complex diseases and in selecting single nucleotide 
polymorphisms (SNPs) and their associated allele in case and control groups.
16-18
 In our 
study, we implemented the Network Flows approach to deconvolute mixed fragment spectra 
of acetylated isomers. Although these isomers share multiple fragment ions, they produce 
distinct fragment ion patterns that can be transformed into a set of network flow problems. 
Fig. 3.1A shows a schematic overview of the deconvolution conducted by Iso-PeptidAce for 
a series of mixed MS/MS spectra generated from two hypothetical co-eluting isomeric 
peptides labeled X and Y. For every mixed spectrum acquired across the elution curve, 
fragment ion intensities (Fig. 3.1A, step 1) are modeled into maximum network flow 
problems (flow capacity shown as empty bar charts in Fig. 3.1A, step 2). The networks are 
filled with fragment ion patterns for isomers X and Y (Fig. 3.1A, step 3) and merged into a 
single network with excess flow (represented as overrunning color bars in Fig. 3.1A, step 4). 
The resulting network is processed iteratively by a multivariate optimization technique 
known as Gradient Descent
19
 (Fig. 3.1A, step 5), to remove the excess flow in the network. 
Each iteration step converges towards the maximum flow, that refers to the optimal ratio of X 
and Y in the mixed spectrum (Fig. 3.1A, left inner circle). Finally, individual elution curves 
are generated based on the abundance ratios of MS/MS spectra (Fig. 3.1A, right inner circle) 
and the peak intensity or peak area of the precursor ions. 
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Figure 3.1 Deconvolution of co-eluting acetylated isomers by Iso-PeptidAce.  
A) Schematic showing the process of spectral deconvolution by Iso-PeptidAce. The input 
files and parameters used for deconvolution of mixed isomers are listed on the right side of 
the panel. The process involves building an individual elution curve for X and for Y based on 
ratios computed for each MS/MS events. Isomeric peptide ratios are computed in 5 steps: 1) 
acquire and normalize fragment intensities of mixed spectra; 2) model fragment intensities as 
a network flow with fixed capacities; 3) find the maximum flow for peptide X and for peptide 
Y; 4) combine both X and Y network flow capacities into the same network flow model; 5) 
iteratively reduce the ratio of X and Y until the maximum flow of is reached. B) Left panel: 
Elution profiles of a mixture of acetylated isomers before (dashed line) or after (colored lines) 
deconvolution. Right panel: The relative intensity of representative fragment ions extracted 
from the deconvoluted isomers at four different retention times, RT 20.84, 20.94, 21.03 and 
21.12 min. C) Bar graphs showing the amount of each peptide isomer determined by Iso-
PeptidAce as a function of the amount of the same peptide injected as part of mixtures of 
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known amounts of mono-, di- or tri-acetylated groups (from top to bottom). The mean value 
and the standard deviation for each dilution point are shown in Table S3.3 A-C. The amount 
determined at each dilution point was normalized to the 80 fmol signal response. The 
amounts of peptides K5ac and K12ac (upper panel); K5_8ac, K5_16ac and K8_16ac (middle 
panel); K5_8_12ac and K5_12_16ac (lower panel) were varied from 5 to 320 fmol. Peptides 
K8ac and K16ac (upper panel); K5_12ac, K8_12ac and K12_16ac (middle panel); 
K5_8_16ac and K8_12_16ac (lower panel) were added to the mixture at fixed amount of 80 
fmol. Each bar graph represents the mean of two technical replicates with error bars showing 
the relative distance of the maximum and the minimum values from the mean. Error bars 
indicate standard deviation of the mean of two technical replicates. 
 
3.4.2. Extraction of elution profiles and fragment ion patterns 
We first used Iso-PeptidAce for MS/MS spectra of synthetic peptides from acetylated isomers 
of histone H3 and H4 (Tables S3.1). All possible non-acetylated and acetylated forms of H4 
peptide 1-SGRGKGGKGLGKGGAKRHR-19 were synthesized, and the purity of each 
peptide was confirmed by MS analyses. These peptides were propionylated, digested by 
trypsin and subjected to LC-MS/MS analysis on a Q Exactive Plus instrument.  
We obtained three isomeric groups of H4 peptides acetylated at one, two or three lysine 
residues, and members of each group generally have very narrow retention time differences 
(Fig. S3.1). To normalize precursor intensity, we determined the signal intensity response for 
each peptide as a function of the amount injected. We observed that mono- or multiply 
acetylated isomers yielded a higher response than their propionylated counterparts (Fig. 
S3.2A). We then prepared equimolar mixtures of peptides for each group of isomers and 
analyzed them by LC-MS/MS. Although propionylated H4 peptides were readily separated 
into non-acetylated, mono-, di-, tri- and tetra-acetylated peaks (denoted as Ac0, 1, 2, 3, and 4 
in Fig. S3.3A, top panel), we observed that peptides within the same isomeric group co-eluted 
and produced composite MS/MS spectra (Fig. S3.3 A-B). In addition, these peptides shared 
multiple fragment ions (Fig. S3.4 A-E). Figure S3.4E shows a three-dimensional view of the 
distribution of selected fragment ions derived from the four mono-acetylated isomers. 
H4K5ac and H4K16ac are the only H4 peptides that produced unique fragment ions at m/z 
1253.7 and 530.3, respectively (Fig. S3.4E, see blue and purple bars). The peak intensities of 
these fragments can be used to infer relative abundances of H4K5ac and H4K16ac in a given 
sample. This approach has been previously implemented in existing software tools such as 
IsoScale.
5
 However, the other two mono-acetylated isomers H4K8ac and H4K12ac did not 
produce unique fragments (Fig. S3.4E, red and green bars). These peptides share all of their 
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fragments with either H4K5ac or H4K16ac, and as a result fragment ion ratios cannot be used 
directly to measure the relative proportion of individual peptides. In Iso-PeptidAce, 
deconvolution of MS/MS spectra containing fragments of the four mono-acetylated isomers 
is achieved by exploiting the distinguishing features associated with isomer-specific fragment 
ion patterns. Here, the fragment ion pattern is defined by the retention time at which the 
peptides were eluted and selected for fragmentation, the peak height and m/z of each 
fragment ion, and the sites of modification. For example, the fragment ion pattern for 
H4K8ac is different from that of H4K12ac by the presence of additional y-ion fragments at 
m/z 785.5 and 955.6, and the absence of y-ion fragments at m/z 771.4 and 941.6 and b-ion at 
m/z 299.2. In addition, their shared fragments (e.g. m/z 242.1, 544.3 and 1239.7) differ 
slightly in peak intensities. Thus, by exploiting such isomer-specific differences, Iso-
PeptidAce deconvoluted the co-eluting mono-acetylated peptides into four distinct elution 
profiles where the apex of individual isomer peaks were separated by a few seconds (Fig. 
3.1B, left panel, colored solid lines). The elution curve prior to the deconvolution is shown in 
Figure 3.1B (gray dashed line). Using Iso-PeptidAce, we were also able to show the relative 
intensity of selected fragment ions extracted from the deconvoluted isomers (Fig. 3.1B, right 
panel). Most of these fragments are shared between the different isomers, but their 
distribution and proportion varies across peptides. Fragment patterns representative of 
H4K8ac and H4K12ac were more prominent at the beginning of elution profiles, whereas 
those of H4K5ac and H4K16ac were observed at later time points. Similarly, deconvolution 
of the di- and tri-acetylated isomers by Iso-PeptidAce enabled the resolution of each isomeric 
peptide (Fig. S3.5). 
We then investigated the performance of Iso-PeptidAce using dilution series prepared from 
mixtures of known amounts of propionylated and acetylated isomeric H4 peptides each 
ranging from 5 to 320 fmols. Two to three peptides from each isomeric group were selected 
and added to the dilutions at a fixed amount of 80 fmols (Table S3.2A-C). Raw MS and 
MS/MS files from these samples were submitted to Iso-PeptidAce for deconvolution. The 
amount of peptide detected as a function of amount injected (in fmol) for the mono-, di- and 
tri-acetylated groups of isomers is shown in Fig. 3.1C (see Table S3.3A-C for the mean 
values and standard deviations). In the mono-acetylated mixtures we observed an increase in 
the relative proportion of peptides H4K5ac and H4K12ac whereas peptides H4K8ac and 
H4K16ac remained unchanged in each mixture (Fig. 3.1C, upper panel, and Table S3.3A). 
Similarly, we observed increasing levels of H4K5ac/K8ac, H4K5ac/K16ac and 
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H4K8ac/K16ac in the di-acetylated mixtures (Fig. 3.1C, middle panel, and Table S3.3B) and 
of H4K5ac/K8ac/K12ac and H4K5ac/K12ac/K16ac in the tri-acetylated mixtures (Fig. 3.1C, 
bottom panel, and Table S3.3C) in accordance to their expected abundance. Thus, Iso-
PeptidAce successfully deconvoluted mixed spectra generated from different co-eluting 
acetylated isomers present at concentrations ranging over almost two orders of magnitude. 
3.4.3. Temporal profiling of histone acetylation following HDAC inhibition 
We tested our software using tryptic digests of histones isolated from human K562 cells 
treated with HDAC inhibitors (Fig. 3.2A). Cells were treated in duplicate for 1, 6 or 24 h with 
DMSO (control) or with the HDAC inhibitors MS-275, SAHA and JNJ-26481585. Histones 
were isolated by acid extraction and fractionated by liquid chromatography (Fig. S3.6). 
Fractions containing histones H3 or H4 were subjected to propionylation, tryptic digestion 
and LC-MS/MS analysis prior to data deconvolution using Iso-PeptidAce (Fig. 3.2A).  
Our results show that, 24 h after treatment with SAHA or JNJ-26481585, approximately 50% 
of H4 peptides 4-GKGGKGLGKGGAKR-17 were acetylated at the four available sites, 
whereas only 20% of H4 molecules were tetra-acetylated in cells treated with MS-275 (Fig. 
3.2B). Using Iso-PeptidAce we then determined acetylation site occupancies at positions 
H3K18, H3K23, H4K5, H4K8, H4K12 and H4K16 (Table S3.4A-B). The level of H3K23ac 
is higher than that of H3K18ac in both untreated and treated samples (Fig. 3.2C and Table 
S3.4A). Although previous studies have reported trace amounts of H3K18 methylation in 
mammalian cells
20
, we did not detect this modification in our samples. Cells treated with all 
HDACi demonstrated similar increase of H4 acetylation with time. We observed more than 
8-fold increase in acetylation at sites H4K5, H4K8 or H4K12 after 24 h treatment with 
MS275, SAHA or JNJ (Fig. 3.2D, and Table S3.4B). Up to 3-fold increase in acetylation was 
observed at position H4K16. 
Although a number of studies have previously shown that HDACis MS-275 and SAHA 
induce global increases in histones H3 and H4 acetylation, there was no efficient technique to 
measure sitespecific acetylation stoichiometries of lysines in the N-terminal tail of H4 
because some of the acetylated isomers cannot be resolved by nano-LC and do not generate 
isomer-specific fragments. In our study we observed that both MS-275 and SAHA caused a 
major increase in acetylation of the four lysines in the N-terminal tail of H4. In addition, for 
the first time, we report site-specific changes in histone acetylation caused by the more 
recently characterized pan-HDACi JNJ-26481585.
21
 This drug, also known as Quisinostat, is 
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currently in phase II clinical trial and exhibits antitumor activity in human multiple myeloma 
and leukemic cells
22-25
 , and recent studies have shown that JNJ-26481585 elicits global 
increases in acetylation of histones H3 and H4.
25, 26
 However, due to the inherent limitations 
of immunoassays, these studies did not report the specific lysine residues affected by the drug 
treatment of the stoichiometries of acetylation the result from treatment with JNJ-26481585. 
Our approach allowed identification of several H3 and H4 sites that increased in acetylation 
after JNJ-26481585 treatment. When compared with MS-275 and SAHA, JNJ-26481585 
caused a more rapid and higher fold-increase in acetylation at all the sites that we 
investigated (Figs.3.2B-D). Consistent with these results, JNJ-26481585 has been reported to 
be 500-fold more potent than SAHA at inhibiting HDAC1.
21
 
These examples illustrate that Iso-PeptidAce provides an automated and rapid approach to 
quantify changes in acetylation site occupancies on histone lysine residues. Our method is 
implemented as a software tool that deconvolutes mixed spectra derived from two or more 
co-eluting isomeric acetylated peptides. In turn, this enables an accurate assessment of 
acetylation site occupancies at each of the lysines within tryptic peptides. 
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Figure 3.2 Acetylation site occupancies of H3 and H4 before or after HDACi treatment.  
A) Histone isolation and MS analysis workflow. Total histones were isolated from human 
erythroleukemic (K562) cells treated for 1, 6 or 24 h with DMSO (control) or with the 
HDACi MS-275, SAHA and JNJ-26481585. Total histones were fractionated into individual 
core histones via off-line HPLC. Fraction containing histones H3 and H4 were subjected to 
propionylation, tryptic digestion and LC-MS/MS analysis. Acetylation site occupancy for 
each lysine residue was determined based on Iso-PeptidAce reported peptide intensities. B) 
Relative abundances of un-modified (Ac0), mono- (Ac1), di- (Ac2), tri- (Ac3), and tetra-
acetylated (Ac4) peptide 4 -GKGGKGLGKGGAKR-17 before (DMSO) and after treatment 
with HDACis MS-275, SAHA, and JNJ-26481585. C) Acetylation site occupancies of 
histone H3 at positions K18 and K23, and D) histone H4 at positions K5, K8, K12 and K16. 
Each bar graph represents the mean of two technical replicates with error bars showing the 
relative distance of the maximum and the minimum values from the mean. 
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3.4.4. Identification of acetylation patterns in CAF1-bound histones 
Acetylation of multiple residues in newly synthesized histones has been implicated in 
nucleosome assembly
27
. However, the molecular function and the biological implications of 
this acetylation have remained unclear because of redundancy among several acetylation sites 
in new H3 and H4 molecules. The capability of Iso-PeptidAce to determine acetylation 
patterns in situations where samples are limiting was evaluated for affinity-purified histones 
bound to chromatin assembly factor 1 (CAF1), a protein complex that deposits new H3/H4 
molecules onto nascent DNA during replication
28
.  
As previously described
28
, we purified the CAF1 complex from asynchronously growing 
yeast cells via a tandem affinity purification (TAP)-tagged Cac2 subunit. We also purified 
total histones from the same culture in order to compare their acetylation patterns with those 
of histones bound to CAF1 (Fig. 3.3A). The sites and stoichiometries of H3/H4 acetylation 
were clearly different in CAF1-bound versus total histones (Figs. 3.3B-D, Table S3.5). We 
also detected mono-, di- and tri-methylation of H3K36 in the total histones, however, these 
PTMs were absent in CAF1-bound samples (Table S3.5). In CAF1-bound H3 molecules, we 
found a high acetylation site occupancy (between 49 and 79%) at each of five lysine residues 
previously known to be acetylated in new histones from S. cerevisiae: H3K56, K9, K14, K23 
and K27 but not at K18 (Fig. 3.3B). This high degree of acetylation at multiple sites 
demonstrates that essentially all the H3 molecules bound to CAF1 are acetylated. In contrast, 
a large fraction (64%, Fig. 3.3C) of H4 molecules bound to CAF1 were not acetylated at any 
of the four lysine residues located in their N-terminal tail. These results provide an 
explanation to a long-standing paradox. Hat1 is an enzyme that acetylates new H4 molecules 
at lysines 5 and 12, sites of acetylation that are conserved from yeast to humans.
27
 Given this, 
the paradox was that S. cerevisiae cells lacking Hat1 or cells where lysines 5 and 12 were 
mutated showed essentially no phenotype unless several lysines of H3 were also mutated to 
block their acetylation.
29, 30
 The fact that, in S. cerevisiae, the acetylation of new H3 
molecules is far more abundant than that of new H4 molecules provides an explanation for 
this puzzle. 
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Our results also revealed an unexpected acetylation pattern in new H4 molecules where, in 
addition to lysines 5 and 12, lysine 16 is acetylated (Fig. 3.3C-D). Until now, the dogma was 
that new H4 molecules were predominantly acetylated at lysines 5 and 12, but not at lysine 
16. This was based on pulse labeling of new histones with [
3
H]-lysine and Edman sequencing 
to quantify PTH derivatives of acetyl-lysine and lysine
31
. The sensitivity of this technique 
rapidly decreases as a function of distance from the N-terminus and this may account for the 
fact that lysine 16 acetylation in new H4 molecules was previously missed. Based on mass 
spectrometry, the presence of K16 acetylation in new H4 molecules bound to S. cerevisiae 
CAF1 was previously reported
28
 but its prevalence was unknown. For the first time, our 
experiments demonstrate that the most abundant form of H4 bound to S. cerevisiae CAF1 
consists of molecules that are tri-acetylated at K5, K12 and K16, with significantly lower 
amounts of mono- and di-acetylated forms that also contain K16 acetylation (Fig. 3.3C). 
Consistent with this, the acetylation site occupancies at K5, K12 and K16 were roughly 20% 
each in CAF1-bound H4, a pattern strikingly different from that observed in total histones 
(Fig. 3.3D). In S. cerevisiae, the integrity of heterochromatin depends upon removal of 
H4K16 acetylation by the deacetylase Sir2
32
. Our results imply that deacetylation of H4K16 
in new molecules deposited onto DNA during replication is likely important for propagation 
of heterochromatin structure in proliferating cells. 
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Figure 3.3  Acetylation site occupancies of CAF1-bound H3 and H4. 
A) Schematic representation of the experimental workflow. Tandem Affinity Purification 
(TAP)-Cac2 was purified from 3.5 L of cell culture and the remainder (0.5 L) was processed 
for total histone extraction. Histones from both samples were fractionated by HPLC and 
analyzed by LC-MS/MS. B) Comparison of lysine acetylation site occupancies in total 
histone H3 (lower panel) and CAF1 bound H3 (upper panel). C) Extracted ion 
chromatograms of histone H4 peptide 4 -GKGGKGLGKGGAKR -17 acetylated at zero 
(Ac0), one (Ac1), two (Ac2), three (Ac3) or four (Ac4) lysine residues in CAF1 bound (left 
panel) or total histones (right panel). The predominant acetylation pattern in each isomeric 
group is highlighted in red. D) Comparison of acetylation site occupancies at positions H4K5, 
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H4K8, H4K12 and H4K16 in CAF1 bound H4 (upper panel) and total histone H4 (lower 
panel). Each bar graph represents the mean of two technical replicates with error bars 
showing the relative distance of the maximum and the minimum values from the mean.  
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3.5. Discussion 
Iso-PeptidAce was initially created to solve a specific problem that had apparently been 
neglected, even though it was pointed out by Smith et al. more than twelve years ago.
5
 The 
problem of determining the relative abundance of multiply acetylated forms derived from the 
N-terminal tail of histone H4, which contains four lysines that can be acetylated, is 
compounded by the fact that several acetylated isomers co-elute during liquid 
chromatography and cannot be distinguished from each other based on the masses of MS
2
 
fragments. The value of determining the relative abundance of acetylated isomers was 
illustrated by our studies of new histone molecules bound to CAF1. The predominant pattern 
of acetylation that we found consisted of H4 molecules tri-acetylated at K5, K12 and K16. 
Although further studies are necessary to assess its biological significance, the prevalence of 
this acetylation pattern has implications for both replication-coupled nucleosome assembly 
and the roles of histone deacetylases in the propagation of heterochromatin structures in 
proliferating cells. 
We expect that Iso-PeptidAce will be an asset to investigate a broad range of biological 
problems related to protein lysine acetylation and other combinatorial patterns of PTMs. For 
instance, Iso-PeptidAce will be valuable to determine the in vivo substrate specificity of the 
multitude of bromodomain (BRD)-containing proteins that exist in model organisms and 
human cells
3
. Because large protein complexes contain multiple BRDs located in different 
polypeptide subunits, deciphering their physiologically relevant acetylated substrates remains 
a formidable task. Although our approach is limited to patterns of PTMs that are confined to 
single peptides, previous in vitro studies have clearly shown that a number of BRDs bind 
with higher affinity to peptides that contain acetylated lysines located in close proximity
3
. We 
therefore anticipate that, when coupled with methods to co-purify protein complexes with 
their acetylated substrates, Iso-PeptidAce will help identify combinatorial patterns of lysine 
acetylation that are recognized by protein complexes involved in several biological processes. 
Proteomics studies performed in several species have identified a myriad of acetylation sites 
in proteins with a wide range of biological functions
33-35
. In many cases, several lysines 
located near each other have been reported but, without isomer deconvolution, it is not 
possible to determine exactly which lysines are acetylated or whether a predominant pattern 
of acetylation does exist. Table S3.6 shows seven examples of known acetylated peptides 
where isomers could now be distinguished based on their fragmentation patterns using Iso-
124 
 
 
 
PeptidAce. In addition, when combined with recently developed multiplexed parallel reaction 
monitoring approaches
20, 36
, we anticipate that our method will prove valuable for 
deconvolution of a large set of isomeric peptides bearing various combinations of PTMs that 
include, but are not restricted to lysine acetylation. 
It is known that in addition to lysine acetylation and methylation, histones are also modified 
with numerous other types of PTMs including mono- or di-methylation of arginine, 
crotonylation, butyrylation and formylation of lysine residues. In the current study we did not 
determine the later type of PTMs as our method is targeted toward known peptides and PTM 
combinations. Therefore, based on our dataset, we cannot rule out the possibility that other 
type of PTM combinations might exist on the peptides we reported in this study. Meanwhile, 
when coupled with recently developed multiplexed parallel reaction monitoring approaches
20, 
36
 we anticipate that our method will prove valuable for deconvolution of a large set of 
isobaric peptides bearing variable combinations of PTMs.  
We also expect that our method will prove an asset to investigate a broad range of biological 
problems related to protein lysine acetylation. For instance, our approach will be valuable to 
determine the in vivo substrate specificity of the multitude of bromodomain (BRD)-
containing proteins that exist in model organisms and human cells
3
. Previous in vitro studies 
have clearly shown that BRDs derived from chromatin-modifying enzymes bind with higher 
affinity to peptides that contain acetylated lysines located in close proximity
3
. Moreover, 
because large protein complexes contain multiple BRDs located in different subunits of a 
given complex, deciphering their physiologically relevant acetylated substrates remains a 
formidable task. Proteomics studies performed in several species have identified a myriad of 
acetylation sites in proteins with a wide range of biological functions
33-35
. We therefore 
anticipate that, when coupled with methods to co-purify protein complexes with their 
acetylated substrates, the method described here will help identify combinatorial patterns of 
lysine acetylation that are recognized by protein complexes involved in numerous biological 
processes. 
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3.7. Supplementary data 
 
Table S3.1  Lists of synthetic H3 and H4 peptides and their concentration in mM. 
List of synthetic histone (A) H3 and (B) H4 peptides and their concentration in mM. The 
concentration of each peptide was determined based on triplicate UV absorbance 
measurements at 205 nm. 
 
A) H3 peptides 
Peptide Concentration (in mM) 
Peptide 1: H3K18_K23NoAc 4.74 
Peptide 2: H3K18Ac 5.58 
Peptide 3: H3K23Ac 5.42 
Peptide 4: H3K18_K23Ac 5.60 
 
B)  H4 peptides 
Peptide Concentration (in mM) 
Peptide 1: H4NoAc 0.60 
Peptide 2: H4K5Ac 0.51 
Peptide 3: H4K8Ac 0.57 
Peptide 4: H4K12Ac 0.77 
Peptide 5: H4K16Ac 0.79 
Peptide 6: H4K5_8Ac 0.71 
Peptide 7: H4K5_12Ac 0.68 
Peptide 8: H4K5_16Ac 0.76 
Peptide 9: H4K8_12Ac 0.70 
Peptide 10: H4K8_16Ac 0.70 
Peptide 11: H4K12_16Ac 0.71 
Peptide 12: H4K5_8_12Ac 0.69 
Peptide 13: H4K5_12_16Ac 0.75 
Peptide 14: H4K8_12_16Ac 0.74 
Peptide 15: H4K5_8_16Ac 0.82 
Peptide 16: H4K5_8_12_16Ac 0.66 
 
Table S3.2  Synthetic H4 peptide standard dilutions. 
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Standard curves for seven dilutions of mixtures of H4 (A) mono-, (B) di- and (C) tri 
acetylated peptides with peptide amounts ranging from 5 to 320 fmol were prepared. Two 
peptides from the mono- or tri-acetylated group and three peptides from the di-acetylated 
group were added to the mixture at fixed amount of 80 fmol. 
 
A) Mono-acetylated isomers 
Sample # 
Amount injected. (fmol) 
K5Ac K8Ac K12Ac K16Ac 
1 5 80 5 80 
2 10 80 10 80 
3 20 80 20 80 
4 40 80 40 80 
5 80 80 80 80 
6 160 80 160 80 
7 320 80 320 80 
 
B) Tri-acetylated isomers 
Sample 
# 
Amount injected. (fmol) 
K5/8/1
2Ac 
K5/12/16
Ac 
K8/12/16
Ac 
K5/8/16
Ac 
1 5 80 5 80 
2 10 80 10 80 
3 20 80 20 80 
4 40 80 40 80 
5 80 80 80 80 
6 160 80 160 80 
7 320 80 320 80 
 
C) Di-acetylated isomers 
sample 
# 
Amount injected. (fmol) 
K5/8Ac K5/12Ac K5/16Ac K8/12Ac K8/16Ac K12/16Ac 
1 5 80 5 80 5 80 
2 10 80 10 80 10 80 
3 20 80 20 80 20 80 
4 40 80 40 80 40 80 
5 80 80 80 80 80 80 
6 160 80 160 80 160 80 
7 320 80 320 80 320 80 
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Table S3.3  Deconvolution of mixture spectra by Iso-PeptidAce. 
Amount of each peptide isomer determined by Iso-PeptidAce after deconvolution of mixtures 
of known amounts of (A) four mono-, (B) four tri- and (C) six di-acetylated isomeric groups. 
Sample at 80 fmols was used for normalisation of peptide intensities. 
A) mono-acetylated H4 peptides (Mean of two technical replicates + range error bars) 
 
B) Tri-acetylated H4 peptides (Mean of two technical replicates + range error bars) 
 
C) Di-acetylated H4 peptides (Mean of two technical replicates + range error bars) 
 
* Values in this row represent signal response measurements from only one replicate. 
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Table S3.4  Calculated acetylation site occupancies. 
Acetylation site occupancies of (A) H3 and (B) H4 peptides before or after HDACi 
treatment.Acetylation site occupancy of, for instance H4K5ac, was determined by dividing 
the sum of normalized intensities of all peptides containing acetylated Lys-5 by the sum 
ofnormalized intensities of all forms of acetylated and un-acetylated H4 peptide 4 
GKGGKGLGKGGAKR-17. 
A. H3_acetylation site occupancy (Mean of two technical replicates + range error bars) 
Samples H3K18 H3K23 
DMSO-1h 4.23 + 0.14 26.56 + 0.66 
DMSO-6h 6.03 + 0.14 31.45 + 0.93 
DMSO-24h 5.89 + 0.74 32.06 + 0.98 
MS275-1h 5.74 + 0.15 32.03 + 4.85 
MS275-6h 10.64 + 1.89 51.95 + 6.32 
MS275-24h 27.11 + 1.67 63.35 + 0.81 
SAHA-1h 17.19 + 2.46 55.89 + 0.89 
SAHA-6h 31.94 + 0.28 71.92 + 1.22 
SAHA-24h 37.70 + 6.36 79.73 + 0.77 
JNJ-1h 15.58 + 1.17 59.95 + 0.02 
JNJ-6h 32.76 + 2.66 76.55 + 1.39 
JNJ-24h 44.17 + 1.53 82.77 + 1.21 
 
B. H4_acetylation site occupancy (Mean of two technical replicates + range error bars) 
Samples H4K5ac H4K8ac H4K12ac H4K16ac 
DMSO-1h 2.68 + 0.59 2.63 + 0.46 5.14 + 0.53 29.27 + 1.27 
DMSO-6h 3.05 + 0.07 2.86 + 0.02 5.88 + 0.04 28.42 + 1.00 
DMSO-24h 3.43 + 0.60 3.79 + 0.51 7.52 + 0.98 32.27 + 0.08 
MS275-1h 3.42 + 0.16 3.66 + 0.35 7.12 + 0.58 31.79 + 0.52 
MS275-6h 13.54 + 0.78 13.43 + 1.25 22.77 + 1.21 57.81 + 0.45 
MS275-24h 36.79 + 2.90 35.66 + 1.47 55.16 + 0.05 80.28 + 0.23 
SAHA-1h 16.24 + 1.89 17.98 + 1.65 33.03 + 3.86 57.19 + 0.79  
SAHA-6h 44.96 + 1.19 38.59 + 1.91 63.45 + 0.81 80.77 + 0.17 
SAHA-24h 61.35 + 0.21 51.05 + 3.30 77.49 + 0.40 89.77 + 1.16 
JNJ-1h 13.51 + 1.96 14.83 + 1.43 26.48 + 3.10 51.90 + 3.30 
JNJ-6h 47.15 + 1.38 39.41 + 0.06 64.59 + 0.85 80.96 + 0.49 
JNJ-24h 57.67 + 0.39 47.59 + 1.18 68.25 + 2.07 89.00 + 0.80 
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Table S3.5  LC/MS intensity data for CAF-1-bound and total H3 and H4 peptides. 
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(continued…Table S3.5) 
 
Note: Each intensity value is the Mean of two technical replicates + range error bars) 
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Table S3.6  List of known acetylation sites in selected bromodomains substrates. 
Peptides containing multiple acetylated lysine residues generated from p53, GATA1, Cyclin 
T1, or MyoD are shown. List of publications for each of the previously identified acetylation 
sites are indicated. 
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Table S3.7  Raw intensity data for control and HDACi treated samples. 
For each sample Iso-PeptidAce reports five different groups of peptides: one un-acetylated 
(m/z 747.94), four mono-acetylated (m/z 740.93), six di-acetylated (m/z 733.93), four tri-
acetylated (m/z 726.92) and one tetra-acetylated (m/z 719.91). 
 
Sample 
Precursor 
m/z 
K
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2
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6
p
r
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a
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c
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1
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a
c
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K
5
-8
-1
2
a
c
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K
5
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K
5
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DMSO-1h 747.9412 5E+07 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
DMSO-1h 740.9334 0 1E+06 6E+05 2E+06 2E+07 0 0 0 0 0 0 0 0 0 0 0 
DMSO-1h 733.9255 0 0 0 0 0 30356 1E+05 4E+05 2E+05 7E+05 2E+06 0 0 0 0 0 
DMSO-1h 726.9177 0 0 0 0 0 0 0 0 0 0 0 68875 2E+05 3E+05 5E+05 0 
DMSO-1h 719.9099 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2E+05 
DMSO-6h 747.9412 3E+08 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
DMSO-6h 740.9334 0 7E+06 4E+06 1E+07 1E+08 0 0 0 0 0 0 0 0 0 0 0 
DMSO-6h 733.9255 0 0 0 0 0 1E+05 9E+05 3E+06 1E+06 4E+06 1E+07 0 0 0 0 0 
DMSO-6h 726.9177 0 0 0 0 0 0 0 0 0 0 0 6E+05 7E+05 2E+06 2E+06 0 
DMSO-6h 719.9099 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1E+06 
DMSO-24h 747.9412 3E+08 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
DMSO-24h 740.9334 0 7E+06 4E+06 1E+07 1E+08 0 0 0 0 0 0 0 0 0 0 0 
DMSO-24h 733.9255 0 0 0 0 0 1E+05 8E+05 3E+06 1E+06 5E+06 1E+07 0 0 0 0 0 
DMSO-24h 726.9177 0 0 0 0 0 0 0 0 0 0 0 7E+05 1E+06 1E+06 3E+06 0 
DMSO-24h 719.9099 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2E+06 
JNJ-1h 747.9412 1E+08 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
JNJ-1h 740.9334 0 4E+06 2E+06 9E+06 7E+07 0 0 0 0 0 0 0 0 0 0 0 
JNJ-1h 733.9255 0 0 0 0 0 95795 2E+06 3E+06 1E+06 7E+06 2E+07 0 0 0 0 0 
JNJ-1h 726.9177 0 0 0 0 0 0 0 0 0 0 0 9E+05 1E+06 6E+06 9E+06 0 
JNJ-1h 719.9099 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2E+07 
JNJ-6h 747.9412 2E+07 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
JNJ-6h 740.9334 0 2E+06 9E+05 3E+06 2E+07 0 0 0 0 0 0 0 0 0 0 0 
JNJ-6h 733.9255 0 0 0 0 0 0 3E+06 3E+06 7E+05 5E+06 2E+07 0 0 0 0 0 
JNJ-6h 726.9177 0 0 0 0 0 0 0 0 0 0 0 4E+05 3E+06 2E+07 1E+07 0 
JNJ-6h 719.9099 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 4E+07 
JNJ-24h 747.9412 1E+07 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
JNJ-24h 740.9334 0 5E+06 2E+06 4E+06 3E+07 0 0 0 0 0 0 0 0 0 0 0 
JNJ-24h 733.9255 0 0 0 0 0 0 5E+06 1E+07 2E+06 1E+07 4E+07 0 0 0 0 0 
JNJ-24h 726.9177 0 0 0 0 0 0 0 0 0 0 0 1E+06 2E+07 4E+07 2E+07 0 
JNJ-24h 719.9099 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1E+08 
MS275-1h 747.9412 1E+08 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
MS275-1h 740.9334 0 3E+06 1E+06 4E+06 5E+07 0 0 0 0 0 0 0 0 0 0 0 
MS275-1h 733.9255 0 0 0 0 0 94043 4E+05 1E+06 4E+05 2E+06 5E+06 0 0 0 0 0 
MS275-1h 726.9177 0 0 0 0 0 0 0 0 0 0 0 2E+05 3E+05 5E+05 1E+06 0 
MS275-1h 719.9099 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 4E+05 
MS275-6h 747.9412 8E+07 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
MS275-6h 740.9334 0 6E+06 2E+06 7E+06 7E+07 0 0 0 0 0 0 0 0 0 0 0 
MS275-6h 733.9255 0 0 0 0 0 42800 2E+06 9E+06 1E+06 1E+07 2E+07 0 0 0 0 0 
MS275-6h 726.9177 0 0 0 0 0 0 0 0 0 0 0 4E+05 3E+06 7E+06 8E+06 0 
MS275-6h 719.9099 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 5E+06 
MS275-24h 747.9412 6E+07 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
MS275-24h 740.9334 0 1E+07 4E+06 2E+07 1E+08 0 0 0 0 0 0 0 0 0 0 0 
MS275-24h 733.9255 0 0 0 0 0 4E+05 1E+07 3E+07 1E+07 4E+07 8E+07 0 0 0 0 0 
MS275-24h 726.9177 0 0 0 0 0 0 0 0 0 0 0 2E+06 2E+07 5E+07 5E+07 0 
MS275-24h 719.9099 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1E+08 
SAHA-1h 747.9412 8E+07 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
SAHA-1h 740.9334 0 3E+06 2E+06 7E+06 6E+07 0 0 0 0 0 0 0 0 0 0 0 
SAHA-1h 733.9255 0 0 0 0 0 36592 2E+06 3E+06 1E+06 4E+06 2E+07 0 0 0 0 0 
SAHA-1h 726.9177 0 0 0 0 0 0 0 0 0 0 0 9E+05 1E+06 6E+06 1E+07 0 
SAHA-1h 719.9099 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2E+07 
SAHA-6h 747.9412 6E+07 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
SAHA-6h 740.9334 0 5E+06 2E+06 9E+06 7E+07 0 0 0 0 0 0 0 0 0 0 0 
SAHA-6h 733.9255 0 0 0 0 0 1E+05 1E+07 1E+07 2E+06 2E+07 7E+07 0 0 0 0 0 
SAHA-6h 726.9177 0 0 0 0 0 0 0 0 0 0 0 1E+06 7E+06 5E+07 3E+07 0 
SAHA-6h 719.9099 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1E+08 
SAHA-24h 747.9412 2E+07 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
SAHA-24h 740.9334 0 5E+06 1E+06 5E+06 3E+07 0 0 0 0 0 0 0 0 0 0 0 
SAHA-24h 733.9255 0 0 0 0 0 2E+05 7E+06 1E+07 5E+06 1E+07 5E+07 0 0 0 0 0 
SAHA-24h 726.9177 0 0 0 0 0 0 0 0 0 0 0 3E+06 1E+07 6E+07 3E+07 0 
SAHA-24h 719.9099 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1E+08 
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Figure S3.1 Peptides within the same isomeric groups exhibit very narrow retention.  
Shown in each column are the extracted ion chromatograms of (A) four mono-acetylated 
(m/z 740.93, +2), (B) six di-acetylated (m/z 733.93, 2+), and (C) four tri-acetylated (m/z 
726.92, +2) isomers derived from the H4 peptide 4-GKGGKGLGKGGAKR-17. 
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Figure S3.2 MS signal responses of synthetic H3 and H4 peptides.  
After in vitro propionylation and trypsin digestion of synthetic peptides, the relative MS 
response of each peptide was determined based on the curve of ion intensity versus amount 
injected for the non-acetylated and acetylated forms of (A) H3 peptide 18-KQLATKAAR-26 
and (B) H4 peptide 4-GKGGKGLGKGGAKR-17. The tables on the right show the slopes of 
the lines determined from the linear equation that best-fit (as measure by R2 values) the 
signal responses. 
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Figure S3.3 Co-elution and co-fragmentation of acetylated isomers.  
A) LC-MS trace of a mixture of sixteen H4 peptides, and extracted ion chromatograms of co-
eluting four mono-, six di- and four tri-acetylated isomers of peptide 4-
GKGGKGLGKGGAKR-17 (top to bottom panels). B) Mixed MS/MS spectra of four mono-, 
six di- and four tri-acetylated isomers (from top to bottom panel). 
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Figure S3.4 Isomeric peptides produce distinct fragment ion patterns.  
Representative fragment ion spectra of four mono-acetylated isomers of the peptide 4-
GKGGKGLGKGGAKR-17: (A) H4K5ac, (B) H4K16ac, (C) H4K8ac, and (D) H4K12ac. 
The ‘y’ type fragment ions are indicated in each spectrum. E) A three-dimensional view of 
the distribution of selected ‘b’ and ‘y’ type fragment ions derived from the individual mono-
acetylated isomers. The ‘b’ type fragment ions are shown at m/z 228.1 (b2, K5ac), 242.1 (b2, 
K5pr) and 299.2 (b3, K5pr). The ‘y’ type fragment ions are m/z 530.3, 544.30, 771.4, 785.5, 
941.6, 955.6, 1239.7 and 1253.7. 
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Figure S3.5 Deconvolution of di- and tri-acetylated isomers of histone H4.  
Elution profiles before (dashed line) or after (colored lines) deconvolution of a mixture of (A) 
six di-acetylated, and (B) four tri-acetylated isomers of the peptide 4-
GKGGKGLGKGGAKR-17. Distributions of fragment peaks of the deconvoluted di- (C) and 
tri-acetylated (D) isomers. 
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Figure S3.6 Fractionation of total histones by RP-HPLC.  
Total histones were baselineseparated as H2B, H4, H2A and H3.1 in increasing order of 
retention time. Histone H3.1 and H4 fractions were pooled and dried completely in a speed-
vac concentrator. Pump A: 0.1% trifluoroacetic acid in 100% filtered water (v/v). Pump B: 
0.1% trifluoroacetic acid in 100% acetonitrile (v/v)., flow rate:150μl/min, Absorbance 
wavelength: 214 nm, Column: Zorbax C8, 5μm, 2.1x150 mm. 
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3.8. Supplementary method  
Iso-PeptidAce : In-silico separation of co-eluting peptides 
Overview 
Here we describe Iso-PeptidAce, a stand-alone software for the in-silico separation of co-
eluting peptide isomers in high resolution mass spectrometry data. Peptide isomers of interest 
need to be synthesized and processed individually in a high resolution mass spectrometer, 
with dynamic exclusion turned off. Samples with unknown proportions of co-eluting peptide 
isomers processed in the same instrument, with a similar method will be separated by the 
software. Iso-PeptidAce can also quantify (relatively) co-eluting peptides from mixed 
samples. To our knowledge, this is the first software capable of such a feat. 
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List of histone H4 peptides used for testing Iso-PeptidAce 
Peptide 1  GK(propionylation of K)GGK(propionylation of K)GLGK(propionylation of K)GGAK(propionylation of K)R 
Peptide 2 GK(acetylation of K)GGK(propionylation of K)GLGK(propionylation of K)GGAK(propionylation of K)R 
Peptide 3 GK(propionylation of K)GGK(acetylation of K)GLGK(propionylation of K)GGAK(propionylation of K)R 
Peptide 4 GK(propionylation of K)GGK(propionylation of K)GLGK(acetylation of K)GGAK(propionylation of K)R 
Peptide 5 GK(propionylation of K)GGK(propionylation of K)GLGK(propionylation of K)GGAK(acetylation of K)R 
Peptide 6 GK(acetylation of K)GGK(acetylation of K)GLGK(propionylation of K)GGAK(propionylation of K)R 
Peptide 7 GK(acetylation of K)GGK(propionylation of K)GLGK(acetylation of K)GGAK(propionylation of K)R 
Peptide 8 GK(acetylation of K)GGK(propionylation of K)GLGK(propionylation of K)GGAK(acetylation of K)R 
Peptide 9 GK(propionylation of K)GGK(acetylation of K)GLGK(acetylation of K)GGAK(propionylation of K)R 
Peptide 10 GK(propionylation of K)GGK(acetylation of K)GLGK(propionylation of K)GGAK(acetylation of K)R 
Peptide 11 GK(propionylation of K)GGK(propionylation of K)GLGK(acetylation of K)GGAK(acetylation of K)R 
Peptide 12 GK(acetylation of K)GGK(acetylation of K)GLGK(acetylation of K)GGAK(propionylation of K)R 
Peptide 13 GK(acetylation of K)GGK(acetylation of K)GLGK(propionylation of K)GGAK(acetylation of K)R 
Peptide 14 GK(acetylation of K)GGK(propionylation of K)GLGK(acetylation of K)GGAK(acetylation of K)R 
Peptide 15 GK(propionylation of K)GGK(acetylation of K)GLGK(acetylation of K)GGAK(acetylation of K)R 
Peptide 16 GK(acetylation of K)GGK(acetylation of K)GLGK(acetylation of K)GGAK(acetylation of K)R 
 
Symbols used 
● MS1i, MS2i = Injection Time for MS1 and MS2 Scans, in milliseconds 
● iMS = ions per milliseconds 
● #ion = Number of monoisotopic precursor ions fragmented in a scan 
● psm = Peptide Spectrum Match 
● fi = Fragment Intensity 
● nfi = Normalized Fragment Intensity 
● n = Number of fragments considered per characterized peptide 
● rt = Scan Time 
● 𝛥𝑚𝑧= Precursor mass error, in ppm 
● mif = Matching fragment ion divided by the number of theoretical ion tested 
● 𝑐𝑗= Number of ions detected for peptide j 
● aMz = List of selected fragment masses 
● ac = Area Under the Curve 
● pc = Peptide Count (Estimation of the number of a certain peptide in a sample) 
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Description of how spectral deconvolution is carried out by Iso-PeptidAce  
Raw file extraction 
Information is extracted from Raw files using ProteoWizard
50
 and MsFileReader. MS2 peak 
lists (masses and intensities) are stored per precursor mass and sorted by retention time. 
Spectrum precursor intensity, MS1 and MS2 injection times are also extracted.  
Precursor intensity counts are converted to ions per millisecond (iMS):  
𝑖𝑀𝑆 =  𝑃𝑟𝑒𝑐𝑢𝑟𝑠𝑜𝑟 𝐼𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦 𝐶𝑜𝑢𝑛𝑡 𝑀𝑆1 𝑖𝑛𝑗𝑒𝑐𝑡𝑖𝑜𝑛 𝑡𝑖𝑚𝑒⁄  
For each different precursor mass in a file, a curve describing the number of ions flowing in 
the system at any given time is built using the computed iMS values. Linear interpolation is 
used to compute the area under the curve for a given time point. In particular, the number of 
ions that entered the CTrap and became fragmented (#ion) is estimated as the area under the 
curve between the beginning (rt) and the end of the scan (rt + MS2i). 
#𝑖𝑜𝑛 =  𝐴𝑟𝑒𝑎 𝑈𝑛𝑑𝑒𝑟 𝑇ℎ𝑒 𝐶𝑢𝑟𝑣𝑒 (𝑓𝑟𝑜𝑚: 𝑟𝑡, 𝑡𝑜: 𝑟𝑡 +  𝑀𝑆2𝑖) 
These operations are made for each file (both mixed samples and synthetic peptide runs). For 
the synthetic peptide runs, spectrum fragment intensity counts (fi) are normalized (nfi) using 
the number of ions (#ion) that became fragmented. 
𝑛𝑓𝑖 =  𝑓𝑖 #𝑖𝑜𝑛⁄  
Peptide Spectrum Matching 
Iso-PeptidAce uses PeptidAce peptide spectrum matching abilities (which is derived from 
Morpheus) to automatically identify peptide sequences and modifications across synthetic 
peptide runs. PeptidAce uses a no-enzyme in-silico protein digestion routine to parse the 
provided Fasta file for potential matches. All modifications (specified in the 
“Modifications.csv” user configurable Comma Separated Values file) are searched for. This 
automatic identification is useful to discover impurities in the peptide synthesis process. 
PeptidAce matches peptide sequences to spectra by comparing theoretical ions (fragments a, 
b, c, x, y and z) within a specified ppm tolerance window. Peptide spectrum matches (psm) 
are scored by their cumulated normalized fragment intensities (nfi), number of matching ions 
versus unmatched theoretical ions (mif) and precursor accuracy (𝛥𝑚𝑧, normalized between 
[0,1]): 
𝑝𝑠𝑚 𝑠𝑐𝑜𝑟𝑒 = 0.33 ∙ 𝛥𝑚𝑧 + 0.33 ∙ 𝑚𝑖𝑓 + 0.33 ∙ 𝑛𝑓𝑖 
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In case of discrepancy (precursor with inconsistent psm across the elution curve), psm scores 
of similar peptides are summed together and the best peptide is associated to the precursor. 
Ambiguous spectra assigned to different peptides are discarded.  
Describing the system as a Maximum Flow problem 
 
The network flow was built from mixed spectra and spectra acquired from peptide isomers. 
The objective, finding the maximum flow of the system, is stated as such: 
How many ions of peptide isomer does it take to optimally fill the mixed 
spectrum fragment intensity counts? 
For each synthetic peptide found, normalized fragment intensities (nfi) of every spectrum 
were averaged. The n most intense fragments were chosen for each synthetic peptide. Only 
fragment masses with consistent normalized intensities (standard deviation above 50% of the 
mean) were considered reproducible enough. Unstable fragments were flagged and ignored in 
following analyses. 
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For synthetic peptides of similar masses, these n fragments were used to build a list of 
fragment masses (𝑎𝑀𝑧), both with common and unique fragment masses. The nfi of their 
averaged spectrum was used to associate intensities to a list of fragment masses (𝑎𝑀𝑧𝑗, one 
𝑎𝑀𝑧 for each potential isomer j). A similar list of intensity count (𝑎𝑀𝑧𝑚) is built for the 
mixed spectrum m of matching precursor mass. For each mixed spectrum m, the Maximum 
Flow is defined by the sum of 𝑎𝑀𝑧𝑗 that optimally fills the 𝑎𝑀𝑧𝑚 fragment intensity counts 
(were 𝑐𝑗 is the number of ions for the j isomer, and 𝑎𝑀𝑧𝑡 is the theoretical list being built):  
𝑎𝑀𝑧𝑡 = ∑ (
𝑗
𝑖𝑠𝑜𝑚𝑒𝑟𝑠 𝑐𝑗  ∙ 𝑎𝑀𝑧𝑗) and  𝑎𝑀𝑧𝑡 ≤ 𝑎𝑀𝑧𝑚 
Thus, the network flow can be described as the source being connected to peptide isomers j 
(edges of unknown capacity) which are themselves connected to every selected fragment aMz 
(edge capacity determined by 𝑐𝑗) linking to the sink (edge capacity determined by 𝑎𝑀𝑧𝑗). 
When the maximum flow is reached, the first set of edges from the source represents the ratio 
of each peptide isomer found in the mixed spectrum. 
Gradient Descent 
 
 
Because of the dependencies between fragment intensities within a synthetic peptide 
spectrum, traditional approaches (such as PreFlow Push) could not be used. Instead, a 
Gradient Descent was implemented.  
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The Gradient Descent is an iterative approach with each step being closer to the Maximum 
Flow than the previous iteration. The initial state of the gradient descent (c value for each j 
isomer) is computed as the number of times each j isomer can fit in the mixed spectrum.  
𝑐𝑗 = 𝑎𝑀𝑧𝑚 𝑎𝑀𝑧𝑗⁄  
This puts the system in an Overflow state (some fragment intensities within the theoretical 
𝑎𝑀𝑧 (𝑎𝑀𝑧𝑡) are over their capacity). There might also be Underflow (fragments of 𝑎𝑀𝑧𝑡 
lower than their capacity in 𝑎𝑀𝑧𝑚).  
Iteratively, until there is no Overflow in the network, the j isomer with the highest 
Overflow/Underflow score (objective function) has its 𝑐𝑗  value reduced (ions are removed 
one unit at a time). Ambiguous states are resolved randomly. 
Deconvolution 
In PeptidAce, the peak tops and areas under the curve of precursors are both reported for 
quantification purposes. Iso-PeptidAce also reports area under the curve of the individual 
isomers populating a mixed precursor elution profile. For each isomer j, the number of ions 
populating the spectrum (deduced by each Gradient Descent result) is used to compute the 
number of ions per millisecond flowing in the system at different time points. The resulting, 
deconvoluted curve is traced through linear interpolation, which is in turn used to compute 
the area under the curve (𝑎𝑐𝑗) for that peptide.  
Quantification 
If peptide intensities are properly normalized based on the synthetic sample runs, it is 
possible to use this method for absolute quantification of peptides. When concentrations of 
spiked synthetic peptides are known, Iso-PeptidAce’s area under the curve can be converted 
into absolute peptide counts. Assuming that synthetic peptide samples were processed exactly 
as the mixed spectrum samples, the number of peptides j in the sample m (𝑝𝑐𝑚𝑗) is defined 
by the area under the curve (𝑎𝑐𝑚𝑗) normalized by the synthetic peptide sample s information 
(peptide count in sample 𝑝𝑐𝑠𝑗, and area under the curve 𝑎𝑐𝑠𝑗). 
𝑝𝑐𝑚𝑗 = 𝑎𝑐𝑚𝑗 ∙ (𝑝𝑐𝑠𝑗 𝑎𝑐𝑠𝑗⁄ ) 
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Results 
Experimental design 
To assess the precision of the approach, we designed an experiment to test deconvolution 
across different peptide isomer concentration ratios. Because of its high level of complexity, 
characterization of acetylation sites in the Histone H4 peptide [1] was selected. The software 
method was tested for the mono, di and tri-acetylated versions of the peptides while all other 
lysine sites were propyonylated. The next table depicts the concentrations normalized using 
the equimolar run (observed / expected):  
 
 
Automatic identification of synthetic peptides 
Automatic identification of peptide sequence and modification did not yield in any particular 
error. However, we did find impurities in the synthesized peptide samples. For instance, 
incomplete or non-acetylated forms of the peptides were seen in small quantities (less than 
0.2% of total intensity). Cross contamination of peptide forms was tested by running Iso-
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PeptidAce on sample containing only one peptide form. The resulting contamination intensity 
detected were too low to be worth accounting for. 
Consistency of the Gradient Descent approach 
Despite the fact that each gradient descent is done independently of the others, the results are 
surprisingly consistent across the mixed elution profile. As shown in the figure below, the 
deconvoluted elution profile for the  mixed peptide spectrum (left panel) is comparable to the 
profile obtained for the individual peptide spectrum (right panel). Both profiles have 
comparable  elution time range (x-axis) and intensityvalues (y-axis).. 
Elution profiles of mixed peptide spectra (left panel) and the individual synthetic peptide 
spectrum (right panel) after deconvolution by the gradient descent approach 
 
 
Expected versus Observed Concentration 
The precision of the method is shown in the next figure, where observed peptide 
concentration ratios are plotted against their expected values. The average difference between 
observed and expected concentration varies from 1.7% to 4.3% with a maximum recorded 
error of 35% (Di-Acetylation, 320fMol sample). These numbers are well within the error 
estimates of expected peptide count per sample (80% purity per synthetic peptide plus errors 
introduced during dilutions). 
 
 
 
 
 
148 
 
 
 
 
 
 
Conclusion 
Iso-PeptidAce was successfully tested for three types of peptide positional isomers on a Q-
Exactive. Peptide fragmentation was done in HCD, but in theory should work equally well 
with other fragmentation methods. All mixed spectra samples were resolved with accuracies 
below the errors that were expected from sample preparation and manipulation. Furthermore, 
the included user interface makes the tool readily accessible to all scientists, not just 
bioinformaticians. 
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About PeptidAce 
PeptidAce is an open source C# library that includes a lot of tools for peptide spectrum 
matching. It was based on the Morpheus open source project, with the ultimate aim of 
improving no-enzyme in-silico digestion of huge, unannotated transcriptome databases. It 
excels at identifying non-tryptic peptides and can identify peptides with non-standard 
fragmentation patterns. It can also be used for deep spectrum annotation, matching peaks to 
all types of fragments and modifications. The source code and the documentation of the 
library are accessible from the github page: 
https://github.com/olivierlizotte/PeptidAce 
About Iso-PeptidAce 
The user interface for Iso-PeptidAce is built using .Net 4. It is compatible with 64 bit versions 
of Windows 7 (and up). To work with Thermo instruments, MsFileReader (64 bit version) 
must be installed first. Iso-PeptidAce installer can be downloaded for free from IRIC’s 
Proteomic Platform website: 
http://proteomics.iric.ca/tools/Iso-PeptidAce 
 
 
 
 
 
 
 
 
 
 
 
150 
 
 
 
3.9. References 
1. Unnikrishnan, A., Gafken, P. R. & Tsukiyama, T. Dynamic changes in histone acetylation 
regulate origins of DNA replication. Nat Struct Mol Biol 17, 430-437, (2010). 
2. Zentner, G. E. & Henikoff, S. Regulation of nucleosome dynamics by histone 
modifications. Nat Struct Mol Biol 20, 259-266, (2013). 
3. Filippakopoulos, P. & Knapp, S. The bromodomain interaction module. FEBS Lett 586, 
2692-2704, (2012). 
4. Filippakopoulos, P. et al. Histone recognition and large-scale structural analysis of the 
human bromodomain family. Cell 149, 214-231, (2012). 
5. Smith, C. M. et al. Mass spectrometric quantification of acetylation at specific lysines 
within the amino-terminal tail of histone H4. Analytical Biochemistry 316, 23-33, (2003). 
6. Feller, C., Forné, I., Imhof, A. & Becker, Peter B. Global and Specific Responses of the 
Histone Acetylome to Systematic Perturbation. Molecular Cell 57, 559-571, (2015). 
7. Sidoli, S. et al. Middle-down hybrid chromatography/tandem mass spectrometry 
workflow for characterization of combinatorial post-translational modifications in 
histones. PROTEOMICS 14, 2200-2211, (2014). 
8. Yuan, Z.-F. et al. EpiProfile Quantifies Histone Peptides With Modifications by 
Extracting Retention Time and Intensity in High-resolution Mass Spectra. Molecular & 
Cellular Proteomics 14, 1696-1707, (2015). 
9. Bern, M. et al. Deconvolution of mixture spectra from ion-trap data-independent-
acquisition tandem mass spectrometry. Anal Chem 82, 833-841, (2010). 
10. Wang, J., Bourne, P. E. & Bandeira, N. MixGF: spectral probabilities for mixture spectra 
from more than one peptide. Mol Cell Proteomics 13, 3688-3697, (2014). 
11. Zhang, B., Pirmoradian, M., Chernobrovkin, A. & Zubarev, R. A. DeMix workflow for 
efficient identification of cofragmented peptides in high resolution data-dependent 
tandem mass spectrometry. Mol Cell Proteomics 13, 3211-3223, (2014). 
12. Courcelles, M., Bridon, G., Lemieux, S. & Thibault, P. Occurrence and detection of 
phosphopeptide isomers in large-scale phosphoproteomics experiments. J Proteome Res 
11, 3753-3765, (2012). 
13. Ahuja, R. K., Magnanti, T. L. & Orlin, J. B. Network Flows: Theory, Algorithms, and 
Applications. (PRENTICE HALL, 1993). 
14. Cho, D.-Y., Kim, Y.-A. & Przytycka, T. M. Chapter 5: Network Biology Approach to 
Complex Diseases. PLoS Comput Biol 8, e1002820, (2012).  
15. Albert, R. Scale-free networks in cell biology. Journal of Cell Science 118, 4947-4957, 
(2005).  
151 
 
 
 
16. Dutt, S., Dai, Y., Ren, H. & Fontanarosa, J. in Bioinformatics and Computational Biology 
Vol. 5462 Lecture Notes in Computer Science (ed Sanguthevar Rajasekaran) Ch. 21, 211-
223 (Springer Berlin Heidelberg, 2009).  
17. SNYMAN, J. A. Practical Mathematical Optimization: An Introduction to Basic 
Optimization Theory and Classical and New Gradient-Based Algorithms. (Springer 
Publishing, 2005).  
18. Tang, H. et al. Multiplexed Parallel Reaction Monitoring Targeting Histone 
Modifications on the QExactive Mass Spectrometer. Analytical Chemistry 86, 5526-5534, 
(2014).  
19. Li, Q., Burgess, R. & Zhang, Z. All roads lead to chromatin: multiple pathways for 
histone deposition. Biochim Biophys Acta 1819, 238-246 (2013).  
20. Zhou, H., Madden, B. J., Muddiman, D. C. & Zhang, Z. Chromatin assembly factor 1 
interacts with histone H3 methylated at lysine 79 in the processes of epigenetic silencing 
and DNA repair. Biochemistry 45, 2852-2861, (2006).  
21. Kelly, T. J., Qin, S., Gottschling, D. E. & Parthun, M. R. Type B histone acetyltransferase 
Hat1p participates in telomeric silencing. Mol Cell Biol 20, 7051-7058 (2000).  
22. Qin, S. & Parthun, M. R. Histone H3 and the histone acetyltransferase Hat1p contribute 
to DNA double-strand break repair. Mol Cell Biol 22, 8353-8365 (2002).  
23. Sobel, R. E., Cook, R. G., Perry, C. A., Annunziato, A. T. & Allis, C. D. Conservation of 
deposition-related acetylation sites in newly synthesized histones H3 and H4. Proc Natl 
Acad Sci U S A 92, 1237-1241 (1995).  
24. Rusche, L. N., Kirchmaier, A. L. & Rine, J. The establishment, inheritance, and function 
of silenced chromatin in Saccharomyces cerevisiae. Annu Rev Biochem 72, 481-516, 
(2003).  
25. Arts, J. et al. JNJ-26481585, a Novel “Second-Generation” Oral Histone Deacetylase 
Inhibitor, Shows Broad-Spectrum Preclinical Antitumoral Activity. Clinical Cancer 
Research 15, 6841-6851, (2009).  
26. Stühmer, T. et al. Preclinical anti-myeloma activity of the novel HDAC-inhibitor JNJ-
26481585. British Journal of Haematology 149, 529-536, (2010).  
27. Tong, W.-G. et al. Preclinical antileukemia activity of JNJ-26481585, a potent second-
generation histone deacetylase inhibitor. Leukemia Research 34, 221-228, (2010).  
28. Deleu, S. et al. The effects of JNJ-26481585, a novel hydroxamate-based histone 
deacetylase inhibitor, on the development of multiple myeloma in the 5T2MM and 
5T33MM murine models. Leukemia 23, 1894-1903 (2009).  
29. Venugopal, B. et al. A Phase I Study of Quisinostat (JNJ-26481585), an Oral 
Hydroxamate Histone Deacetylase Inhibitor with Evidence of Target Modulation and 
Antitumor Activity, in Patients with Advanced Solid Tumors. Clinical Cancer Research 
19, 4262-4272, (2013).  
152 
 
 
 
30. Carol, H. et al. Initial testing (stage 1) of the histone deacetylase inhibitor, quisinostat 
(JNJ-26481585), by the Pediatric Preclinical Testing Program. Pediatric Blood & Cancer 
61, 245-252, (2014).  
31. Gallien, S. et al. Targeted Proteomic Quantification on Quadrupole-Orbitrap Mass 
Spectrometer. Molecular & Cellular Proteomics 11, 1709-1723, (2012).  
32. Chen, Y. et al. Quantitative acetylome analysis reveals the roles of SIRT1 in regulating 
diverse substrates and cellular pathways. Mol Cell Proteomics 11, 1048-1062, (2012).  
33. Downey, M. et al. Acetylome profiling reveals overlap in the regulation of diverse 
processes by sirtuins, gcn5, and esa1. Mol Cell Proteomics 14, 162-176, (2015).  
34. Weinert, B. T. et al. Proteome-wide mapping of the Drosophila acetylome demonstrates a 
high degree of conservation of lysine acetylation. Sci Signal 4, ra48, (2011).  
35. Shechter, D., Dormann, H. L., Allis, C. D. & Hake, S. B. Extraction, purification and 
analysis of histones. Nat. Protocols 2, 1445-1457 (2007).  
36. Abshiru, N. et al. Chaperone-mediated acetylation of histones by Rtt109 identified by 
quantitative proteomics. Proteomics 81, 80-90 (2013). 
37. Zeng, L., Zhang, Q., Gerona-Navarro, G., Moshkina, N. & Zhou, M.M. Structural Basis 
of Site-Specific Histone Recognition by the Bromodomains of Human Coactivators 
PCAF and CBP/p300. Structure 16, 643-652 (2008). 
38. Choudhary, C. et al. Lysine Acetylation Targets Protein Complexes and Co-Regulates 
Major Cellular Functions. Science 325, 834-840 (2009). 
39. Wu, S.Y. & Chiang, C.M. Crosstalk between sumoylation and acetylation regulates p53‐
dependent chromatin transcription and DNA binding, Vol. 28. (2009). 
40. Joubel, A., Chalkley, R.J., Medzihradszky, K.F., Hondermarck, H. & Burlingame, A.L. 
Identification of New p53 Acetylation Sites in COS-1 Cells. Molecular & Cellular 
Proteomics 8, 1167-1173 (2009). 
41. Sen, N., Kumari, R., Singh, Manika I. & Das, S. HDAC5, a Key Component in Temporal 
Regulation of p53-Mediated Transactivation in Response to Genotoxic Stress. Molecular 
Cell 52, 406-420 (2013). 
42. Li, A.G. et al. An Acetylation Switch in p53 Mediates Holo-TFIID Recruitment. 
Molecular Cell 28, 408-421 (2007). 
43. Tang, Y., Zhao, W., Chen, Y., Zhao, Y. & Gu, W. Acetylation Is Indispensable for p53 
Activation. Cell 133, 612-626 (2008). 
44. Boyes, J., Byfield, P., Nakatani, Y. & Ogryzko, V. Regulation of activity of the 
transcription factor GATA-1 by acetylation. Nature 396, 594-598 (1998). 
45. Lamonica, J.M., Vakoc, C.R. & Blobel, G.A. Acetylation of GATA-1 is required for 
chromatin occupancy, Vol. 108. (2006). 
153 
 
 
 
46. Lamonica, J.M. et al. Bromodomain protein Brd3 associates with acetylated GATA1 to 
promote its chromatin occupancy at erythroid target genes. Proceedings of the National 
Academy of Sciences 108, E159-E168 (2011). 
47. Schröder, S. et al. Two-pronged Binding with Bromodomain-containing Protein 4 
Liberates Positive Transcription Elongation Factor b from Inactive Ribonucleoprotein 
Complexes. Journal of Biological Chemistry 287, 1090-1099 (2012). 
48. Sartorelli, V. et al. Acetylation of MyoD Directed by PCAF Is Necessary for the 
Execution of the Muscle Program. Molecular Cell 4, 725-734 (1999). 
49. Wei, L., Jamonnak, N., Choy, J., Wang, Z. & Zheng, W. Differential binding modes of 
the bromodomains of CREB-binding protein (CBP) and p300 with acetylated MyoD. 
Biochemical and Biophysical Research Communications 368, 279-284 (2008). 
50. Kessner, D., Chambers, M., Burke, R., Agus, D. & Mallick, P. Bioinformatics 24, 2534-
2536 (2008). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
154 
 
 
 
 
 
 
CHAPTER 4: Unraveling site-specific and combinatorial acetylations of 
histones using high-resolution mass spectrometry in HAT and HDAC 
mutants of fission yeast 
Nebiyu Abshiru
1,2,4
, Roshan Elizabeth Rajan
2,3,4
, Alain Verreault
1,3
, Pierre Thibault
1,2 
 
1
Department of Chemistry, Université de Montréal, P.O. Box 6128, Station centre-ville, 
Montréal, 
 Québec, H3C 3J7, Canada. 
2
Institute for Research in Immunology and Cancer, Université de Montréal, C.P. 6128, 
Succursale centre 
 ville, Montréal, Québec, H3C 3J7, Canada. 
3
Molecular Biology Programme, Université de Montréal, P.O. Box 6128, Station centre-ville, 
Montréal, 
  
Québec, H3C 3J7, Canada. 
 
Manuscript: In revision 
 
Author contributions: 
N.A. designed and carried out the proteomics experiment. R.E.R. isolated histones from control and 
mutant fission yeast strains. N.A. analyzed data, wrote the first draft of the manuscript, and generated 
figures. P.T and A.V. conceived and led the project. N.A., R.E.R., P.T. and A.V. wrote the final draft 
of the manuscript. 
 
 
 
155 
 
 
 
4.1. Abstract  
 
Histone acetylation is regulated by the opposing activities of two enzyme families known as 
histone acetyltransferases (HATs) and histone deacetylases (HDACs). The dynamic interplay 
between these two enzymes regulates global histone acetylation levels. This process is crucial 
in the maintenance of chromatin reorganization and gene expression as dysregulation of 
either enzymatic activity can cause severe defects in the genome integrity of cells. The fission 
yeast, Schizosaccharomyces pombe, genome encodes for few HATs and HDACs. The 
substrate specificities of most of these enzymes were previously determined by antibody-
based methods whereby only a limited number of sites were tested. Even less is known about 
their role in the establishment and regulation of combinatorial acetylation codes, which are 
valuable in mediating functional chromatin-effector protein interactions. Here, we employed 
a targeted quantitative mass spectrometry (MS)-based approach to conduct an in-depth 
analysis of site-specific and combinatorial acetylations of histones H3 and H4 in S. pombe 
lacking major HAT and HDAC activities. Our analysis identified several known and novel 
HAT and HDAC target sites. We also found that the S. pombe Class I HDAC known as Clr6 
has a striking preference for combinatorial H3 and H4 acetylation motifs rather than the 
individual marks. In addition, our study uncovered a few short-range crosstalks between 
acetylated lysines and di- or tri-methylated H3K9. We anticipate that the results from this 
study will greatly improve our current understanding of the mechanisms involved in HAT- 
and HDAC-mediated gene regulation and heterochromatin assembly. 
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4.2. Introduction 
Histone posttranslational modifications (PTMs) are known to play a crucial role in the 
maintenance of higher-order chromatin structures and transcription regulation.
1-3
 Numerous 
studies conducted during the last decade have identified over fifteen different types of PTMs 
on the core histones H2A, H2B, H3 and H4.
4
 The majority of these PTMs are localized on the 
unstructured N-terminal histone tail which extends outside the nucleosome core.  
Acetylation is one of the best characterized histone PTM. This modification mediates 
changes in higher-order chromatin structures. For example, acetylation of histone H4 at 
lysine 16 (H4K16) was shown to inhibit chromatin condensation and formation of higher 
order chromatin fiber.
5
 Histone acetylation is also involved in the regulation of the 
transcriptional activity of genes.
6,7
 Acetylation of histones is regulated by the opposing 
activities of two major enzyme families known as histone acetyltransferases (HAT) and 
histone deacetylases (HDACs).
8
 HATs specifically catalyze the acetylation of lysine residues, 
whereas HDACs specialize in removing the acetyl marks. Based on their catalytic domains 
and sequence homology, eukaryotic HATs are grouped into three major families
9,10
: i) Gcn5-
related N-acetyltransferases (GNATs), named after the founding member Gcn5; ii) the 
MYST HATs, named for the founding members of this family: Morf, Ybf2, Sas2 and Tip60; 
and iii) CBP/P300. HAT activity generally leads to destabilization of the nucleosome 
structure, and hence their function is often associated with transcriptional activation and 
increased gene expression.
11
 In agreement with this notion, many HATs are known to be 
recruited at promoter and transcriptionally active regions via interaction with gene-specific 
activator proteins.
12,13
 For example, in budding yeast, the HAT Gcn5 is recruited to the 
promoter regions of active genes via interaction with the activator protein Gcn4, which leads 
to acetylation of histone H3 at positions K9 and K14.
14
 Conversely, the removal of acetyl 
marks from histones by HDACs generally results in chromatin condensation. This process is 
historically associated with transcriptional repression and heterochromatin formation
15,16
, 
although this has been demonstrated only in a limited number of cases. HDACs are grouped 
into four major classes
17,18
: Class I: HDAC-1, -2, -3 and -8; Class-II: HDAC-4, -5, -6, -7, -9 
and -10; Class III: sirtuins or SIRT 1–7; and Class IV: HDAC11. HDACs carry out their 
function by associating with repressor complexes. One example is the Sin3 multiple-protein 
co-repressor complex which interacts with the HDAC Rpd3 in S. cerevisiae
19
 and HDAC1/2 
in humans
20
. Most HDAC complexes do not directly bind to DNA; instead they are targeted 
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to specific genomic loci via interaction with other DNA-binding proteins. For example, in S. 
cerevisiae, the Sin3/Rpd3 complex interacts with the DNA-binding protein called Ume6 to 
target the deacetylation of histone H4K5 and repress transcription of the adjacent genes.
21,22
  
The genome of the fission yeast, Schizosaccharomyces pombe, encodes for few HATs and 
HDACs. It contains two MYST family HATs: Mst1 and Mst2. Mst1, the likely orthologue of 
S. cerevisiae Esa1 and human Tip60, is an essential gene and is implicated in a variety of 
functions including DNA damage response, and in centromere assembly.
23
 In contrast, Mst2 
is a non-essential gene required in negative regulation of telomere silencing.
24
 The substrate 
specificity of Mst2 has been previously examined using Western analysis.
25
 Histones isolated 
from Mst2 mutant strains exhibited a reduced level of H3K14ac, whereas no significant 
change was observed in the levels of H3K9ac and H3K18ac. Its specificity toward histone H4 
and other H3 sites (e.g. K23 and K27) was not reported. Gcn5 is the only GNAT family HAT 
that is so far identified in S. pombe. This HAT is conserved in both S. cerevisiae and humans 
and is required in transcriptional activation of genes.
26
 The substrate specificity of S. pombe 
Gcn5 was so far examined for only three sites on histone H3 (K9ac, K14ac and K18ac).
25
 All 
three sites were significantly reduced in strains lacking the Gcn5 activity.  
Moreover, the S. pombe genome encodes for a total of six deacetylases representing three 
HDAC classes: Clr6 and Hos2 are (Class I); Clr3 (Class II); and Sir2, Hst2 and Hst4 (Class 
III). Clr6, an orthologue of S. cerevisiae Rpd3 and human HDAC1/2, is an essential gene 
required in genome-wide heterochromatin silencing.
27,28
 According to previous Western 
analysis, loss of Clr6 activity induces hyperacetylation of histones H3 and H4 at positions 
H3K9, H3K14, H4K5, H4K12 and H4K16.
29
 However, its activity toward many other sites 
(e.g. H3K18, H3K23, H3K27 and H4K8) was not tested. The other Class I HDAC, Hos2, was 
shown to primarily target H4K16ac at highly active genes.
29
 Its activity led to increased gene 
expression at coding regions, a role which is contrary to the classical function of HDACs.
30
 
The only S. pombe Class II HDAC, Clr3, was previously shown to act cooperatively with the 
Class III HDAC Sir2 to promote gene silencing at mating-type loci, centromeres and 
telomeres.
28,31
 The primary targets for Clr3 and Sir2 were found to be H3K14ac and H3K9ac, 
respectively. The Class III HDACs Hst2 and Hst4 were shown to promote gene repression in 
various cellular processes.
32
 Hst4 was recently implicated in the regulation of H3K56ac in cell 
cycle progression and DNA-damage tolerance.
33
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Previous studies employed traditional biochemical approaches such as Western analysis, and 
ChIP to define the substrate specificity of S. pombe HATs and HDACs.
25,29,31,34
 These 
approaches, however, suffer from several limitations. Site-specific antibody detection 
requires one specific antibody for each site that needs to be studied, and hence lacks the 
capability to map combinatorial modifications. Recent findings show that antibodies exhibit 
promiscuity when two or more PTMs are placed too close together.
35
 In agreement with this 
finding, many antibodies raised against histone H4 acetyl-lysines preferentially detected 
poly-acetylated epitopes rather than their specific target site.
36
 Antibodies are also limited in 
their abilities to provide stoichiometries of acetylation, which has proven valuable in 
measuring and monitoring acetylation dynamics in various biological processes.
37,38
 
Recently, we developed a method that combines high resolution LC-MS/MS with 
bioinformatics tools, that enables quantification of histone peptides harboring multiple co-
existing acetylation marks .
39
 This method allowed characterization of acetylation patterns in 
total histone extracts and in affinity-purified histones bound to chromatin-modifying 
complexes. In the present work, we employed this approach for in-depth quantitative and 
comprehensive analysis of the substrate specificity of S. pombe HATs Mst2 and Gcn5, and 
HDACs Clr6, Clr3, Sir2, and Hos2. The substrate specificity of these enzymes toward core 
histones H3 and H4 was examined. Our results are generally in agreement with previous 
findings. However, our method also allowed us to unravel several novel substrate specificity 
sites. The HDAC Clr6 exhibited a striking preference for combinatorial acetylation motifs 
over individual acetyl-lysines on histones H3 and H4. We also characterized a few short-
range PTM crosstalks that took place in response to HDAC depletions. 
 
 
 
 
 
 
 
159 
 
 
 
4.3. Methods 
 
4.3.1. Strains and media 
The S. pombe HDAC strains used in this study are listed in Table S4.1A. Strains were grown 
at 25˚C in YE5S medium (Yeast Extract Supplemented with 5 amino acids). 40 We confirmed 
the phenotypic expression of antibiotic and auxotrophic markers of all strains by PCR and 
growth on appropriate plates. The mating types of the strains were tested by PCR. 
 
4.3.2. Histone extraction 
Histones were extracted by adapting a protocol used for acid extraction of histones from 
budding yeast.
41
 Starting from saturated overnight cultures, strains were grown at 25°C in 
400 ml YE5S medium until they reached O.D595 1.0 -1.5. Cells were harvested and washed 
sequentially with 100 ml water, 25 ml DTT buffer (0.1M Tris-HCl pH 9.5, 10 mM DTT) and 
25 ml Spheroplasting buffer (20mM HEPES (NaOH) pH 7.4, 1.2 M Sorbitol). The wet cell 
pellets were weighed, resuspended in 12.5 ml Spheroplasting buffer containing Zymolyase 
100T  (5 mg/g of cell pellet).  The pellets were gently resuspended in Nuclear Isolation 
Buffer, NIB (15 mM 2-(N-morpholino) ethane sulfonic acid (KOH) pH 6.6, 60 mM KCl, 15 
mM NaCl, 5 mM MgCl2, 1 mM CaCl2, 0.25 M Sucrose,  0.8% v/v Triton X-100, 1 mM 
PMSF). The NIB wash was repeated twice followed by Wash ‘A’ (10 mM Tris-HCl pH 8.0, 
75 mM NaCI, 0.5% v/v NP 40, 30 mM NaButyrate , 1 mM PMSF) and Wash ‘B’ (10 mM 
Tris-HCl pH 8.0, 0.4 M NaCI, 30 mM NaButyrate,1 mM PMSF). The nuclear pellet was 
resuspended in 0.25 M HCl for 15 min, which extracts histones and other acid-soluble 
proteins. Trichloroacetic acid (TFA) was added to a final concentration of 20% v/v to the 
supernatant that contains histones. The histone pellet was washed with acetone, air-dried and 
resuspended in water for offline purification of intact histones by RP-HPLC. 
Histone fractionation by RP-HPLC  
Bulk histones from both the WT and mutant strains were fractionated into individual core 
histones using an Agilent narrow-bore Zorbax C8 reverse-phase column (2.1 x 150 mm, 5μm, 
300Å) on an Agilent 1200 HPLC system. The mobile solvent was comprised of solvent A, 
which is aqueous 0.1% TFA (Sigma) and solvent B is 0.1% TFA in 100% acetonitrile (ACN). 
Approximately 5 μg of bulk histones were loaded onto the C8 column at a flow rate of 150 
μl/min. Histones were eluted from the column using a gradient of 5 – 80% solvent B in 60 
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minutes. Fractions were collected in a 96-well plate every half minute. Fractions containing 
histones H3 or H4 were pooled and dried in a SpeedVac concentrator.  
4.3.3. Propionylation and tryptic digestion of histone proteins  
In-solution tryptic digestion of core histones was performed as previously described with 
minor modifications.
42
 Briefly, a total of 2 μg of the HPLC purified histones H3 and H4 were 
subjected to two rounds of propionylation by adding 200 μl of freshly prepared 2:1 (v/v) 
water: propionic anhydride (Sigma) mixture and vortexing the mixture for 30 minutes at 
room temperature. After each propionylation reaction, the samples were left to dry in a 
Speed-vac at 4
o
C. To prepare the histone samples for digestion a buffer exchange was made 
by adding to each sample 200 μl of 50 mM ammonium bicarbonate and drying one final 
round in the Speed-vac. The dried histone samples were resuspended back into the digestion 
buffer and vortexed for 5 minutes in order to re-dissolve the proteins. Our digestion solution 
was prepared by adding 200 μl of 50 mM ammonium bicarbonate in a Vial containing 20 μg 
of lyophilized trypsin (Promega). About 0.5 μl of this solution was added to each histone 
sample and digested overnight at 37
o
C. After digestion, samples were dried completely in a 
SpeedVac and then resuspended in 0.2% formic acid prior to LC-MS/MS analyses. 
4.3.4. LC-MS/MS analysis of histone peptides 
Chromatographic separation of histone peptides was achieved on an EASY-nLC II system 
(Thermo scientific). Solvent A was comprised of 0.2% formic acid (FA) in milli-Q water, and 
Solvent B contained 0.2% FA in acetonitrile (ACN). A total of 2 μg of the histone digest was 
loaded and desalted on an in-house packed Jupiter C18 (3 μm particles, Phenomenex) trap 
column (4 mm length, 360 μm i.d.) using Solvent A at a flow rate of 10 μl/min. After 5 
minutes of desalting, the peptides were eluted onto an in-house packed C18 analytical column 
(18 cm length, 150 μm i.d.) that is connected directly to the electrospray source ESI of a Q-
Exactive Plus instrument (Thermo scientific). The peptides were eluted into the MS with a 
linear ramp of Solvent B from 5 to 60% at a flow rate of 600 nl/min over 60 min. MS data 
were acquired for two to three technical replicates per sample. The MS instrument was 
operated in positive ion mode, and capillary voltage of 1.6 kV. MS scans were acquired in the 
Orbitrap analyzer over the range of 250 – 1500 m/z at a resolution of 70,000 and automatic 
gain control target value of 1.0 x 10
6
. Data were acquired using the parallel reaction 
monitoring (PRM) instrument method. An inclusion list containing m/z, charge state and 
collision energy (CE) values of H3 and H4 peptides was used to trigger MS/MS acquisition 
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(Table S4.1B). Every precursor ion found in the inclusion list was automatically selected for 
fragmentation in the HCD cell at a normalized CE setting of 27. The fragments were 
analyzed in the Orbitrap at a resolution of 35,000 and a target value of 5.5 x 10
5
. The 
dynamic exclusion setting was disabled in order to acquire multiple MS/MS spectra per 
peptide.  
 
4.3.5. Data analysis  
MS data were analyzed manually using Thermo Xcalibure Qual Browser software 
(Xcalibur™ version 2.2 SP1) and an in-house built algorithm, Iso-PeptidAce. Iso-PeptidAce 
analysis was performed as previously described (reference, isopeptidace paper). Raw LC-
MS/MS files and FASTA sequences of histones H3 and H4 were submitted to Iso-PeptidAce 
for peptide-spectrum matching and deconvolution of mixed MS/MS spectra of co-eluting 
Isomers. The following default parameters were used by the algorithm: Precursor mass 
tolerance: 8 ppm, fragment mass tolerance: 0.05 Da, the minimum number of fragment ions 
(per isomer) considered for deconvolution: 5, types of fragment ions considered: b and y, 
digestion enzyme: trypsin, missed cleavages: Iso-PeptidAce uses no-enzyme in-silico protein 
digestion routine to parse the provided FASTA file for potential matches. PTMs included in 
peptide-spectrum matching: oxidation of methionine residue (M, 15.9949), phosphorylation 
of serine, threonine or tyrosine (S/T/Y, 79.9663), deamidation of aspargine and glutamine 
(N/Q 0.98400.9847), acetylation of lysine (K, 42.0106), propionylation of lysine (K, 
56.0262), methylation of lysine (K, 14.0157), di-methylation of lysine ( K, 28.0313), tri-
methylation of lysine (K, 42.0470), acetylation of protein N-terminus ( 42.0106). All the 
PTMs were considered as variable modifications. The output from Iso-PeptidAce is an Excel 
spreadsheet containing precursor intensity data for each peptide found in our inclusion list. 
Acetylation site occupancy at a given Lys residue was determined from the ratio of the sum 
of intensities of peptides bearing the ac-Lys to the sum of intensities of all peptides (modified 
and unmodified) containing this residue. 
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4.4. Results  
4.4.1. Measurement of H3 and H4 peptides by PRM- LC-MS/MS  
The general experimental workflow is shown in Figure 4.1A. Histone proteins were isolated 
from WT or mutant HAT (Δmst2, Δgcn5, and Δmst2.Δgcn5) and HDAC (Δclr6, Δclr3, Δsir2, 
and Δhos2) fission yeast strains. Clr6 is essential for S. pombe viability43 and we could not 
use a strain with a complete deletion of the clr6
+
 gene. Instead, we used a clr6-1 
hypomorphic mutant strain that was grown; along with all the other strains, at the semi-
permissive temperature of 25C. HPLC fractionated histones were propionylated to prevent 
trypsin cleavage at lysine residues that are not acetylated in vivo. Near complete 
propionylation efficiency was achieved for peptides comprising up to two free lysine 
residues. Peptides eluting from the analytical column were analyzed using a PRM mode 
whereby an inclusion list containing precursor m/z, charge state and collision energy was 
used to trigger MS/MS acquisition. The PRM approach allows the acquisition of high 
resolution and accurate mass MS/MS spectra in the orbitrap mass analyzer. The capability of 
this approach to detect and quantify histone modifications of extremely low in abundance 
(e.g. H3K18 methylation) was recently demonstrated. 
44
  
Some histone tryptic peptides exist in multiple modified isoforms that can only be partially 
separated or co-elute from the analytical column. For example, the two isomeric H3 peptides 
shown in Figure 4.1A (Step 7, XIC panel) - K9acK14un (m/z 500.28+2, ac-acetylated, un – 
unacetylated)) and K9unK14ac (m/z 500.28+2) eluted from the RP column in the same 
retention time window. Moreover, these peptides produced composite MS/MS spectra with 
multiple shared fragment ions (Figure 4.1A, Step 7, MS/MS panel). Here, the intensities of 
isomer-specific fragments (e.g. fragment m/z 742 for K9acK14pr and 728 for K9prK14ac) 
were used to determine the relative abundance of each peptide. We investigated changes at 
five acetylation sites (K9, K14, K18, K23 and K27) and two methylation sites (K9 and K36) 
on the H3 tail. On histone H4, we examined changes in acetylation of four sites including K5, 
K8, K12 and K16.  
4.4.2. Determination of acetylation site occupancies  
In our study, differentially modified peptides that share the same sequence were easily 
resolved by the reverse-phase (RP) column. For example, the two isobaric H3 peptides 
K27prK36me2K37pr (m/z 519.9788+3) and K27acK36me3K37pr (m/z 519.9787+3) were 
chromatographically separated (Figure S4.1). However, acetylated isomers of the H4 peptide 
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4-GKGGKGLGKGGAKR-17 eluted in the same retention time window and produced 
composite MS/MS spectra with indistinguishable fragment ions. The capability of Iso-
PeptidAce for deconvoluting composite MS/MS spectra of mixtures of up to six isomeric 
peptides was previous demonstrated. In the current study, we employed this algorithm to 
deconvolute acetylated isomers in the mutant and wild-type fission yeast histone samples. 
The main steps in this process are summarized in Figure 4.1B (see reference x for more 
details, isopeptidace paper). Raw LC-MS/MS files were submitted to Iso-PeptidAce for 
deconvolution of mixed spectra (steps in the deconvolution process are highlighted in Figure 
4.1B, left panel). The amounts of H3 or H4 peptides injected in the different samples were 
normalized based on the signal responses of reference peptide H3: 41-YRPGTVALR-49 (m/z 
344.8698, 3+; m/z 516.8010, 2+) or H4: 46-ISALVYEETR-55 (m/z 618.8270, 2+).  
In the fission yeast samples, the H4 peptide 4-GKGGKGLGKGGAKR-17 was present in five 
different isoforms (depending on the number of acetyl-lysines): un-acetylated (0Ac), mono- 
(1Ac), di- (2Ac), tri- (3Ac), and tetra-acetylated (4Ac). The mono-, di, and tri-acetylated 
groups were each comprised of four, six and four isomeric peptides that elute in the same 
retention time window from the RP column (Figure 4.1C, panel ‘Before deconvolution’). 
Meanwhile, deconvolution by Iso-PeptidAce allowed us to obtain reconstructed peak profiles 
for the individual peptide within each isomeric group (Figure 4.1C, panel ‘After 
deconvolution’). The normalized intensities of the reconstructed peaks were used in 
determining acetylation site occupancies.  
4.4.3. Analysis of global histone acetylation in HAT mutants 
To assess the effects of HAT and HDAC depletions on the global H3 or H4 acetylations, the 
normalized peak intensities of all the acetylated peptides (including all charge states) were 
summed together. The global changes in acetylation are presented as the abundance fold 
change (FC) ratios of the summed intensities in the mutant relative to the wild-type samples 
(hereafter referred to as ‘control, Ctl’). As shown in Figure 4.2A (also Table S4.2A), no 
significant change was observed in the global acetylation level of histone H4 in the Gcn5 
and/or Mst2 mutants. In contrast, we observed a striking 14-fold decrease in the acetylation 
level of H3 in strains lacking both Gcn5 and Mst2. Depletion of the individual HAT had a 
relatively minor effect on the total H3 acetylation.  
Among the HDAC mutants, the strain lacking Clr6 deacetylase induced the most significant 
increase in the global acetylation of both H3 and H4 (Figure 4.2B and Table S4.2B). We 
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observed up to 4-fold increase in total H4 acetylation and up to 2-fold in H3 acetylation 
relative to the control. Strains lacking the Hos2 deacetylase also exhibited up to 2-fold 
increase in the acetylation of both histones. However, we did not see any significant change 
in global acetylation in Sir2 and Clr3 mutants.  
To further investigate the effects of Clr6 and Hos2 depletions on histone H4, we determined 
the mutant-to-control abundance fold change ratios for the five different isoforms of the 
peptide 4-GKGGKGLGKGGAKR-17. Our analysis showed that, in the Clr6 mutant, nearly 
19% of the H4 peptide is present in the tetra-acetylated form (H4_4Ac), which is a 6-fold 
increase compared to the 3% detected in the control sample (Figure 4.2C and Table S4.3 A-
B). The levels of the di- (H4_2Ac) and tri-acetylated (H4_3Ac) isoforms were also elevated 
by up to 2- and 5-fold, respectively. The mono-ac (H4_1Ac) isoform did not change 
significantly, whereas the non-acetylated peptide (H4_0Ac) was reduced by about 2-fold. 
These results are also evident from the comparison of the distributions of the different 
acetylated isoforms in the extracted ion chromatograms (XICs) illustrated in Figure 4.2D, 
middle panel; which shows a linear increase in isoform abundance in the order 1Ac, 2Ac, 
3Ac, and 4Ac. Similarly, for the Hos2 mutant, the most significant change was observed for 
the tetra-acetylated isoform, which exhibited a 4-fold increase in abundance relative to the 
control. Moreover, the levels of the di- and tri-acetylated isoforms increased by up to 2- and 
3-fold, respectively. The increased abundances of the multiply acetylated isoforms is also 
evident from the XICs illustrated in Figure 4.2D, bottom panel. Overall, these results suggest a 
role of Clr6 and Hos2 in the global deacetylation of both histones H3 and H4. 
4.4.4. Gcn5 and Mst2 target several H3 sites in S. pombe  
Very few studies have reported the substrate specificity of fission yeast Gcn5 and Mst2. 
Nugent et al.
25
 recently conducted a Western analysis to characterize the site specificity of 
both HATs. Gcn5 depletion caused reduction in H3K9ac, H3K14c and H3K18ac, whereas 
Mst2 depletion affected only H3K14ac. This study was, however, limited to only three sites 
on histone H3 and none on H4, possibly because site-specific antibody detection requires one 
specific antibody for each additional site that needs to be assayed. Here we employed a 
quantitative mass spectrometry-based approach to profile changes in acetylation levels of 
several sites in a single LC-MS/MS run.  
In order to examine the site specificity of each HAT we determined the fold change ratios of 
mutant-to-control acetylation site occupancies for each lysine on the N-terminal tails of H3 
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and H4. Moreover, to assess changes in the abundance of a particular PTM motif, we 
determined the mutant-to-control log2 ratios of the normalized intensities of peptides 
harboring this motif. These ratios are presented as heatmaps in which color intensities depict 
the extent of increase or decrease in the abundance of a particular motif.  
Our results confirmed two of the three previously identified Gcn5 target sites, that is, H3K9ac 
and H3K18ac. H3K18ac was by far the most affected PTM, which is hardly seen in our data 
(Figure 4.3A, top panel and Table S4.4 A-B). The two PTM motifs harboring this mark, 
K18acK23un and K18acK23ac, were equally affected, each showing more than two orders of 
magnitude reduction in their LC-MS signal response relative to the control (Figure 4.3B and 
Table S4.4C). Similarly, we observed up to 14-fold reduction in the occupancy of H3K9ac in 
the Gcn5 mutant. The LC-MS signal responses of the two peptides bearing this PTM motif, 
K9acK14un and K9acK14ac, were reduced by about 16-fold.  
In addition to the previously reported sites, we also identified and quantified a new Gcn5 
target site, which is H3K27ac. This PTM mark is the third most affected site with a 7-fold 
decrease in site occupancy (Figure 4.3A, top panel and Table S4.4 A-B). Moreover, peptide 
motifs bearing both H3K27ac and a di- or tri-methylation at H3K36 were affected the most, 
which are marked by a 30-fold reduction in their corresponding LC-MS signal responses 
relative to the control (Figure 4.3B and Table S4.4C).  
However, contrary to previous reports, we did not see a decrease in H3K14ac in the Gcn5 
mutant (see Figure 4.3A, top panel). To examine this observation in more detail, we extracted 
ion chromatograms (XICs) representing the acetylated and non-acetylated forms of the H3 
peptide 9-KSTGGKAPR-17 from the raw LC-MS data for the Gcn5 depleted and control 
samples. The overlayed XIC peaks (Δgcn5/control) for four peptides that are acetylated at 
K9, K14, or both, and a non-acetylated form are illustrated in Figure 4.3C (panels 1-4). The 
y-axis in each XIC panel was scaled to the signal response of the most abundant peptide. 
Based on these analysis, we saw a reduction in K14ac in the Gcn5 only when this mark is 
present in the di-acetylated motif H3K9acK14ac (Figure 4.3C, panel 3). This motif, however, 
represents only 1% of the total population of H3 peptides detected with the same sequence. 
Interestingly, the mono-acetylated motif K9unK14ac (Figure 4.3C, panel 2), which represents 
a corresponding 30%, did not shown any significant change in abundance in response to 
Gcn5 depletion. These results suggest the lack of any major activity of Gcn5 toward H3K14.  
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Our analysis of histone H3 peptides from the Mst2 mutant confirmed the specificity of this 
HAT for H3K14ac (Figure 4.3A, middle panel and Table S4.4 A-B). The most dramatic 
change was observed when this mark co-exists with a tri-methylated K9 in the motif 
K9me3K14ac, which decreased 4-fold in the Mst2 mutant (Figure 4.3B and Table S4.4C). In 
contrast, the fold-decrease in the mono-acetylated motif K9unK14ac was only about 2-fold. 
We also identified and quantified a new Mst2 target site, H3K23ac, which exhibited a 4-fold 
reduction in occupancy in response to Mst2 depletion. Here, the most significant change was 
observed for the mono-acetylated motif K18unK23ac, suggesting the strong activity of Mst2 
toward this site.  
Overall, the impact of Mst2 depletion on H3 acetylation was lower when compared to the 
number and extent of affected sites in the Gcn5 mutant. This difference is clearly observable 
from the corresponding heatmaps depicted in Figure 4.3B (compare ‘Δgcn5’ and ‘Δmst2’ 
columns). Meanwhile, as expected, when both Gcn5 and Mst2 are depleted simultaneously 
the occupancies of acetylation at all the five H3 sites were significantly reduced (Figure 4.3A, 
bottom panel and Table S4.4 A-B). The changes were more dramatic for the di-acetylated 
motifs K9acK14ac and K18acK23ac mutant (Figure 4.3B and Table S4.4C), which were 
barely detected in the MS. Overall, in contrast to previous observations, our results suggest a 
non-overlapping role for Gcn5 and Mst2 in acetylating the H3 tail.  
So far, there has been no report on the activities of S. pombe Gcn5 and Mst2 toward histone 
H4. Here, we assessed the activity of both HATs toward four H4 sites, which are K5, K8, 
K12 and K16. As shown in Figure 4.3D (and Table S4.5 A-B), depletion of Gcn5 and/or 
Mst2 did not affect the acetylation site occupancy of the H4 sites. To check if the HATs 
showed motif-specific activity, we determined mutant-to-control abundance ratios for the 15 
different acetylated isoforms of the peptide 4-GKGGKGLGKGGAKR-17. We observed a 
moderate change in the abundance of only few isoforms, for example: up to 2-fold decrease 
in K5ac in the single mutants and K8/16ac in the double mutant (Figure 4.3E and Table 
S4.5C). The overall change in abundance for the 15 isoforms was essentially lower than 2-
fold, suggesting the lack of activity of Gcn5 and Mst2 toward the H4 tail. 
4.4.5. Clr6 is specific for multiple sites on H3  
So far, few studies have reported the activity of S. pombe HDACs toward histone H3. Using 
site-specific antibodies raised against acetylated histones Bjerling et. al.
31
 and Wiren et. al.
29
 
characterized the specificity of Clr6, Clr3, Sir2 and Hos2 for K9ac and K14ac in histone H3. 
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These studies, however, did not report the activity of the HDACs toward many other sites, 
e.g. H3K18ac, H3K23ac, and H3K27ac. Moreover, the technique employed in these studies 
allowed the analysis of changes in acetylation on a per-site basis, and thus potential 
alterations in the combinatorial acetylation motifs were not reported. In the current study, we 
assessed the activity of the HDACs toward multiple sites on H3 by determining the mutant-
to-control fold change ratios of acetylation site occupancies. We also quantified changes in 
abundances of several acetylation motifs to look for combinatorial modifications that best 
convey the specificity of the HDACs.  
Our analysis confirmed the activity of Clr6 toward the two previously characterized H3 sites 
(K9ac and K14ac). We observed up to 4-fold increase in the occupancy of acetylation at both 
sites in response to Clr6 depletion (Figure 4.4A and Supplementary 6A-B). However, 
analysis of motif-specific changes revealed that Clr6 depletion had very little effect on the 
singly acetylated motifs K9acK14un or K9unK14ac, which showed on average 2-fold 
increase in abundance (Figure 4.4B and Table S4.6C). In comparison, we observed a 
dramatic 13-fold increase in the abundance of the di-acetylated motif K9acK14ac, suggesting 
the strong preference of Clr6 for the combinatorial motif.  
We also report three additional Clr6 target sites on histone H3: K18, K23 and K27. 
Acetylation site occupancy at each of these sites increased by an average 5-fold in response 
to Clr6 depletion (Figure 4.4A and Supplementary 6A-B). Similar to the above observation, 
Clr6 exhibited a strong preference for the di-acetylated motif K18acK23ac, which was 
elevated by 15-fold in the Clr6 mutant (Figure 4.4B and Table S4.6C). Moreover, loss of Clr6 
activity caused a major increase in the occupancy of H3K27ac. Intriguingly, acetylation on 
K27 increased linearly with increasing number of methylations on K36, with the largest 
change recorded for the motif K27acK36me3 (Figure 4.4C). However, we did not detect any 
modification on K37 other than propionylation, which was introduced during the in vitro 
chemical derivatization of the intact histones.  
4.4.6. Methylation-dependent activity of Clr3 toward H3K14ac  
Several Western and ChIP analyses have previously shown the specificity of Clr3 for K14ac 
localized in heterochromatin domains such as mating-type loci, centromeres, and 
telomeres.
29,31,34,45
 Clr3 was also shown to affect K14ac in bulk histones.
31
 In the current 
study, we investigated changes in the overall occupancy of K14ac in Clr3 mutant relative to 
the control. As shown in Figure 4.4A (and Table S4.6 A-B), Clr3 depletion did not 
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significantly affect the overall occupancy of K14ac, or any of the other sites we investigated. 
This result was very intriguing for us particularly considering previous reports of Clr3 
activity in bulk histones, and thus we were expecting K14 to be hyperacetylated. This 
prompted us to look deeper into our data to check if there were alterations in the abundances 
of five different acetylation motifs containing K14ac, which are, K9me2K14ac, 
K9me3K14ac, K9acK14un, K9unK14ac and K9acK14ac. The peptide with the motif 
K9me1K14ac was not sufficiently detected in our study. As shown in Figure 4.4B (and Table 
S4.6C), we found 2.5- and 4.5-fold increase in the abundances of the motifs K9me2K14ac 
and K9me3K14ac, respectively. In contrast, we did not see any significant change in the 
abundance of the singly acetylated peptide K9unK14ac. To further confirm this observation 
we extracted chromatographic peaks representing each of the above acetylated motifs and a 
non-modified form (K9unK14un) from the raw LC-MS data for the control and Clr3 mutant 
samples. The overlayed mutant-to-control (Δclr3/Ctl) XICs for each motif are illustrated in 
Figure 4.4D. According this data, the relative abundances of the peptides K9acK14un, 
K9unK14ac, K9acK14ac and K9unK14un were essentially the same in the mutant and control 
samples (Figure 4.4D, see panels 1-4). However, the relative abundances of K9me2K14ac and 
K9me3K14ac increased significantly in the Clr3 mutant (Figure 4.4D, panels 5 and 6). Overall, 
these results suggest that Clr3 requires the presence of a di- or tri-methylated K9 in order to target 
K14ac on the H3 tail. 
4.4.7. Sir2 and Hos2 exhibit mild activity toward H3  
The function of Sir2 has been widely implicated in the regulation of heterochromatin 
assembly in fission yeast. In cooperation with Clr3 it promotes the recruitment of gene 
silencing complexes at the mating-type loci, telomeres and centromeres.
46
 Previous in vitro 
and in vivo studies showed the activity of Sir2 toward K9ac and K14ac.
47,48
 In the current 
study, we observed moderate increases in the occupancies of K9ac and K18ac in the Sir2 
mutant relative to the control (Figure 4.4A and Supplementary 6A-B). These changes were 
mostly attributed to increased abundances of the di-acetylation motifs K9acK14ac and 
K18acK23ac, which were elevated by 1.7- and 2.4-fold, respectively (Figure 4.4B and Table 
S4.6C).  
We also assessed the impact of Hos2 depletion on the occupancy of acetylation in H3. We 
observed a 2-fold increase in the occupancy of K9ac (Figure 4.4A and Supplementary 6A-B), 
whereas occupancies of K14ac, K18ac, K23ac, and K27ac were essentially unaffected. The 
increased occupancy of K9ac was largely attributed to the higher abundance of the di-
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acetylated motif K9acK14ac, which increased 3-fold in the Hos2 mutant (Figure 4.4B and 
Table S4.6C). The corresponding change for the singly acetylated peptide K9acK14un was 
not significant.  
4.4.8. Clr6 mutation caused a major increase in combinatorial H4 acetylation  
We first assessed the impact of Clr6 depletion on the occupancy of acetylation at the 
individual H4 sites. Our analysis showed that the occupancy of K5ac, K8ac, K12ac, and 
K16ac were elevated by, respectively, 3.7-, 3.0-, 2.8- and 1.6-fold (Figure 4.5A, Table S4.7 
A-B). This result suggested that the loss of Clr6 activity had minimal effect on K16ac. To 
further confirm this observation we examined the changes in the abundances of all the fifteen 
acetylated isoforms of the peptide 4-GKGGKGLGKGGAKR-17. 
As shown in Figure 4.5B (and Table S4.7C), the mono-acetylated motifs K5ac, K8ac, K12ac, 
and K16ac were barely affected by Clr6 mutation. Meanwhile, of the six di-acetylated 
isoforms, only three were significantly affected by the mutation. These are K5/8ac, K5/12ac 
and K8/12ac, which increased by up to 7.5-, 3.5- and 2.5-fold, respectively. The 
corresponding changes for K5/16ac, K8/16ac, and K12/16ac were not significant (average 
fold change less than 1.5). In our analysis, the most dramatic change was observed for the tri-
acetylated motif K5/8/12ac, which increased 13-fold in the Clr6 mutant. The corresponding 
increases for the three other tri-acetylated motifs K5/8/16ac, K5/12/16ac, and K8/12/16ac 
were on average 3-fold. Surprisingly, the fold increase for the tetra-acetylated isoform 
K5/8/12/16ac (~6-fold) was 50% lower than that of K5/8/12ac, also suggesting the strong 
preference of Clr6 for the tri-acetylated motif. Noticeably, a common feature of those motifs 
largely affected by Clr6 depletion is that they comprise at least two of the three acetyl-lysines 
K5, K8, and K12; with the most preferred combination being the tri-acetylated motif 
K5/K8/12ac. 
4.4.9. Hos2 mutation caused a major increase in  H4K16 acetylation 
The specificity of Hos2 for H4K16ac has been previously reported.
29
 Interestingly, unlike 
many other HDACs, Hos2-mediated deacetylation of K16ac has been shown to promote 
transcriptional activation in both S. pombe and S. cerevisiae.
30
  
We first assessed the impacts of Hos2 depletion on the occupancy of the individual H4 sites. 
Hos2 depletion, in addition to a previously reported increase in K16ac, resulted in a 2-3-fold 
increase in the overall occupancy of K5ac, K8ac and K12ac (Figure 4.5A, Table S4.7 A-B). 
To further confirm this unexpected result, we examined the changes in abundances of each of 
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the 15 acetylated isoforms of the peptide 4-GKGGKGLGKGGAKR-17. Our analysis showed 
that the increase in occupancy observed for the first three lysines was largely attributed to the 
fact that these residues co-exist with K16ac-containing motifs in the di-, tri, or tetra-
acetylated forms. As shown in Figure 4.5B (and Table S4.7C), the only mono-acetylated 
motif that showed a significant increase in abundance in the Hos2 mutant is K16ac, which 
was elevated by about 2-fold. Moreover, among the six di-acetylated isoforms, those 
harboring the K16ac mark (K5/16ac, K8/16ac, and K12/16ac) were preferentially affected by 
the loss of Hos2 activity. Similarly, the K16ac-containing tri-acetylated motifs K5/8/16ac, 
K5/12/16ac and K8/12/16ac exhibited an average 2.8-fold increase in abundance. However, the 
corresponding increase for the motif lacking the K16ac (K5/8/12ac) was not significant. The most 
dramatic change was observed for the tetra-acetylated motif K5/8/12/16ac, which increased 4-
fold in the Hos2 mutant. Overall, these results suggest the preference of Hos2 for multiply 
acetylated motifs comprising K16ac rather than the individual mark. 
4.4.10.  Sir2 and Clr3 mutations did not alter H4 acetylation pattern 
Previous in vitro deacetylation assay using 
14
C-labeled NAD+ showed that Sir2 efficiently 
deacetylates H3K9ac and H4K16ac.
47
 Moreover, a very recent in vitro analysis, using a  
32
P-labeled NAD+ reported that Sir2 preferentially deacetylates H3K4 and H4K16ac, and to a 
lower extent H3K9ac and H3K14ac. Although both the above studies reported the activity of 
Sir2 toward H4K16ac, a previous in vivo ChIP analysis did not observe any major activity of 
Sir2 toward H4.
29
 In the current study, we assessed the fold changes in acetylation site 
occupancy of the H4 sites K5, K8, K12, and K16 in the Sir2 mutant relative to the control. In 
agreement with the previous ChIP analysis, we did not find any major activity of Sir2 toward 
H4 (Figure 4.5 A-B, Table S4.7 A-C). Similarly, Clr3 exhibited no major activity toward H4 
(Figure 4.5 A-B). 
4.4.11.  HDAC mutants display altered H3K9 methylation levels  
Clr3 and Sir2 were previously shown to mediate the level of H3K9 methylation at silent 
mating-type locus and centromeres.
46,47
 Their deacetylase activity leads to a simultaneous 
increase in H3K9 methylation. In contrast, little is known about the correlations between Clr6 
or Hos2 activity and H3K9 methylation. Characterization of such type of PTM interactions 
allows us to fully understand the mechanisms involved in HDAC-mediated heterochromatin 
assembly and gene regulation. Thus, we investigated how depletion of Clr3, Clr6, Sir2, or 
Hos2 impact the global methylation levels of H3K9 and H3K36.  
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Figure 4.6A shows the mutant-to-control occupancy fold change ratios of three methylation 
states (me1, me2 and me3) of H3K9 and H3K36. In agreement with previous reports, Clr3 
and Sir2 depletions generally resulted in reduction of occupancies of K9me2 and K9me3 
(Figure 4.6A, upper panel and Table S4.8 A-B). The most significant change was observed 
for K9me3, which showed a 5-fold reduction in the Clr3 mutant. This result is also evident 
from the analysis of abundances of the individual methylation motifs shown in Figure 4.6B, 
top-left panel (and Table S4.8C). In the Clr3 mutant, the fold-decrease in the abundances of 
the motifs K9me1K14un, K9me2K14un, K9me3K14un were 1.4, 2.9 and 5.6, respectively. 
For Sir2 mutant, we observed an average 2-fold reduction for each motif. Meanwhile, in both 
Clr3 and Sir2 mutants, the abundances of the motifs K9me2/3K14ac significantly increased, 
which is attributed to elevated level of K14ac, a site we observed to be targeted by both 
HDACs. Clr3 or Sir2 depletion had little effect on the level K36 methylation.  
In contrast, Clr6 and Hos2 depletions resulted in a major increase in K9 methylation. For 
each mutant, we saw 3- and 2-fold increases in the occupancies of K9me2 and K9me3, 
respectively (Figure 4.6A, upper panel and Table S4.8 A-B). Clearly, K9me2 is more affected 
than K9me3. Analysis of the individual methylation motifs confirmed these observations 
(Figure 4.6B, bottom panels and Table S4.8C). In the Clr6 mutant, the fold-increases in the 
abundances of the motifs K9me1K14un, K9me2K14un and K9me3K14un were, respectively, 
1.4, 2.5 and 2.1. The corresponding fold-increases in the Hos2 mutant were, respectively, 1.7, 
2.9 and 2.3. Interestingly, the combined incremental effects of Clr6 depletion on K9 
methylation and K14 acetylation resulted in a dramatic increase in the abundances of the 
motifs K9me2K14ac and K9me3K14ac, which increased 6- and 4-fold, respectively. 
Similarly, the depletion of Hos2 caused 2-3-fold increase in the abundances of the 
corresponding motifs. Meanwhile, both Clr6 and Hos2 depletions did not affect the level of 
K36 methylation (Figure 4.6 A-B, lower panels). The fold-increases observed for the motifs 
K27acK36me1, K27acK36me2 and K27acK36me3 in the Clr6 mutant were essential 
attributed to the elevated level of K27ac, a site we characterized to be targeted by Clr6, but 
not Hos2. Overall, our results revealed two distinct patterns of K9 methylation states in the 
HDAC mutants. While Clr3 and Sir2 depletions correlate with global reduction in the 
heterochromatin marks K9me2 and K9me3, the loss of Clr6 and Hos2 activities resulted in 
elevated levels of both PTM marks. 
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4.5. Discussion 
The histone code hypothesis suggests that histone PTMs act in a combinatorial fashion to 
modulate chromatin-based processes
49
. However, the lack of high-throughput methodologies 
for comprehensive analysis of histones has so far limited our capability to fully map 
combinatorial PTM patterns. A number of studies have for many years relied on site-specific 
antibodies to detect histone modifications. While this approach still provides crucial 
information regarding the genomic localization of PTMs, its ability to map the global 
landscape of multiple co-occurring PTMs is limited. Comparatively, MS-based approaches 
have proven valuable in determining PTM stoichiometries
38,50
, mapping combinatorial 
modification patterns
51
; and characterization of short and long range crosstalks among 
various histone modifications
52
. In the current study, we employed a targeted quantitative 
MS-based strategy to profile changes in histone acetylation occupancies in fission yeast 
strains lacking major HAT (Gcn5 and/or Mst2) and HDAC (Clr3, Clr6, Hos2 and Sir2) 
activities. Although previous studies have reported substrate specificities of these 
enzymes
25,29
, the methodologies employed in these studies allowed analysis of only few 
acetylation sites. In addition, site specific acetylation occupancies were not reported. 
Consequently, the goal of the current study was to conduct a quantitative in-depth analysis of 
multiple acetylation sites on the N-terminal tails of H3 and H4. We also aimed to assess the 
roles of each HAT and HDAC in regulating combinatorial histone PTM patterns.  
Comprehensive analysis of histone tryptic peptides generated from wild-type and mutant 
HAT and HDAC strains identified several known and novel target sites. In addition to 
previously characterized sites, we found that HATs Gcn5 and Mst2 could also catalyze 
acetylation of, respectively, H3K27 and H3K23. We also saw a reduction in the occupancy of 
H3K4ac in the Gcn5 mutant (data not shown), but due to the extremely low-abundance of this 
PTM we could not reproducibly detect it in our samples. In budding yeast, Gcn5, together 
with a HAT known as Rtt109, have been shown to catalyze the acetylation of H3K4ac in 
vivo.
 53
 Despite previous reports of Gcn5 activity toward H3K14
54
, we found no major change 
in the occupancy of H3K14ac in the Gcn5 mutant. Overall, our data suggest that S. pombe 
Gcn5 and Mst2 together catalyze up to six acetylation sites on the H3 tail. Interestingly, the 
two HATs target complementary sites on the H3 tail. It is known that lysine acetylation 
facilitates transcriptional activation by disrupting the repressive state of nucleosomal DNA. 
Consequently, the division of labor between Gcn5 and Mst2 could be one way of accelerating 
the acetylation process to meet the demands of rapidly progressing transcriptional machinery.  
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Similarly, we identified novel substrate specificity sites for some of the HDACs we studied. 
For Clr6, we found three new target sites on H3 (K18, K23 and K27) and one on H4 (K8). 
Hos2 exhibited mild activity toward H3K9ac and H3K14ac, in addition to its primary target 
site - H4K16ac. In contrast to previous observations, our data showed that Clr6 has very little 
activity toward H4K16ac. Interestingly, Clr6 and Hos2 exhibited complementary activity 
toward the H4 N-terminal tail. Clr6 is specific for K5ac, K8ac and K12ac, whereas Hos2 
specifically targets K16ac. Previous genome-wide analysis of Clr6 and Hos2 target sites 
identified independent and distinct roles for the two HDACs.
34
 Histone deacetylation by Clr6 
was found to have a role in gene repression at promoter regions, whereas deacetylation by 
Hos2 was associated with increased gene expression at coding regions. However, based on 
our results, the lack of activity of Clr6, Clr3 or Sir2 for K16ac suggests that Hos2 might also 
be required for deacetylation of this site at promoter regions.  
A key goal of this study was also to examine the impact of HAT or HDAC deletions on 
combinatorial PTM marks. Perhaps the most striking observation of our study is the fact that 
Clr6 mutation caused major changes in combinatorial H3 and H4 acetylation motifs. Clr6 
depletion resulted in hyperacetylation of the di-acetylated motifs H3K9acK14ac and 
H3K18acK23ac (Figure 4.4B) and tri-acetylated H4K5, 8, 12ac (Figure 4.5B). However, we 
found no significant change in the abundance of mono-acetylated H3 and H4 peptides. Clr6 
was previously shown to be recruited to both euchromatin and heterochromatin via 
interaction with transcription factors and co-repressor complexes.
27
 Clr6 interaction with the 
activating transcription factor Atf1/Pcr1 is required for deacetylation of both histones H3 and 
H4 at the silent mating-type region.
27
 In addition, Clr6 was found to exist in two independent 
HDAC-Sin3 co-repressor complexes (complex I and II) to target promoters, transcribed 
chromosomal regions and centromeres.
55
 Despite these crucial findings, there is no clear 
mechanism as to how Clr6 targets the various regions of the fission yeast genome. According 
to our result, it is possible that Clr6 might be directly involved in deacetylating the 
combinatorial acetylation motifs described above. Alternative, it is possible that Clr6 
mutation might give enhanced access to certain HAT to acetylate mutlple lysine residues in 
histones H3 and H4. Another possible explanation for the high abundance of combinatorial 
acetylation motifs is that there are some HATs that are rapidly acetylating histones and 
converting them from mono-acetylated forms to combinatorial motifs. Thus, our discovery of 
the preference of Clr6 for the tri-acetylated H4 molecules provides an important clue for 
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future investigations involving characterization of mechanisms of Clr6-mediated gene 
regulation. 
Notably, our analyses also unraveled a few short-range PTM crosstalks on histones H3 and 
H4 tails. The loss of HDACs generally leads to an increase in histone acetylation and 
reduction in repressive histone methylation marks (e.g. H3K9me3 and H3K27me3). In the 
Clr3 mutant, we observed a negative crosstalk between the PTM marks H3K14ac and 
H3K9me2/me3 (Figure 4.7A). The loss of Clr3 induced hyperacetylation of H3K14ac and a 
concomitant decrease in the level of H3K9me3, and to a lesser extent H3K9me2 (Figure 4.6 
A-B). Similar observations were made by Yamada et al.
46
, whereby a western analysis 
showed reduction in H3K9me3 in the Clr3 mutant. Meanwhile, conflicting reports were made 
on the impact of Clr3 depletion on the level of H3K9me2. While Yamada et al. reported a 
slight increase in H3K9me2, a very recent study by Castonguay et al.
56
 showed a major 
decrease in this mark. Our analysis strongly agrees with the latter observation.  
The mechanism by which the opposing marks H3K14ac and H3K9me2/me3 regulate gene 
silencing in fission yeast is not fully characterized. However, an interesting model had been 
previously proposed.
46
 According to this model, Clr3 is recruited to its target site via 
interaction with activating transcription factors Atf1/Pcr1. This interaction allows the 
recruitment of the heterochromatin proteins (HPs) Swi6 and Ch2, and the H3K9 
methyltransferase known as Clr4. Conceivably, the loss of Clr3 would abolish the binding of 
the HPs and Clr4, which potentially leads hypomethylation of H3K9 and disruption of the 
heterochromatin domain. Interestingly, a crucial role for Sir2 was implicated in this process, 
whereby depletion of Sir2 caused a severe defect in binding of Clr3 at the mating type-
region.
46
 This study also suggested the cooperativity and redundancy between Clr3 and Sir2 
activities in maintaining heterochromatin silencing. In a more recent western analysis, Sir2 
was shown to deacetylate H3K14ac, in addition to the previously known H3K9ac, for 
targeting Clr4 to centromeres.
48
 In agreement with these observations, our analysis showed 
that Sir2 depletion significantly increased the abundance of the di-acetylated motif 
H3K9acK14ac (Figure 4.4 A-B). We also observed a similar increase in the abundance of the 
motif H3K18acK23ac (Figure 4.4 A-B), which was not previously reported. On the other 
hand, the levels of H3K9me2 and H3K9me3 were reduced in the Sir2 mutant. These results 
suggest that Sir2 activity might actually have a much wider impact on the landscape of 
histone H3 PTMs.  
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In both S. pombe and S. cerevisiae, Hos2-mediated deacetylation of histones was implicated 
in gene activation at coding regions
30,57,58
, which is contrary to the traditional view of 
HDACs as gene repressors. In support of this observation, it has been shown that depletion of 
S. pombe Hos2 results in down-regulation of more than 9% of the genome.
29 
This mutation 
also led to a major increase in H4K16ac, which possibly suggest a negative correlation 
between the PTM and gene activity. 
 The impact of Hos2 depletion on the methylation level of H3K9 was not previously reported. 
Traditionally, hypermethylation of H3K9 is strongly associated with gene repression. In our 
study, we found an inter-histone positive crosstalk between H3K9 methylation and H4K16ac 
in the Hos2 mutant (Figure 4.7B). The occupancy of both H3K9me2/me3 and H4K16ac were 
strongly elevated (Figure 4.6 A-B). Meanwhile, it is also possible that if the residues H4K16 
and H3K9 are not present in the same nucleosome, it is difficult for them to interact, and thus 
the increase in the occupancy of both PTMs could be purely mutually exclusive. 
Alternatively, hyperacetylation of H4K16ac might indirectly alter the methylation state of 
H3K9. Interestingly, Hos2 depletion majorly affected the H3K9me2 mark as opposed to the 
widely known repressive mark H3K9me3. While the latter modification is mostly found at 
constitutive heterochromatin regions, numerous studies in higher eukaryotes show that 
H3K9me2 is highly enriched at repressed loci of euchromatin regions.
59-61
 Thus, the higher 
level of H3K9me2 we observed in the Hos2 mutant is in line with the function of the HDAC 
at the euchromatin domain.  
In summary, the comprehensive and quantitative MS-based approach allowed us to 
characterize several known and novel targets sites of S. pombe HATs and HDACs. 
Meanwhile, based on the current data we cannot distinguish between direct and indirect 
targets of the enzymes. This requires further in vitro biochemical assays that involve 
determining the rate of acetylation or deacetylation of histones mediated by affinity purified 
fission yeast HATs or HDACs. We anticipate that the results presented in this workwill be 
indispensable in future genetic and biochemical studies involving the fission yeast. Our study 
also highlighted on the division of labor between HATs or HDACs activities in regulating 
chromatin-associated processes. Moreover, this study demonstrated the exceptional 
advantage in using MS-based approaches in profiling combinatorial histone codes and 
characterization of functional crosstalks among the various histone PTMs.  
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4.7. Main figures 
 
Figure 4.1 PRM-LC-MS/MS analysis of histone peptides. 
A) Overview of the experimental procedure. 1. Histones were isolated from cultured wild-
type and mutant S.pombe strains. 2. Bulk histones were fractionated into individual core 
histones (H2A, H2B, H3, and H4) using offline HPLC. 3. Fractions containing histones H3 
and H4 were pooled, and subjected to propionylation and tryptic digestion. 5. Approximately 
2 µg of core histones H3 and H4 peptides were separated by reverse-phase C18 column that 
is directly connected to the ESI source of Q-Exactive Plus MS. 6. Histone peptides were 
analyzed by PRM method whereby an inclusion list was used to trigger MS/MS acquisitions. 
7. PRM data were analyzed based on peak intensities of XICs generated manually using the 
Xcalibur software (Thermo Scientific) or using in-house built algorithm- Iso-PeptidAce. XIC 
panel: Shows the co-elution of isomeric H3 peptides- K9acK14un (m/z 500.28
+2
, ac-
acetylated, un – unacetylated) and K9unK14ac (m/z 500.28+2); MS/MS panel: Shows the co-
fragmentation of the isomers. Isomer-specific fragments are highlighted in blue (from 
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K9acK14un) or red (K9unK14ac). B) Deconvolution of acetylated isomers of histones. Left 
panel: Raw LC-MS/MS were submitted to Iso-PeptidAce for deconvolution of mixed MS/MS 
spectra of co-eluting isomers. The output from Iso-PeptidAce is a .csv file containing 
precursor intensities for each deconvoluted isomer.  These intensity values were used to 
calculate site occupancies of acetyl-lysines. Right panel: Steps in the deconvolution of mixed 
MS/MS spectra using IsopeptidAce. C) Deconvolution of acetylated isomer of fission yeast 
histone H4.  
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Figure 4.2 Global H3 and H4 acetylations in HAT and HDAC mutants.  
Fold change ratios of abundances of global H3 and H4 acetylations in (A) HAT mutants: 
Δgcn5, Δmst2, and Δgcn5.Δmst2 (Δg.Δm); and (B) HDAC mutants: Δclr6, Δhos2, Δclr3, and 
Δsir2 relative to control samples. The fold change (FC) ratios were determined based on the 
summed intensities of all acetylated H3 or H4 peptides detected in the mutant relative to the 
control. C) Fold change ratios of abundances of mono-, di-, tri-, and tetra-acetylated and a 
non-aceylated isoforms of the H4 peptide 4-GKGGKGLGKGGAKR-17 in the HDAC 
mutants relative to the control samples. These fold-change ratios were determined based on 
the intensities of each isoform obtained after Iso-Peptidace analysis. D) Extracted ion 
chromatograms illustrating the differential abundances of the five acetylated and non-
acetylated isoforms of the H4 peptide in WT sample (Top panel), Δclr6 (middle panel), 
Δhos2 (bottom panel). Error bars indicate standard deviations from two-three replicates. 
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Figure 4.3 Site-specific acetylation of H3 and H4 in HAT mutants.  
A) Fold changes in the occupancy of H3K9ac, H3K14ac, H3K18ac, H3K23ac and H3K27ac 
in ∆gcn5, ∆mst2 and ∆gcn5.∆mst2 (∆g.∆m) (top to bottom panels) relative to the control 
sample.  B) Heapmap illustration of the log2 mutant-to-control fold-changes in the 
normalized LC-MS signal responses of H3 peptides harboring distinct acetylation motifs. C) 
Overlayed extracted ion chromatograms (XICs) illustrating differences in abundances of 
K14ac containing peptides (panel 1-3) and a non-acetylated peptide (panel 4) in ∆gcn5 
relative to the control. The indicated percentages represent the relative abundances (in %) of 
the corresponding isoforms among the total H3 peptides detected with the same sequence. 
The y-axis in each XIC panel category was scaled to the signal response of the most abundant 
peptide.  D) Fold changes in the occupancy of H4K5ac, H4K8ac, H4K12ac, and H4K16ac in 
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∆gcn5, ∆mst2 and ∆gcn5.∆mst2 (∆g.∆m) (top to bottom panels) relative to the control. B) 
Heapmap illustration of the log2 mutant-to-control fold-changes in the LC-MS signal 
responses of acetylated H4 peptide isoforms. Error bars indicate standard deviations from 
two-three replicates. 
 
 
Figure 4.4 Site-specific acetylation of H3 in HDAC mutants.  
A) Fold changes in the occupancy of H3K9ac, H3K14ac, H3K18ac, H3K23ac and H3K27ac 
in HDAC mutants relative to the control. B) Heatmap illustration of the mutant-to-control 
log2 fold changes in the normalized LC-MS signal responses of acetylated peptide motifs. C) 
Mutant-to-control normalized intensity ratios of the non-acetylated (K27unK36un) and 
K27ac-containing isoforms of the peptide 27-KAAPATGGVKKPHR-40. D) Overlayed XICs 
illustrating changes in the relative abundances of a non-modified (panel 4) and K14ac-
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containing (panels 1-3 and 5-6) isoforms of the peptide 9-KSTGGKAPR-17 in Clr3 mutant 
relative to the control. The y-axis in each XIC panel was scaled to the signal response of the 
most abundant peptide. Error bars indicate standard deviations from two-three replicates. 
 
 
 
Figure 4.5 Site-specific acetylation of H4 in HDAC mutants.  
A) Fold changes in the occupancy of H4K5ac, H4K8ac, H4K12ac, and H4K16ac in the 
HDAC mutants relative to the control. B) Heatmap illustration of the log2 fold changes of the 
normalized LC-MS signal responses of 15 acetylated motifs in the mutant relative to the 
control sample. Error bars indicate standard deviations from three replicates. 
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Figure 4.6 Analysis of H3-K9/K36 methylation levels in HDAC mutants.  
A) Fold changes in the occupancy of H3K9me1/me2/me3 (top panel) and 
H3K36me1/me2/me3 (bottom panel) in HDAC mutants relative to the control. B) 
Normalized abundance ratios of H3K9 and H3K36 methylation motifs in Clr3, Sir2, Clr6 and 
Hos2 mutants relative to the control. Error bars indicate standard deviations from two-three 
replicates. 
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 Figure 4.7 Representative histone PTM crosstalks in fission yeast. 
A) An illustration of a negative crosstalk between the co-occurring marks H3K9me2/me3 and 
H3K14ac. Depletion of the Clr3 HDAC induced hyperacetylation of H3K14 and a 
simultaneous reduction in the level of H3K9me3, and to a lesser extent H3K9me2. B) An 
illustration of inter-histone positive crosstalk between the markss H3K9me2/me3 and 
H4K16ac. Depletion of Hos2 resulted in hyperacetylation of H4K16ac and a concomitant 
increase in H3K9me2, and to a lesser extent H3K9me3. The arrows indicate an increase (↑) 
or a decrease (↓) in the abundance of the corresponding marks. 
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4.8. Supplementary data  
Table S4.1 (A) Fission yeast strains and (B) PRM inclusion list  
A. Fission yeast HDAC Strains 
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B. PRM inclusion list. 
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Table S4.2  Global H3 and H4 acetylations in HAT and HDAC mutants. 
Analysis of global H3 and H4 acetylations in HAT and HDAC mutants. Fold change ratios of 
global H3 and H4 acetylations in (A) HAT and (B) HDAC mutants relative to the control 
sample. 
                                   A)  
Sample 
Relative Abundance FC (HAT/Ctl) 
H3-Ac H4-Ac 
Δmst2 0.45 ± 0.02 1.17 ± 0.04 
Δgcn5 0.77 ± 0.05 1.11 ± 0.02 
ΔgΔm 0.07 ± 0.01 1.12 ± 0.11 
 
                                  B) 
Sample 
Relative Abundance FC (HDAC/Ctl) 
H3-Ac H4-Ac 
Δclr6 3.25 ± 0.43 2.08 ± 0.13 
Δhos2 1.54 ± 0.17 1.55 ± 0.39 
Δclr3 1.13 ± 0.10 0.84 ± 0.02 
Δsir2 0.83 ± 0.02 0.73 ± 0.12 
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Table S4.3  Global changes in H4 acetylation in response to HDAC depletion. 
Relative abundances of a non-acetylated (H4_0Ac) and mono- (H4_1Ac), di- (H4_2Ac), tri-
(H4_3Ac), and tetra-acetylated (H4_4Ac) isoforms of the H4 peptide 4-
GKGGKGLGKGGAKR-17. B) Relative abundance fold change ratios of the non-acetylated 
and acetylated isoforms of the H4 peptide in the HDAC mutant relative to the control sample. 
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Table S4.4  H3 acetylation site occupancies in HAT mutants. 
A) Acetylation and methylation site occupancies of  H3 lysine residues. B) Fold change ratios 
of occupancies of acetylation and methylation sites in H3 in the HAT mutant relative to the 
control. C) Log2 fold change ratios of the normalized intensities of H3 acetylation motifs in 
the mutant to the control. 
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Table S4.5  H4 acetylation site occupancies in HAT mutants. 
A) Acetylation site occupancies of  H4K5ac, H4K8ac, H4K12ac, and H4K16ac. B) Fold 
change ratios of  occupancies of H4K5ac, H4K8ac, H4K12ac, and H4K16ac in the mutant 
relative to the control. C) Log2 fold change ratios of the normalized intensities of acetylated 
isoforms of the H4 peptide 4-GKGGKGLGKGGAKR-17 in the mutant to the control.   
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Table S4.6  H3 acetylation site occupancies in HDAC mutants. 
A) Acetylation and methylation site occupancies of H3 lysine residues in WT and HDAC 
mutants. B) Fold change ratios of occupancies of acetylation and methylation sites in H3 in 
the HDAC mutants relative to the control. C) Log2 fold change ratios of the normalized 
intensities of H3 acetylation motifs in the mutant to the control. 
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Table S4.7  H4 acetylation site occupancies in HDAC mutants. 
A) Acetylation site occupancies of  H4K5ac, H4K8ac, H4K12ac, and H4K16ac the wild-type 
and HDAC mutants. B) Fold change ratios of occupancies of H4K5ac, H4K8ac, H4K12ac, 
and H4K16ac in the mutant relative to  the control. C) Log2 fold change ratios of the 
normalized intensities of acetylated isoforms of the H4 peptide 4-GKGGKGLGKGGAKR-17 
in the mutant to the control.   
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Table S4.8  H3-K9/K36 methylation site occupancies in HDAC mutants. 
A) Methylation site occupancies of  H3K9me1/me2/m3 and H3K36me1/me2/me3 in the 
wild-type and mutant samples. B) Fold change ratios of occupancies of H3K9me1/me2/m3 
and H3K36me1/me2/me3 in the mutant relative to the control. C) Log2 fold change ratios of 
the normalized intensities of various H3 methylation motifs in the mutant to the control.   
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Figure S4.1 
 
 
Figure S4.1 Representative XIC of chromatographically resolved isobaric peptides.  
Differentially modified isoforms of the peptide 27-KAAPATGGVKKPHR-40 
(K27acK36me3K37pr and K27prK36me2K37pr) were chromatographically separated by the 
RP analytical column.   
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CHAPTER 5: Conclusions and Future Perspectives 
 
 
5.1. Conclusions 
The scope of this thesis was the development of MS-based analytical strategies for 
comprehensive and quantitative analysis of histone modifications. An improved method for 
the measurement of the global and site specific changes in histones acetylation was 
developed. This method was supplemented by a new algorithm for deconvolution and 
quantification of isomeric peptides. We have validated the applicability of these analytical 
tools in a variety of biologically relevant systems.  
The measurement of histone PTMs using the traditional bottom-up approach involves in vitro 
propionylation reaction to derivatize histone proteins followed by trypsin digestion and LC-
MS/MS analysis. This approach has been widely used as it allows comprehensive analysis of 
numerous PTMs with high reproducibility, high dynamic range, and low detection limits. In 
chapter two of this thesis, an improved comprehensive bottom-up approach was described 
that combines intact mass analysis with peptide sequencing to characterize histone PTMs. 
This approach is modified from a similar method that was previously developed in our lab
1
. 
In the improved approach, peptide sequencing was performed in an LTQ-Orbitrap MS 
instead of the previously used QTOF instrument. In addition, unlike the previous approach, 
no MRM assays were needed to validate PTM identifications. The ultra-fast scanning 
capability of the ion trap coupled with the high resolution and high mass accuracy of the 
Orbitrap allows rapid sequencing of numerous peptides and accurate quantification of PTM 
abundances. This is particularly useful for analysis of complex peptide mixtures. In addition, 
the improved approach greatly reduces the amount of time and energy spent on data 
acquisition and analysis by avoiding the laborious process of MRM assay development. 
We employed the above approach to study the chaperone control of the substrate specificity 
of S. cerevisiae HAT Rtt109. Many of the previous studies conducted in this area focused on 
few acetylation sites on either H3 or H4, but not both. Moreover, these studies used 
antibodies raised against specific lysine residues to detect acetylations and as a result 
quantitative information on the extent of acetylation by Rtt109 was largely unavailable. Our 
bottom-up proteomics approach, however, surpasses the limitations posed by the traditional 
antibody-based techniques, and hence allows us to accurately measure the overall changes in 
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catalytic activity and/or the chaperone-mediated selectivity for individual sites. Our data 
showed the role of histone chaperones Asf1 and Vps75 in directing the activity of Rtt109 
toward distinct H3 and H4 sites. Rtt109 interaction with Vps75 promotes the acetylation of 
mainly H3K9 and H3K23, with the former being the most preferred site. According to 
previous genetic and biochemical studies the HAT Gcn5 is also known to acetylate K9 in 
newly synthesized H3 molecules.
2,3
 These studies also suggest that the two HATs, Rtt109 and 
Gcn5, function in parallel to promote nucleosome assembly and maintain genome integrity in 
yeast.
 
Our data also showed for the first time that Rtt109-Vps75 exhibits moderate activity 
toward H4 sites.
 
In contrast, Rtt109-Asf1 showed a striking specificity for H3K56, but no significant activity 
toward H4 sites. The later observation was very surprising to us because previous structural 
analyses have shown that Asf1 binds newly synthesized H3-H4 dimers through its conserved 
155-amino acid N-terminal domain
4
 and yet, the complex Rtt109-Asf1 selectively acetylates 
only the H3 molecules. In humans and Drosophila, the Asf1 chaperone interacts with the 
HAT CBP to promote acetylation of H3K56.
5,6
 Humans have two ASF1 isoforms, ASF1A 
and ASF1B, which differ mainly in their C-terminal region. H3K56 acetylation by Rtt109-
Asf1 complex plays a critical role in the regulation of DNA accessibility and transcriptional 
activation
7,8,9
. A similar chaperone control of the activity of Rtt109 toward the linker histone 
H1 was recently described.
10
 Overall, our results demonstrate the applicability of the MS-
based approach in studying enzyme kinetics and in defining how chaperone proteins direct 
substrate selectivity of HATs. 
 
Although the above MS-based approach was very useful for comprehensive PTM analysis, 
one of its limitations is that it cannot accurately determine PTM stoichiometries in isomeric 
histone peptides. Isomers present a major challenge to the conventional bottom-up approach 
when the localization of PTMs is of special interest, as is the case in most histone proteomics. 
The identification and quantification of PTMs even in as simple as a mixture of two isomeric 
peptides requires rigorous and time consuming manual validation. In addition, as can be 
imagined, the reproducibility of results obtained by manual analysis is highly affected by user 
experience. In fact, in the case of histone H4, it was totally impossible to distinguish between 
multiple acetylated isomers based on just their precursor chromatographic peaks and 
fragment m/z values. These analytical challenges led us to further modify our previous 
approach and include capabilities for deconvoluting isomeric peptides by the algorithm Iso-
PeptidAce. A few previously developed algorithms such as isoScale
11
 and EpiProfile
12 
rely on 
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the availability of distinguishing fragment ions in order to efficiently deconvolute isomeric 
peptides, while Iso-PeptidAce deconvolutes mixed spectra even when there are no such 
fragments in the MS/MS spectra. The algorithm EpiProfile requires prior knowledge of 
peptide retention times, whereas Iso-PeptidAce distinguishes between isomers based solely 
on fragment ion distributions in the mixed spectra.  
The applicability of Iso-PeptidAce was validated in a variety of biological problems, which 
are presented in Chapters three and four. We first investigated the impact of three HDACis 
(MS-275, SAHA and JNJ-26481585) on the acetylation levels of histones H3 and H4 isolated 
from human erythroleukemic cells. HDACis are considered one of the most promising 
therapeutic agents for cancer treatment although their mechanisms of action are poorly 
characterized.
13 
They induce hyperacetylation in histones. Given the crucial roles of histone 
acetylation in transcription, replication and apoptosis, it is likely that HDACis could target 
many of these processes in cancer cells. In addition to histones, HDACis also impact several 
other proteins including transcription factors.
14 
Over the last decade, numerous HDACis have 
been tested for antitumor activities, and among the most widely studied are MS-275 and 
SAHA. The later was approved by the FDA for treatment of cutaneous T-cell lymphoma.
15
 
We used Iso-PeptidAce to deconvolute and quantify multiple isomeric peptides derived from 
H3 and H4 before and after treatment with the drugs. Cells treated with all HDAC inhibitor 
demonstrated similar patterns of increase in the proportion of acetylated peptides. We 
determined major increases in acetylation of H3 K18 and K23, and H4 K5, K8, K12 and K16. 
Between the three HDAC inhibitors, SAHA and JNJ-26481585 induced the most dramatic 
increase in acetylation of the above lysines. To our knowledge, this is the first study 
demonstrating the effects of the JNJ-26481585 HDACi on site specific acetylation of 
histones. The drug was previously shown to have antitumor activity against several types of 
cancer and is currently in Phase II clinical trial.
16
  
We also demonstrated the applicability of Iso-PeptidAce by discovering a novel acetylation 
pattern of histone H4 bound to budding yeast CAF-1 - a protein complex known to deposit 
newly synthesized H3/H4 molecules during DNA replication. A number of previous 
biochemical studies showed that CAF-1-bound new H3 molecules are marked by very 
abundant acetylation of multiple lysine residues, while new H4 are marked by di-acetylation 
at positions K5 and K12.
17
 Using affinity purification techniques we isolated CAF-1-bound 
histones, which were subjected to LC-MS/MS analysis and deconvolution by Iso-PeptidAce. 
While our results for the H3 sites were in agreement with the previous observations, Iso-
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PeptidAce analysis of the H4 peptides showed a strikingly different acetylation pattern than 
the previous studies. Instead of the widely known di-acetylation motif we observed that CAF-
1-bound H4 molecules contain the tri-acetylation mark K5_12_16. The occupancy of 
acetylation at each of these sites was roughly 20%. In contrast, histone H4 purified from bulk 
nuclear extracts were differentially acetylated at the four sites - K5, K8, K12 and K16 in 
increasing order of acetylation occupancy (15 to 65%). The later result is consistent with the 
"zip" model for histone acetylation which states that acetylation of H4 proceeds from K16 to 
K5.
18
 Our data clearly challenged the existing dogma on the acetylation pattern of H4 
molecules bound to CAF-1. Although it is still not fully understood what role this acetylation 
pattern has in DNA replication-dependent histone deposition, our findings provide an 
important step forward in elucidating its function. On the other hand, these results 
demonstrate the unique capability of Iso-PeptidAce for studying combinatorial PTM patterns.  
Finally, the application of our MS-based approaches was further demonstrated in a study 
aimed at determining the substrate specificity of several HATs and HDACs presented in 
chapter 5 of this thesis. We defined the site specificity of some of the well-known fission 
yeast HATs Gcn5 and Mst2, and HDACs Clr3, Clr6, Sir2, and Hos2. The activities of these 
enzymes toward histones were previously characterized using biochemical approaches such 
as Western blot and ChIP assays. However, these methods are prone to numerous technical 
obstacles including antibody cross-reactivity, and epitope disruption or occlusion when 
additional modifications are present on nearby residues. The methods are also limited by the 
capability to provide stoichiometric information on PTM abundances. In our study, we 
employed the above validated MS-based approaches to determine changes in the acetylation 
site occupancy of multiple lysine residues in histones H3 and H4 isolated from wild type as 
well as mutant fission yeast strains lacking the above HATs and HDACs.  
Our analysis revealed complementary activities of the different enzymes. Strains lacking 
Gcn5 had major reductions in H3 K9, K18 and K27 acetylation levels compared to the wild 
type, while the Mst2 mutant had reduced H3 K14 and K23 acetylations, suggesting 
complementary roles for the two HATs. Supporting this notion, simultaneous depletion of 
both HATs strongly reduced the acetylation of all the five sites. Similar roles were observed 
for the HDACs Clr6 and Hos2. While strains lacking the former HDAC had elevated levels 
of acetylation of H4 K5, 8, and 12, those lacking the latter exhibited a major increase in 
H4K16 acetylation compared to the wild type. Given the high speed with which 
transcriptional machineries progress along the DNA strands, it is likely that the 
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complementary activities of the HATs and HDACs promote the rapid acetylation and 
deacetylation of histones for controlling DNA accessibility during and post-transcription. 
Perhaps one of the most striking findings of this study is that Clr6 preferentially targets 
combinatorial acetylation patterns on histone H4. Out of the fifteen different acetylated 
isoforms derived from the H4 peptide 4-GKGGKGLGKGGAKR-17, only five were 
significantly affected by Clr6 depletion. And among the five, by far the most affected isoform 
is the tri-acetylated peptide H4K5_8_12ac. This is one of the first studies demonstrating the 
preference of HDAC enzymes for combinatorial acetylation motifs. It is almost impossible to 
obtain such data if not for the exceptional capability of Iso-PeptidAce to deconvolute 
multiple co-eluting isomers.     
It is widely accepted that histone PTMs exert their function through dynamic interplay or 
crosstalk between various modifications occurring on a single histone molecule or between 
different histone proteoforms. This notion has led to the formulation of what is known as the 
‘histone code hypothesis’, which states that multiple histone PTMs act combinatorially or 
sequentially to regulate downstream functions.
18, 19
 Supporting this, a number of previous 
studies have characterized functional crosstalks between acetylation and methylation (e.g. 
H4R3me and H4K8/K12ac)
20
, methylation and phosphorylation (e.g. H3K9me3 and 
H3S10ph)
21
, and methylation and ubiquitination (e.g. H3K4me3 and H2BK120ub)
22
.  
We also characterized some interesting crosstalk between acetylation and methylation. In 
both our wild type and mutant samples, the K9 in the H3 peptide 9-KSTGGKAPR-14 was 
found in unmodified, acetylated, mono-, di-, or tri-methylated form, whereas K14 was found 
in either unmodified or acetylated form. In the Clr3 mutant, we observed an increase in 
H3K14ac and a concomitant decrease in H3K9me2/3, suggesting a negative crosstalk 
between the two PTMs. Such crosstalk has previously been associated with the regulation of 
heterochromatin structures.
23
 While increase in acetylation (and/or decrease in methylation) 
is strongly linked with chromatin relaxation, a decrease in acetylation (and/or increase in 
methylation) is widely associated with chromatin condensation. Meanwhile, it should be 
noted that the PTMs alone do not alter the chromatin structure; rather it is the combined 
effects of other PTMs as well as nucleosome repositioning by chromatin remodeling 
complexes. We also discovered an inter-histone positive crosstalk between acetylation and 
methylation, where both H3K9me2/me3 and H4K16ac were elevated in response to Hos2 
depletion. Meanwhile, this result should be viewed with caution and alternative interpretation 
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should be considered. First, our method cannot determine whether or not the H3K9 and 
H4K16 residues are present in the same or different nucleosomal complex. As a result, based 
on the current data, we cannot exclude the fact that this PTMs might not be interacting at all 
and the increase in H4K16ac and H3K9me2/3 are purely mutually exclusive.  
Second, although our analysis showed a concomitant increase in both H3K9me2/me3 and 
H4K16ac, it is not clear how this interaction could be established. Assuming that both 
H3K9me2/3 and H4K16ac are present in the same nucleosome, one possibility is that 
hyperacetylation of H4K16 could have a positive impact on the binding of Clr3 (the enzyme 
responsible for removing H3K14ac), thus promoting transcriptional inactivation via Clr4 
binding and H3K9me2/3 deposition. Alternatively, it is possible that the enzyme responsible 
for acetylating H4K16 positively regulates the binding of H3K9 methyltranferase Clr4 to co-
modify nucleosomes and promote transcriptional repression of target genes. It is also possible 
that Clr4 could be recruited indirectly through H4K16ac binding proteins. 
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5.2. Future perspectives  
The mysteries of histones and their posttranslational modifications are surely not over. These 
proteins appear small and simple from their looks; yet, they have constantly challenged our 
analytical capabilities to fully characterize all their proteoforms (i.e., the forms arising from 
combinatorial modifications). The arrival of cutting-edge mass spectrometry technologies and 
continuous improvements in analytical methodologies have so far improved our success in 
identifying numerous PTMs, in characterizing many enzymes that are responsible for 
installing or removing the PTMs and in defining the histone PTM interactome. Meanwhile, 
further improvements in the existing methodologies are required in order to gain more 
insights into the role of histone PTMs in normal and disease processes.  
The bottom-up approach presented in this thesis allows analysis of PTMs that occur on short 
peptide segments, limiting our capability to decipher long range combinatorial PTMs and 
crosstalks. To address this limitation, the advantages provided by alternative histone 
digestion enzymes such as Glu-C and Asp-N should be exploited. These enzymes provide an 
expanded view of multiple PTMs on the full length N-terminal region of histones.  
The algorithm presented in the thesis can be exploited to include many other PTMs in 
addition to acetylation and methylation. One potential area that needs to be tested is the 
deconvolution of isomeric phosphopeptides. Our lab has previously shown that 3 to 6% of all 
identified phosphopeptides in large scale phosphoproteomics studies represent 
phosphoisomers.
24
 Thus, Iso-PeptidAce can be adapted to deconvolute mixed spectra of such 
isomers.  
Iso-PeptidAce can also be used for investigation of multivalent recognition of combinatorial 
histone PTMs by chromatin factors. Despite the large number of PTMs discovered on the 
histone tails, there is still a huge gap in understanding how these PTMs are read and 
interpreted into meaningful biological outcomes. It is widely believed that histone 
modifications act in combinatorial fashion to regulate the physical properties of the chromatin 
fiber. According to emerging evidences, this is achieved through the binding of chromatin 
modules termed as ‘effectors’ which serve to read specific PTM patterns. Thus, when 
coupled with techniques that allow co-purification of histone-bound chromatin modules, the 
method described in this Thesis can be used to define the mechanisms involved in PTM 
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recognition and the role histone PTMs play in directing the establishment of various 
chromatin-associated processes. 
The specificities of HDACs toward histones are far less characterized in humans compared to 
yeast. HDACs present very promising targets for the treatment of various types of cancers 
and assessment of their catalytic properties is crucial for understanding their role in the 
development of the disease. Recently the human HDAC3 was characterized as a novel 
therapeutic target in multiple myeloma (MM).
25
 According to this study, HDAC3 knockdown 
induced significant MM cell growth inhibition via apoptosis. Treatment of the MM cells with 
a small molecule HDAC3 inhibitor (denoted as BG45) also triggered similar tumor growth 
inhibition. Western analysis using antibodies raised against specific lysine residues also 
showed a major increase in acetylation of core histones H2B, H3 and H4 upon treatment with 
BG45. However, due to the inherent limitations of the technique, this study did not show if 
the HDAC3 targets a single lysine residue or a combinatorial acetylation pattern on the core 
histones. As our results have shown some HDACs specifically target multiply acetylated 
histones rather than a single site. Therefore, the method we presented in this thesis can now 
be used to characterize the specificity of HDAC3 before or after treatment with BG45. 
Moreover, this method can be applied to studies aimed at characterizing the catalytic 
properties of several other human HDACs.  
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Appendix A: Additional supplementary information 
Table S1.1  Human histone variants (HIstome-The Histone Infobase). 
A) Histone H2A variants 
 
 
B). Histone H2B 
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C) Histone H3 
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A) Histone H3 
 
B) Histone H4 
 
Figure S1.1 Sequence alignment of histones from various species 
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Figure S3.7 MS/MS spectra of H3 and H4 peptide isomer  
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